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Abstract 
Like most health interventions, National Immunization Programs (NIPs) are embedded within health 
systems. This means that NIPs and health systems exist in a constant interaction. Vaccine preventable 
diseases are widely recognized as the chief cause of morbidity, disability and mortality worldwide and 
NIPs are understood to be one of the most cost-effective interventions against this burden. In low- 
and middle- income countries (LMICs), where the burden of disease is high, NIPs have been reported 
to perform at suboptimal levels. It has been suggested that this suboptimal performance of NIPs can 
be associated with the poor state of health systems in LMIC. Despite this, the interaction between 
NIPs and health systems is poorly understood. In addition to this, systematic evidence on how health 
systems constraints and facilitators impact on the performance of NIPs in LMICs is scarce. To address 
this evidence gap, a systematic review study was conducted, that involved an initial scoping review of 
the evidence-base on NIPs and health systems in LMICs from which a logic model was developed. This 
logic model was then applied as a guide for a qualitative systematic review aimed at assessing the 
health systems constraints and facilitators of NIP performance in sub-Saharan Africa. The findings of 
this review suggest that well-performing NIPs are those that operate within enabling health systems, 
characterized by the availability of strong political endorsement for vaccines, clear governance 
structures and effective collaboration with global partners. Despite this, significant health systems 
constraints persist and include the limited capacity of health workers in sub-Saharan Africa, weak 
country infrastructure, poor service delivery, inadequate vaccine communication and ineffective 
community engagement in immunization programs. This systematic review study contributes to our 
limited understanding of the interaction between NIPs and health systems. In addition, the findings 
show how system-wide constraints and facilitators impact on the performance of NIPs. These findings 
have relevance for ongoing health systems strengthening initiatives, especially where NIPs are 
concerned. 
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Acronyms 
AIDS  Acquired Immune Deficiency Syndrome 
EPI  Expanded Program on Immunization 
GAVI  Global Alliance for Vaccines and Immunizations 
GVAP  Global Vaccine Action Plan 
HIV  Human Immunodeficiency Virus 
HPV  Human Papillomavirus 
LMICs  Low- and Middle- Income Countries 
MPH  Master of Public Health 
NIP  National Immunization Program 
NITAG  National Immunization Technical Advisory Group 
PAHO  Pan American Health Organization’s 
SAGE  Strategic Advisory Group of Experts 
WHO  World Health Organization 
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Glossary 
Global Development Partners External or third-party agencies who support developing countries to 
achieve global targets by contributing technical, financial and human 
resources 
Expanded Program on Immunization A global health program developed by the WHO with the intent of making 
essential vaccines available to all children 
Health Systems A collective of organizations, people and actions, whose primary intent is to 
promote, restore or maintain health 
Health Systems Constraints Barriers to effective health systems functioning which negatively affect the 
availability, acceptability, affordability and quality of health services  
Health Systems Facilitators Determinants that positively impact the performance of health systems and 
improve the availability, acceptability, affordability and quality of health 
services 
Health Program A health intervention or strategy intended to promote the health of 
populations, and reduce the incidence of morbidity, disability and mortality  
Immunization Administration of a biological preparation, either a vaccine or 
immunoglobulin, to confer immune protection against disease 
Mass Immunization Campaign Administration of vaccines to large populations in one or more locations 
over short periods of time 
National Immunization Program A national health program designed for the timely delivery of vaccines to all 
age groups as deemed appropriate for a given country  
Systematic review Use of systematic methods to identify, collect, critically appraise and 
synthesize secondary data to provide new and meaningful explanations 
Thematic analysis A descriptive approach to analysing a qualitative data set 
Vaccine A biological preparation designed to confer immune protection by 
mimicking natural infection without causing disease 
Source; Author, (drawing on and adapting commonly held definitions) 
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Part A: Review Protocol 
Health systems constraints and facilitators of national immunization programs in low- and 
middle- income countries 
 
“The ultimate goal is to manage quality. But you cannot manage it until you have a way to measure it, and 
you cannot measure it until you can monitor it”- Florence Nightingale1 
Introduction 
Immunization is one of the most cost-effective interventions for reducing the burden of morbidity, disability 
and mortality worldwide (Rémy et al. 2015; Greenwood 2014; WHO et al. 2009; Andre et al. 2008). In support 
of the value of immunization, Plotkin et al. (2013) declare that, “the impact of vaccination on the health of the 
world's people is hard to exaggerate. With the exception of safe water, no other modality, not even antibiotics, 
has had such a major effect on mortality reduction and population growth.”2 For these reasons, national 
immunization programs (NIPs), which serve as platforms for the delivery of routine immunization services, are 
widely recognised as one of the most significant investments in countries’ health systems (Rémy et al. 2015; 
Shen et al. 2014). 
 
Over the past four decades, global efforts have been focused on realizing universal access to essential vaccines 
(WHO 2015; Chan 2014; WHO 2013; WHO et al. 2009). These efforts to expand the reach of vaccines have 
been intensified in low- and middle- income countries (LMICs), particularly within the sub-Saharan African 
region, where the burden of vaccine preventable diseases and need for intervention are the greatest (WHO 
2018; SAGE 2016; WHO 2013). 
 
Global immunization coverage rates have been consistently reported to be lower in LMICs compared to most 
high-income countries (WHO 2018; SAGE 2016; WHO et al. 2009). One of the determinants of this disparity 
has been the state of the health system in LMICs. Compared to high-income countries, health systems in some 
LMICs have been characterized by fragile health infrastructure and poor service delivery (Mills 2014; Shen et 
al. 2014; Kruk and Freedman 2008). Given the importance of health systems functioning to the success and 
sustainability of NIPs, it follows that critical steps need to be taken to ensure optimal health systems 
performance in LMICs (Shen et al. 2014; Balabanova et al. 2010). Such health systems strengthening initiatives 
could be supported by systematic evidence on the state of health systems and NIPs in LMICs. 
 
                                                          
1 Quoted in: Kilshaw ME. 1992. Implementing an effective quality assurance program. In: Gelman D (ed). Medical 
Administration in Canadian Hospitals. Ottawa: Canadian Medical Association, Chapter Fl. 
2 Originally quoted in Plotkin SA, Mortimer EA. 1988. Vaccines. Philadelphia: Saunders.  
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Problem statement and purpose 
The past decade (between 2008–2018) can be considered a watershed period for NIPs worldwide. This period 
has seen the introduction of new vaccines and improved vaccine technologies intended to reinforce global 
efforts towards countering the devastating effects of emerging and re-emerging vaccine preventable diseases 
(WHO 2015). Within this same period, the World Health Assembly implemented the Global Vaccine Action 
Plan (GVAP) which was endorsed by 194 member states to initiate the ‘Decade of Vaccines’. One of the visions 
of the GVAP is to advance the cause of universal access to lifesaving vaccines between 2011 and 2020 (WHO 
2015; WHO 2013). These intensified efforts have also been accompanied by health systems strengthening 
initiatives in LMICs (Adam et al. 2012; Balabanova et al. 2010; Galichet et al. 2010). This is because it has 
increasingly become apparent that the success of NIPs in LMICs is dependent on the performance of the health 
systems which deliver them (SAGE 2016; Shen et al. 2014; Samb et al. 2009).  
 
There is much in the published literature about the public health impact of NIPs in LMICs (Feikin et al. 2016; 
Greenwood 2014; Samb et al. 2009; Andre et al. 2008). In comparison, there is insufficient systematic evidence 
about the interaction of NIPs with the broader health systems within which they are embedded (Hyde et al. 
2012; Bosch-Capblanch et al. 2011). As a result, there is insufficient evidence to assess the capacity of health 
systems to sustain this critical public health intervention in some LMICs. For this reason, a systematic review 
study is proposed for the identification, synthesis and analysis of the existing evidence-base on the interaction 
between NIPs and health systems in LMICs. This much needed systematic evidence could foster proactive 
approaches to maximizing and strengthening the interaction between the programmatic (or NIPs) and the 
systematic (the broader health system) in yielding the greatest possible public health outcomes within LMICs. 
 
Review question 
The proposed systematic review study seeks to address the following research question; How do health 
systems constraints and facilitators impact on the performance of national immunization programs in sub-
Saharan Africa?  
 
Review objectives 
1. To describe the scope of published literature available on NIPs and health systems in LMICs. 
2. To systematically review the existing evidence-base on how health systems constraints and facilitators 
impact on the performance of NIPs in sub-Saharan Africa. 
3. To describe the potential research, policy and practice implications of this systematic review. 
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Methods 
Review approach  
A descriptive study design will be adopted, using a qualitative systematic review approach. Qualitative 
systematic reviews synthesize research evidence from the best available empirical qualitative studies in 
developing evidence-based recommendations on a topic of interest (Butler et al. 2016). Compared to 
quantitative systematic reviews, qualitative approaches are a less commonly used method of enquiry in public 
health research, but are rapidly becoming critical components of the research toolkit (Butler et al. 2016; Evans 
and Pearson 2001). This is because qualitative systematic reviews are invaluable to the comprehensive 
assessment of complex real-world phenomena rooted in experiences and perceptions which cannot be 
measured through standard quantitative approaches. For this reason, qualitative systematic reviews are 
useful for generating rich sources of high-quality evidence necessary to inform policy and practice (Butler et 
al. 2016; Seers 2015; Evans and Pearson 2001).  
 
While there are various formats available for conducting qualitative systematic reviews, the Campbell 
systematic review is the best fit for addressing the proposed review question on account of the research focus 
and the intended outcomes of the review (Campbell Corporation 2017; Campbell et al. 2003; Britten et al. 
2002; Hawker et al. 2002; Dixon-Woods and Fitzpatrick 2001). Campbell systematic reviews are typically 
concerned with factors affecting the successful implementation of interventions as well as the effects of 
interventions, with the intent of informing research, policy and practice (Campbell Corporation 2017).  
 
The review process will span across three phases as shown in Figure 1. Phase 1 will comprise of an initial 
scoping review which will critically appraise the existing evidence-base to provide an in-depth understanding 
of what is already known about NIPs and health systems in LMICs. Themes emanating from Phase 1 will then 
be applied in a systematic review of how health systems constraints and facilitators impact on the 
performance of NIPs in Phase 2. Based on the outcomes of Phase 1 and 2, it will then be possible to make 
relevant research, policy and practice considerations for NIPs and health systems in LMICs (Phase 3). 
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Figure 1: Schematic representation of the phased approach to the systematic review study  
 
Phase 1: Scoping review 
According to Grant and Booth (2009), a scoping review “provides a preliminary assessment of the potential 
size and scope of available research literature”. This initial review process is useful for accommodating the 
large bodies of literature available on broad fields of interest like NIPs and health systems (Peterson et al. 
2017; Davis et al. 2009). In this way, a scoping review can be used to identify gaps for future research (Peterson 
et al. 2017; Davis et al. 2009; Grant and Booth 2009). This method of review often involves a process of 
mapping the existing evidence-base to understand what is already known about the broad review question. 
By contextualizing the knowledge-base it will then be possible to frame a well-defined review question for the 
systematic review to be conducted in Phase 2 (Peterson et al. 2017; Davis et al. 2009). 
 
An electronic literature search for relevant peer-reviewed and grey literature on NIPs and health systems in 
LMICs will be conducted. Search terms and search term synonyms for both NIPs and health systems will be 
used to retrieve literature sources. For NIPs, terms to be used in the search strategy will include, immuni*3; 
vaccination; vaccine, ‘vaccine technology’; ‘vaccination program’; ‘expanded program on immunization’; and 
‘vaccine preventable diseases’. Those for health systems will include ‘global health’; ‘health service’; ‘health 
information’; ‘health financing’; ‘health workforce’; governance; and ‘health systems performance’. The 
geographic focus for the search strategy will be restricted to LMICs as defined by the World Bank 
                                                          
3 The * denotes truncation and prompts the search engine to retrieve all possible variants of the word including 
immunization and immunisation. 
•Scoping review 
on NIPs and 
health systems in 
LMICs 
Phase 1
• Systematic review 
on how health 
systems impact on 
the performance of 
NIPs in LMICs
Phase 2
•Considerations 
for research, 
policy and 
practice
Phase 3
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(http://data.worldbank.org/about/country-and-lending-groups). The expected outcome of the scoping review 
is a descriptive, narrative summary of the evidence-base on NIPs and health systems in LMICs. 
 
Phase 2: Systematic review 
For the systematic review, an electronic search for peer-reviewed and grey literature documenting relevant 
research on health systems constraints and facilitators in sub-Saharan Africa4 will be performed. The 
systematic review will further explore how these health systems constraints and facilitators impact on the 
performance of NIPs, using human papillomavirus (HPV) immunization programs in sub-Saharan Africa as a 
proxy.5 The HPV immunization programs present a unique challenge to health systems in sub-Saharan Africa 
with coverage rates in the region reported to be among the lowest (1.2%) in the world (Bruni et al. 2016).  It 
will be worth exploring how health systems constraints and facilitators impact on the introduction and 
performance of HPV immunization programs in sub-Saharan Africa. For this purpose, literature sources will be 
sought through electronic databases such as PubMed (core clinical journals, MEDLINE, and nursing journals), 
Web of Science (MEDLINE, Web of Science core collection, biological abstracts, SciELO citation index), Scopus 
(includes EMBASE-indexed journals), and EBSCOhost (academic search premier, Africa-wide information, 
eBook collections, health sources – consumer edition, nursing and academic edition, MEDLINE).  
 
To conduct the literature search through these databases, multiple search terms will be generated from the 
review question. Combinations of these search terms and search term synonyms will be created using Boolean 
operators like ‘AND’ and ‘OR’, and then inputted into the search engines of the various databases as 
appropriate. 
 
Inclusion criteria 
The search strategy will include; 
1. Peer-reviewed primary research articles, reviews, electronic books and book chapters, editorials, 
comments and – among other relevant sources of grey literature – dissertations or theses, conference 
proceedings, and reports.  
2. Literature sources published between 2008 and 2018. This will ensure that the most recent evidence is 
systematically reviewed to generate relevant recommendations. 
 
                                                          
4 Sub-Saharan Africa was selected as a geographical focus for the systematic review after Phase 1 (scoping review) was 
completed. During the scoping review, it was identified that health systems constraints on NIP performance appear to 
be more prevalent within sub-Saharan Africa compared to other low- and middle- income regions of the world. The 
review protocol was therefore adapted to reflect this in Phase 2. 
5 An adaptation was made to this protocol after Phase 1 was complete, during which the HPV immunization focus for 
Phase 2 was decided. 
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Exclusion criteria 
The exclusion criteria for the search strategy is as follows: 
1. Literature sources published in languages other than English will be excluded. 
2. Published literature without abstracts or summaries will be excluded as these will be required during 
the initial screening process. Where abstracts or summaries are available but full texts are not 
accessible for review, these will also be excluded. 
3. The search strategy will exclude all literature sources concerned with veterinary immunization 
programs unless they are directly impacting on human health and the health system (for example, 
human rabies vaccination).  
4. Finally, research conducted in LMICs outside of the WHO sub-Saharan African region, or in high-
income countries (as defined by the World Bank) will be excluded. 
 
All full text literature sources will be imported into Rayyan, a web-based application for systematic reviews 
(Ouzzani et al. 2016). Based on the eligibility criteria, full texts will be screened in Rayyan. The full texts selected 
for inclusion will then be critical appraised. 
 
Critical appraisal  
Full texts selected for inclusion in the systematic review will be critically appraised for quality by assessing the 
appropriateness of the research questions or objectives, the methods used, and the findings reported. 
Concepts of ethics, rigour and reflexivity will also be carefully considered. This appraisal process will be 
conducted with the assistance of published appraisal tools6 developed by the Critical Appraisal Skills 
Programme (http://www.casp-uk.net/) for health research. These appraisal tools have been used in previous 
qualitative systematic reviews (Chan 2013; Kane et al. 2007; Walter et al. 2004).  
 
A summary of the quality assessment will be captured onto a database and made available to two independent 
reviewers (MPH supervisors). The independent reviewers will conduct further appraisals of the literature 
sources using the quality assessment summary. Quality assessments made by the primary reviewer and the 
two independent reviewers will then be triangulated and a final decision made about the eligibility of full texts 
for inclusion in the review process. 
 
 
 
                                                          
6 This includes a set of eight critical appraisal tools designed for the assessment of the quality of cohort studies, case 
control studies, diagnostic studies, clinical prediction rule, randomised controlled trials, systematic reviews, qualitative 
studies, and economic evaluations.  
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Data extraction 
Data will be extracted from eligible full texts, identifying health systems constraints and facilitators, and noting 
their relevance to the performance of NIPs in sub-Saharan Africa. A data extraction form will be used to keep 
a systematic record of summaries of the data extracted from each literature source. By generating a historical 
trail, it will be possible to ensure traceability and validity of the data extraction process, as well as reduce the 
risk of human errors during the review process (Tranfield et al. 2003). To ensure reliability of the data 
extracted, the extraction process will be conducted by the primary reviewer and supervised at all stages by 
the two independent reviewers (MPH supervisors). Summaries of the data extracted will also be 
comprehensively audited by all three reviewers and final decisions reconciled. This will be an opportunity to 
resolve any potential discrepancies that may emerge from the data set prior to the analysis stage. Table 1 
shows a template of the data extraction sheet to be used. 
 
Table 1: Template of data extraction sheet 
Study Details Context Data Extraction 
No. Author, 
Year 
Title Country Underlying 
Context 
Availability / 
Type of HPV 
Immunization 
Program 
Main 
Theme 
Health 
Systems 
Constraint 
Health 
Systems 
Facilitator 
Comments 
          
          
          
          
          
Source; Author 
 
Data analysis 
The final audited data summaries will serve as the basis on which the data synthesis and analysis will be 
performed. Typically, thematic analysis is the go-to approach in qualitative systematic review studies (Thomas 
and Harden 2008). This is because the thematic analysis approach is highly flexible and can be used across a 
wide range of epistemologies and research questions to produce rich, detailed, yet complex, nuanced 
accounts from a qualitative data set (Vaismoradi et al. 2013; Thomas and Harden 2008; Braun and Clarke 
2006). A rigorous thematic analysis will be a suitable approach for searching and identifying prominent threads 
and themes on the interaction between NIPs and health systems in sub-Sharan Africa. Thomas and Harden 
(2008) propose three broad stages for thematic synthesis and analysis of qualitative research for systematic 
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reviews, and these will be adopted and performed iteratively. In the first stage, the primary reviewer will fully 
engage with the extracted data in generating initial codes from the text, using inductive and deductive 
approaches. These coded extracts will then be subjected to descriptive treatment to develop themes and 
potential sub-themes which capture the main conceptions about the review focus. It is with these thematic 
extracts that analytic themes will be generated in the final stage to provide meaningful and integrated 
accounts and new explanations of the data set (Nowell et al. 2017; Vaismoradi et al. 2013; Thomas and Harden 
2008; Braun and Clarke 2006). Additionally, themes emanating from the scoping review will be used to 
enhance the data analysis process. Finally, given that health systems are highly context specific, careful 
consideration will be given to the prevailing contexts (geographic, political, sociocultural, socioeconomic and 
disease epidemiology) within sub-Saharan Africa (WHO 2007).  
 
Rigor 
To minimize the risk of information bias and enhance the transparency, trustworthiness and reproducibility of 
the proposed systematic review, this review protocol has been developed to explicitly detail the study design 
and methods to be used (Drucker et al. 2016). Since Campbell systematic reviews encourage the use of a 
diverse source of literature, including both published and grey literature, the risk of selection and publication 
bias will be minimized. In addition to this, published appraisal tools (http://www.casp-uk.net/) will be used to 
assess the risk of selection bias and to evaluate the efforts taken to minimize bias in the research studies 
selected for review. Finally, approaches suggested by Nowell et al. (2017) on how to ensure trustworthiness 
during the thematic analysis process will be adhered to. This will include regular reviewer triangulation and 
peer debriefing, keeping an audit trail throughout the review process, and providing thick descriptions of 
context when analysing and interpreting the data set (Nowell et al. 2017). 
 
Risks and benefits 
As a systematic review, this is a no risk study. However, the findings of the proposed systematic review could 
potentially expose poorly performing health systems within sub-Saharan Africa. Given that any data presented 
will be directly extracted from literature sources already available in the public domain, there will be minimal 
to no risk to these health systems as a consequence of conducting the review. Instead it is anticipated that 
findings from the review could enrich policy debates and guide key decision-makers to ensure the optimal 
performance of their health systems. Essentially, a systematic review of this kind may provide a set of ‘lessons 
learned’ with regards to how critical public health interventions like NIPs could be capitalized on, in scaling-up 
national health systems strengthening efforts within LMICs.  
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Study limitations 
The geographical focus of the proposed systematic review is restricted to the sub-Saharan African region. This 
is a limitation because the outcomes of the review cannot be generalized to countries outside of this 
classification. However, our interest in this geographical region stems fact that sub-Saharan Africa continues 
to underperform in comparison to other regions of the world, where global immunization targets are 
concerned (Mihigo et al. 2017; SAGE 2016).  In addition to this, there is insufficient systematic evidence on the 
subject matter from the sub-Saharan Africa region. The proposed systematic review is therefore intended to 
contribute to bridging the evidence gap in sub-Saharan Africa. Excluding studies published in languages other 
than English could be a missed opportunity as they may contain empirical evidence on the interaction between 
NIPs and health systems that are relevant to this systematic review. Given the time and resource constraints 
for this MPH thesis, it will not be possible to retrieve and translate literature sources which have been 
published in languages other than English. Finally, the use of one immunization program (the HPV 
immunization program) as a single tracer-indicator may not give a comprehensive assessment of the 
performance of NIPs and health systems in all sub-Saharan African countries. In reality, a plurality of NIP 
activities, as well as other health and non-health programs interact within a health system (Samb et al. 2009). 
Ultimately, any analytically generalizable claims drawn from the findings of the proposed systematic review 
will have to be carefully considered in the context of these caveats. 
 
Phase 3: Policy considerations 
Based on the findings of this systematic review study, policy-relevant recommendations will be made for NIPs 
and health systems in sub-Saharan Africa. It is also anticipated that the findings of the review will have 
implications for current practice and future research in the fields of NIPs and health systems in LMICs. 
Appropriate dissemination of the findings will be crucial to informing evidence-based reform in public health 
policy and practice in the real-world setting. Accordingly, this systematic review will be disseminated through 
publications in internationally accredited, peer-reviewed journals and presented at local, national and 
international congresses. The primary author works for the Vaccines for Africa Initiative which hosts annual 
African vaccinology courses. These courses are targeted at key stakeholders working within the field of 
vaccinology throughout the African continent. The Annual African Vaccinology course will therefore serve as 
an effective platform for the dissemination of the findings of the review. Electronic and hard copies of the 
thesis emanating from this systematic review will also be made available for public access through the library 
services at the University of Cape Town. The systematic review is also targeted at key policy makers in both 
health and non-health sectors. For this reason, the findings of the systematic review will also be repackaged 
into policy briefs and presented at relevant workshops that are accessible to these stakeholders. 
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Ethical considerations 
No human subjects will be directly involved in this study. All literature sources that will be used during the 
systematic review are readily available in the public domain. For these reasons, formal ethical clearance to 
conduct this study is not required. All works of other investigators that will be used in the systematic review 
will be duly acknowledged as appropriate.  
 
Timeline 
It is expected that this systematic review study will be conducted over the course of an 11-month period, from 
the initial development of the review protocol to the final thesis submission for examination purposes. The 
various research activities to be performed are as depicted in the proposed timeline provided in Table 2. 
 
Table 2: Timeline of research activities 
Activity 
Proposed Timeline   
March 
2018 
Apr 
2018 
May 
2018 
Jun 
2018 
Jul 
2018 
Aug 
2018 
Sep 
2018 
Oct 
2018 
Nov 
2018 
Dec 
2018 
Jan 
2019 
Review protocol 
development  
           
Scoping review            
Data collection            
Data extraction and 
analysis 
           
Write-up of 
manuscript 
           
Finalization of 
thesis 
           
Source; Author 
 
Estimated budget for the review 
All research activities for this systematic review study will be self-funded and undertaken in the primary 
author’s country of residence in partial fulfilment of the requirements for an MPH degree. As this is a 
systematic review study, there are no direct costs arising as a result of conducting the research. The primary 
author declares to have no conflict of interest. Table 3 provides an estimation of the minimum expected costs. 
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Table 3: Estimated research budget 
Item Description Units Unit Cost (ZAR) Total Cost (ZAR) 
Pens  5 4.00 20.00 
Pencils 5 3.00 15.00 
Note pads 5 10.00 50.00 
Printing (two copies of review protocol 
and the final thesis) 
350 3.50 1225.00 
Incidentals  1000.00 1000.00 
Total  1020.50 2310.00 
Source; Author 
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Part B: Scoping Review 
A scoping review of national immunization programs and health systems in low- and middle- 
income countries 
 
Background 
The World Health Organization (WHO), together with key development partners1, are at the forefront of global 
initiatives to prevent disease and improve the health of populations worldwide. One of these initiatives is to 
provide universal access to potent vaccines2 against infectious diseases through country-level platforms 
known as national immunization programs (NIPs) (WHO 2015; Greenwood 2014; Andre et al. 2008). According 
to the WHO (2018a), NIPs can be defined as the “organizational component of Ministries of Health charged 
with preventing disease, disability, and death from vaccine-preventable diseases in children and adults”. 
 
National immunization programs do not operate in isolation. They are embedded in countries’ health systems 
and often form part of an essential package of primary health services provided by national governments 
(WHO 2015). Well-performing NIPs should be guided by informed health policy and operate within enabling 
health systems (WHO 2018a). National immunization managers and policy-makers thus rely on robust 
evidence to make informed decisions necessary to safeguard the performance of their NIPs (WHO 2018a; 
Bosch-Capblanch et al. 2011; Levine et al. 2011). For this reason, expanding the pool of evidence on NIPs and 
health systems cannot be undervalued. This is particularly relevant for some low- and middle- income 
countries (LMICs) where evidence-based initiatives to improve NIP performance and strengthen health 
systems are limited (WHO 2015; WHO 2013a; Adam et al. 2012; WHO 2007). Additionally, the interface 
between NIPs and their health systems in LMICs is neither sufficiently understood, nor adequately 
documented in the published literature (Samb et al. 2009). Ultimately, there is insufficient evidence to assess 
the capacity of health systems to sustain continuously evolving NIPs in LMICs.  
 
This scoping review maps the existing evidence-base on NIPs and health systems in LMICs. The organizational 
components of NIPs and their functions are presented. In addition to this, the state of health systems in LMICs 
is addressed. This will advance the limited understanding of how NIPs in LMICs interact with their health 
systems. Such evidence could contribute to health systems strengthening initiatives, at least where NIPs are 
                                                          
1 These development partners include WHO’s financial and technical partners, global agencies and civil society 
organizations. 
2 Vaccine potency refers to a quantitative measure of the ability of a vaccine to achieve its intended biological effect, 
such as eliciting a protective immune response in the recipient. 
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concerned. Key themes emerging from this scoping review will also form the basis of a detailed systematic 
review. 
 
Methods 
This scoping review was conducted in two parts; the first to understand what is already known about NIPs in 
LMICs, and the second to collate existing evidence on health systems in LMICs. For this purpose, peer-reviewed 
and grey literature were sourced from several electronic databases; PubMed, Web of Science, Scopus 
(includes EMBASE-indexed journals), and EBSCOhost. Additional searches for grey literature were carried out 
through organizational websites like WHO (http://www.who.int/en/), and GAVI, the Vaccine Alliance (GAVI; 
https://www.gavi.org/). Supplementary searches for peer-reviewed and grey literature which may have been 
missed during the primary searches were also conducted though bibliographic searches, and internet searches 
in Google Scholar. Key terms used in the search strategy are presented in Table 1. There were no publication 
date restrictions applied to the search strategy. This was done to increase access to a wide scope of evidence. 
Only relevant studies conducted in LMICs and published in English were considered for review.  
 
Table 1: Examples of key terms used in the search strategy 
 Search terms 
NIPs Immuni*; vaccination; “immunization program”; “expanded program on immunization”; 
vaccine; “vaccine preventable disease”; “health information systems”; “health policy”; “health 
governance”; “human resource”; “logistics management”; “cold chain”; “service delivery”; 
“health communication”; “health financing” 
Health systems “Health system”; “global health”; “health service delivery”; “health information systems”; 
“health financing”; governance; “health workforce”; “medical technology”; vaccine; “vertical 
health programs”; “health systems strengthening”; “health systems performance” 
LMICs  
Economy terms "deprived countries"; "developing countries"; "less developed country"; "low gross national; low 
income countries"; "middle income country"; “middle income economies"; "poor economy"; 
"third world"; "transitional country"; "under developed economies" 
Country terms LMICs listed as per World Bank classification (http://data.worldbank.org/about/country-and-
lending-groups) 
Region terms “East Asia and Pacific”; “Europe and Central Asia”; “Latin America and the Caribbean”; “Middle 
East and North Africa”; “South Asia”; “Sub-Saharan Africa” 
Source; Author 
Note: The * denotes truncation and prompts the search engine to retrieve all possible variants of the word; 
immunize, immunise, immunization, and immunisation. 
Database-specific LMICs search terms have been compiled and are accessible from the Health Sciences Faculty 
Library website (http://www.medical.lib.uct.ac.za/), University of Cape Town. 
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National Immunization Programs in LMICs 
The WHO (2018b) defines immunization3 as “the process whereby a person is made immune or resistant to 
an infectious disease, typically by the administration of a vaccine.” Vaccines can be defined as biological 
preparations designed to mimic natural infection without causing disease (Backx and Freedman 2013; Clem 
2011). Thus, when administered, vaccines prime the immune system to recognise a specific disease-causing 
organism and destroy it before it can cause disease (WHO 2018b). This actively induced form of immunity is 
often long-lasting (Backx and Freedman 2013; Clem 2011).  
 
The usefulness of immunization in preventing potentially life-threatening diseases in individuals and 
interrupting transmission within populations was recognized very early on as a tool to control and eradicate 
diseases worldwide (Backx and Freedman 2013). It is on this basis that WHO established the Expanded 
Program on Immunization (EPI) in 1974 as a platform for the delivery of routine childhood immunization (Chan 
2014; WHO 2013b; Okwo-Bele and Cherian 2012). A timeline summarizing key moments in the history of the 
EPI is provided in Table 2. 
 
Since the 1980s, WHO member states have progressively adopted the EPI into country-specific NIPs. These 
NIPs serve as a platform for the timely delivery of vaccines considered important for a given country (WHO 
2013b). Key services provided through NIPs include: routine universal childhood immunization, supplementary 
immunization activities including mass immunization campaigns, school-based and adolescent vaccination 
programs, introduction of new, improved or underused vaccines into existing NIPs, emergency vaccination 
responses to pandemic threats or disease outbreaks, and immunization services for at-risk populations such 
as health care workers, veterinarians, international travellers, pregnant women and the elderly (Walldorf et 
al. 2017; Feikin et al. 2016; WHO et al. 2009). 
 
 
 
 
 
 
 
 
                                                          
3 Immunization may be active; involving the administration of a vaccine to confer long term immune protection, or 
passive; involving the transfer of immunity from an immune to a non-immune host to confer short term immune 
protection. The term used throughout this thesis refers to active immunization. 
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Table 2: The expanded program on immunization over the past four decades 
Year Event 
Pre-1974  Edward Jenner reports on a process of vaccination that would protect against small pox in 1798 
 Development and licensure of vaccines against various diseases including small pox begins in earnest 
in the late 1800s 
 WHO launches a global small pox eradication program in 1967 
1974  Poor immunization coverage rates recorded; estimated at < 5% in LMICs 
 Building on the small pox eradication program infrastructure, WHO launches the EPI with the 
objective of ensuring that children throughout the world have access to much needed vaccines 
 Four vaccines are included in the EPI to protect against six childhood deadly diseases; diphtheria, 
tetanus, tuberculosis, measles, polio, and whooping cough   
 Health systems in LMICs at this time are relatively weak or non-functional 
1975 – 1980   Last case of small pox recorded in Merca District, Somalia in 1977 
 A goal is set to make immunization against the six childhood deadly diseases available to every child 
in the world by 1990 
 EPI is progressively adopted by all WHO member states 
1981 – 1986  WHO establishes a standardized immunization schedule in 1984, to be adopted by member states 
for their NIPs  
1987 – 1992  In 1987, ≥700 000 measles-related deaths averted in LMICs by immunization 
 World Health Assembly (comprising all Ministers of Health of all member states) passes a resolution 
in 1988 to eradicate polio by 2000 
 Goal of universal access to immunization is not achieved by 1990 
 Move by most LMICs to institutionalize country-specific immunization programs (or NIPs) based on 
the EPI blueprint 
 In 1991, an amended global target of vaccinating 80% of the world’s children is achieved 
1999 – 2004  WHO establishes the Strategic Advisory Group of Experts (SAGE) on Immunization in 1999 tasked 
with providing WHO with guidance on global policies and strategies 
 In 2000, GAVI is established to support EPI in some LMICs with the intent of extending the reach of 
childhood immunization. GAVI’s financial support of key immunization services in LMICs is a game-
changer in the history of EPI 
 Goal to eradicate polio by 2000 is not achieved. Wild type polio infections remain prevalent in some 
LMICs 
2005 – 2010  In 2005, WHO recommends inclusion of vaccines against Haemophilus influenzae type b, and 
hepatitis B into EPI schedules worldwide 
2011 – 2014  Global immunization coverage in <1-year-olds estimated at 85% by 2011 
 The Global Vaccine Action Plan (GVAP) is implemented in 2011 with a vision to ensure that all children 
in the world have access to life saving vaccines by 2020 
 By 2014, cases of wild type polio infections are reduced globally by 99%, and 80% of the world is 
certified polio-free 
 WHO recommends all NIPs include vaccines against human papillomavirus (HPV), rotavirus, rubella, 
and Streptococcus pneumoniae 
2018  WHO recommends use of new typhoid conjugate vaccine targeted at children ≥6 months of age, 
making early prevention of typhoid possible 
Source; Author (Chan 2014; WHO 2013b; Okwo-Bele and Cherian 2012; Keja et al. 1988) 
 
The public health impact of NIPs in LMICs 
Vaccine preventable diseases are widely recognized as the chief cause of childhood morbidity, disability and 
mortality worldwide (Brenzel 2015; WHO 2013b; Andre et al. 2008). The highest burden of vaccine preventable 
diseases has historically been recorded in LMICs (WHO 2018b; Dbaibo et al. 2016; Brenzel 2015; Gentile et al. 
2010; Miller and Sentz 2006). However, since the advent of universal childhood immunization in 1974, WHO 
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estimates that globally, 2 – 3 million deaths related to vaccine preventable diseases are averted each year. 
This positive impact can be largely attributed to the success of NIPs in reducing the high burden of vaccine 
preventable diseases, particularly in LMICs (Feikin et al. 2016; Chan 2014; WHO 2013b; Okwo-Bele and Cherian 
2012). Some of the greatest public health gains recorded in the literature include the near-eradication of wild 
type polio, the marked progress towards elimination of measles, and a significant decline in under-five 
mortality due to measles, tetanus, diphtheria, pertussis and rotavirus-related diarrhoea (WHO 2018c; Sindhu 
et al. 2017; Feikin et al. 2016; Dbaibo et al. 2016; SAGE 2016; Toole 2016).  
 
Despite the significant progress made, LMICs still have some way to go in controlling the existing burden of 
vaccine preventable diseases (Dbaibo et al. 2016; Toole 2016; SAGE 2016). In the 2016 midterm review of the 
progress made towards universal access to immunization, the Strategic Advisory Group of Experts on 
Immunization (SAGE) highlighted countries like South Sudan, Syria and Yemen, as those struggling to meet 
immunization targets. In these countries, the challenges faced are primarily a result of ongoing political conflict 
(SAGE 2016). The SAGE report also identified other challenges in countries without ongoing political conflict. 
For examples, in some LMICs with stable and predictable political environments, failure to provide reliable 
universal immunization services was associated with weak health systems, suboptimal governance structures, 
and failure to effectively integrate NIPs into routine primary health care (SAGE 2016).  
 
The successes and challenges of routine immunization in LMICs can be considered as a function of all the 
organizational and programmatic elements of NIPs (Shen et al. 2014). Shen et al. (2014) identify eight core 
elements of NIPs, namely; (1) policy, standards, and guidelines; (2) governance, organization, and 
management; (3) human resources; (4) vaccine, cold chain, and logistics management; (5) service delivery; (6) 
communication and community partnerships; (7) data generation and use; and (8) sustainable financing 
(Figure 1). For a well-performing NIP, these eight elements function within an enabling health system. Each of 
these elements are closely related and any weak link could potentially jeopardize the success of NIPs (Shen et 
al. 2014).  
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Figure 1: The critical components of national immunization programs [Source; Author, (drawing on Shen et al. 
2014)] 
 
The vaccine policy landscape in LMICs  
Where NIPs are concerned, the policy landscape often comprises of key decision-making by a network of 
expert advisory committees who operate at global, regional and country levels (WHO 2017). At the global 
level, the WHO, with the support of SAGE, develops policies, standards and technical guidelines on 
immunization priorities and strategies, and assists LMICs in adapting and implementing them (WHO 2017; 
Levine et al. 2011). National governments have the autonomy to generate country-level vaccine policies, 
drawing on WHO recommendations and the public health priorities of the country (Howard et al. 2018; WHO 
2017; Levine et al. 2011). In this regard, country-level policies address – among other issues – new vaccine 
introductions, immunization strategies (examples include the target populations and the vaccine supply 
chain), and NIP financing mechanisms (Pooripussarakul et al. 2016; Li et al. 2016; Levine et al. 2011). To ensure 
a standardized, transparent and accountable national vaccine policy-making process, the WHO recommends 
ENABLING 
HEALTH SYSTEM 
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that all member states commit to Regional Technical Advisory Groups on Immunization and establish National 
Immunization Technical Advisory Groups (NITAGs)4 by 2020 (WHO 2015; Duclos et al. 2013; Levine et al. 2011).  
 
The NITAGs have long been established in most high-income countries with remarkable outcomes for the 
performance of their NIPs (WHO 2017; Duclos et al. 2013). As at the end of 2016, 79 of 194 WHO member 
states5 reported having functional NITAGs that met all six process indicators6. Of this total, 50 were established 
in LMICs; 45 in middle-income countries and five in low-income countries (Howard et al. 2018; SAGE 2017). 
Despite the progress made in establishing NITAGs in LMICs, the technical capacity of newly founded groups is 
still lacking (Howard et al. 2018; SAGE 2017; Duclos et al. 2013). Howard et al. (2018) caution that without 
adequate financial and technical support, the effectiveness and sustainability of NITAGs in LMICs could be 
threatened.  
 
Governance, organization, and management of NIPs in LMICs  
Over the past four decades, the knowledge-base has evolved from considering governance of NIPs as the 
exclusive duty of national governments, to a shared responsibility, involving subnational or district 
governments, the communities they serve and development partners (Shen et al. 2014; WHO 2009a; Gauri 
and Khaleghian 2002). Governance functions may include, but are not limited to;  
 
…developing standards and guidelines; securing vaccine supply and distribution; preparing training 
materials and supervisory tools and implementing training; developing and carrying out 
communication strategies; planning the introduction of new vaccines; organizing immunization 
campaigns; collecting, analysing, and providing reports on vaccine coverage, disease surveillance, and 
budget execution; and maintaining relationships with external agency counterparts (Shen et al. 2014).  
 
To ensure a well-functioning NIP, it is proposed that these managerial and technical functions are devolved to 
the district level and executed through a bottom-up approach (Shen et al. 2014). Accordingly, WHO 
recommends exhaustive planning at the district level, detailing immunization strategies, resource needs, and 
monitoring and evaluation (Shen et al. 2014; WHO 2009a). Where district-level microplanning has been 
                                                          
4 A NITAG is an independent advisory body appointed to inform national immunization policy by providing expert 
recommendations to the government.  
5 Overall, 124 countries reported the existence of a NITAG at various stages of development. Of the 70 countries that 
did not report the existence of a NITAG, 31 were in the African region. 
6 The six process indicators pertain to the existence of a NITAG, (i) with formal terms of reference, (ii) with a legislative 
or administrative basis, (iii) with ≥ five areas of expertise represented, (iv) that meets at least once a year, (v) whose 
agenda and background documents are distributed ≥ one week prior to meetings and (vi) whose members are required 
to disclose conflicts of interest. 
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implemented, a strengthening effect on routine immunization services and the broader health system has 
been reported (Ismail et al. 2017; O'Connell and Wonodi 2016; Diamenu and Eshetu 2005). Shen et al. (2014) 
argue however that the success of district-level governance in the most dependent LMICs is often challenged 
by weak capacity of district health managers as well as resource constraints. Approaches to mitigate these 
challenges in resource-limited LMICs have been proposed and include the strengthening of Inter-agency 
Coordinating Committees to harmonize planning and mobilization of technical, material and financial inputs 
from all stakeholders (Shen et al. 2014; Grundy 2010). In addition to this, it is recommended that countries 
maximize their links with technical advisory bodies and development partners (Shen et al. 2014). 
 
The human resource capacity of NIPs in LMICs  
As NIPs mature and cater for continuously evolving immunization services, the need for an adequate and well-
trained human resource capacity also increases. The capacity of the health workforce has been a major 
challenge in some LMICs. The shortage of health care workers within the sub-Saharan African region has been 
a persistent public health concern (WHO 2018c). Sub-Saharan Africa is known to be the region with the lowest 
number of health care workers (below the WHO target of 2.28 health care workers per 1 000 population) 
(Crisp and Chen 2014; Kinfu et al. 2009). In South Africa for example, staff shortages have been reported as a 
barrier to delivering effective immunization services (Tladi and Mothiba 2016). This means that the 
responsibility of delivering health services including routine immunization is often left to a lean health 
workforce. It has been suggested that NIPs have contributed to resolving the challenge with staff shortages. 
Kamso et al. (2016) found that by funding human resources, the Global Polio Eradication Initiative has 
contributed to narrowing the gap in the capacity of the health workforce within the African region. However, 
other studies report that immunization services such as mass immunization campaigns rather exacerbate the 
situation as health care workers are often absorbed during these campaigns (Bonenberger et al. 2015). 
 
One of the proposed solutions to the human resource problem in LMICs is to strengthen the capacity of the 
existing health workforce. This can be achieved by effectively integrating NIPs into routine primary health care 
and investing in innovative and appropriate training (Shen et al. 2014). For example, the use of training DVDs 
and mobile phones to improve communication and microplanning during immunization programs has been 
piloted in several LMICs with successful outcomes (Ismail et al. 2017; Stokx et al. 2016; Thapa et al. 2016; 
Xeuatvongsa et al. 2016). Aside from building technical capacity, it is also recommended that health care 
workers should be trained to value the importance of generating and using data for NIPs (Shen et al. 2014). In 
addition to this, it is important that health care workers value caregivers and provide acceptable immunization 
services to ensure that they return to complete the immunization schedule. Good immunization practice and 
values can be reinforced through regular and appropriate supervision (Shen et al. 2014). 
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The impact of new vaccine introduction on cold chain and logistics management  
Vaccine cold chain7 and logistics management requirements have drastically evolved as new and improved 
vaccines have been introduced into NIPs (Robertson et al. 2017; Lloyd and Cheyne 2017; Zaffran et al. 2012). 
Cold chain and logistics systems are necessary for storing, transporting, tracking and delivering potent 
vaccines. Most vaccines may permanently lose their potency or induce unintended immunological reactions if 
kept at inappropriate temperatures. Thus, cold chain and logistics systems should consistently meet stringent 
international requirements (Shen et al. 2014; Zaffran et al. 2012). Poorly managed vaccine cold chain and 
logistics systems undermine the performance of NIPs by compromising the potency and availability of 
vaccines. In some low-income countries with already weak vaccine supply chains, introduction of new vaccines 
often becomes an added burden (Brison and LeTallec 2017; Zaffran et al. 2012).  
 
Financing and managing the vaccine cold chain is usually a country-led initiative (Shen et al. 2014). In LMICs, 
this is often wrought with challenges as national governments have other health and non-health programs 
competing for financial resources. Diverting resources to competing priorities compromises the vaccine supply 
chain (Brison and LeTallec 2017; Shen et al. 2014). A review of the evidence shows that while LMICs have made 
substantial progress in financing and managing their cold chain systems, key targets are yet to be met (Brison 
and LeTallec 2017; Ogboghodo et al. 2017; Lee et al. 2016; Torres-Rueda et al. 2015). Studies conducted in 
LMICs suggest that vaccine systems strengthening will require scaling-up cold chain management training for 
health care workers, reinforcing appropriate supervision, and investing in state-of-the-art cold chain 
equipment (Ogboghodo et al. 2017; Brison and LeTallec 2017; Eriksson et al. 2017; Lee et al. 2016; Zaffran et 
al. 2012). Where these measures have been adopted, reductions in vaccines stock-outs and improved access 
to, and coverage of vaccines have been reported (Guillermet et al. 2017; Prosser et al. 2017). Other innovative 
approaches have sought to alleviate the demands on already overburdened health care workers and also 
circumvent resource limitations in LMICs by developing thermostable vaccines with minimal cold chain 
requirements (Zipursky et al. 2014; WHO 2012; Braun et al. 2008).  
 
Vaccine service delivery in LMICs  
The evidence-base on NIPs in LMICs is heavily focused on vaccine service delivery. This is because the quality 
of vaccine service delivery is recognized as integral to vaccine accessibility which impacts on the rate of 
immunization coverage (Shen et al. 2014). Findings from the SAGE 2016 midterm review indicate that global 
immunization coverage has stalled in recent years, increasing by only 1% between 2010 and 2015 (SAGE 2016). 
This is substandard when compared to the immunization coverage rates recorded between 2000 and 2008, 
                                                          
7 Cold chain equipment include active refrigeration systems like cold and freezer rooms for main storage, as well as 
passive systems which include refrigerated vehicles, cold boxes and vaccine carriers for the delivery of vaccines. 
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which consistently increased from 73% to 82% (SAGE 2016). Substantial global disparities in immunization 
coverage have been identified as contributing to the observed stagnation (SAGE 2016). The impact of political 
instability and weak health systems on immunization coverage rates in some countries have been addressed 
previously (see Public health impact of NIPs in LMICs). There is further evidence to suggest that significant 
inequalities in accessing vaccines still exist in some LMICs (Arsenault et al. 2017). These inequalities are 
perpetuated by underlying socioeconomic dimensions. At the country level, poverty has been cited as the 
single most important barrier to vaccine access (Arsenault et al. 2017). At the individual level, maternal factors 
such as old age and low level of education have been identified to influence immunization seeking behaviour 
(Arsenault et al. 2017; Gibson et al. 2015). As it stands, the goal of reaching universal immunization coverage 
by 2020 may not be achieved without effective scale-up of vaccine service delivery in LMICs (SAGE 2016). 
 
The suggested strategies to improve equity in vaccine service delivery include intensifying efforts to extend 
access to hard-to-reach populations like rural communities, the under-immunized8 and the unimmunized9 
(Arsenault et al. 2017; SAGE 2016; Shen et al. 2014). Uddin et al. (2015) evaluated the impact of a mobile 
phone intervention for improving immunization coverage rates in rural, hard-to-reach communities in 
Bangladesh. The study found that text message reminders of immunization dates sent to caregivers 
significantly improved immunization coverage rates within the population (Uddin et al. 2015). A similar 
positive impact was observed in rural communities in the Lao People’s Democratic Republic (Xeuatvongsa et 
al. 2016). In Kenya and the Philippines, text reminders did not only improve immunization coverage rates but 
also increased adherence to national immunization schedules (Garcia-Dia et al. 2017; Gibson et al. 2017). 
 
The state of vaccine communication and community partnerships in LMICs  
Vaccine uptake is also greatly influenced by public trust in vaccines as well as how the public values NIPs 
(Kaufman et al. 2017; Ozawa, Grewal et al. 2016; Shen et al. 2014). Public trust in vaccines can be encouraged 
through advocacy, education, and social and community mobilization. Vaccine communication and 
community mobilization have been gaining popularity in the NIP ‘blueprint’. This is because they are 
increasingly being recognised as key strategies for promoting the use of immunization services (Shen et al. 
2014; Waisbord and Larson 2005). Kaufman et al. (2017) developed a comprehensive framework integrating 
communication interventions from both routine immunization and immunization campaign contexts. Based 
on this framework, the purpose of vaccine communication was to, “inform or educate; remind or recall; 
enhance community ownership; teach skills; provide support; facilitate decision making and enable 
                                                          
8 Under-immunized refers to children whose immunization status is suboptimal for their age according to the 
recommended immunization schedule. 
9 Unimmunized refers to children who have never received the recommended vaccines. 
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communication” (Kaufman et al. 2017). Health care workers serve as one of the most influential sources of 
information on vaccines and immunization. Essentially, the quality of vaccine communication provided by 
health care workers is integral to caregivers’ decision-making. However, it is reported that health care workers 
in some LMICs are ill-equipped to perform this role (Shen et al. 2014; Waisbord and Larson 2005). Accordingly, 
Chama-Chiliba et al. (2017) found that poor communication between health care workers and caregivers in 
Zambia contributed to dissatisfaction with immunization services. 
 
The available literature concurs that vaccine communication can be improved through locally adapted and 
appropriate strategies (Habib et al. 2017; Bedford et al. 2017; Gopichandran 2017; Shen et al. 2014). The 
importance of providing health care workers with adequate training and supervision cannot be overstated. In 
addition to this, there is a need to encourage community engagement throughout the design and 
implementation of immunization services. Community participation has been shown to improve the 
performance of NIPs, even during major health and political crises as reported by Bedford et al. (2017) and 
Habib et al. (2017) respectively. 
 
Gopichandran (2017) suggests that it is through continuous community engagement that public trust in 
vaccines can be encouraged. The level of trust in vaccines is varied worldwide. While vaccine hesitancy is 
prevalent in some high-income countries where the burden of vaccine preventable diseases is low, the trust 
in, and demand for, vaccines is relatively high in LMICs (Shen et al. 2014). Thus, interventions targeted at 
increasing vaccine acceptability in LMICs will generally require renewed investments in vaccine 
communication in order to counter any misinformation (Gopichandran 2017; Shen et al. 2014). 
 
Immunization data generation and use in LMICs  
High quality and reliable immunization data is central to informing policy and programmatic decisions. Two 
main sources of immunization data are identified in the literature, namely the national Demographic and 
Health Surveys, and routine administrative reports (Shen et al. 2014). The challenge in some LMICs is the 
discrepancies in immunization data reported at local, district and national levels, compared to those reported 
by WHO (Shen et al. 2014). In Brazil, for example, Novaes et al. (2015) identified frequent discrepancies in 
immunization coverage data recorded at the local facility level, compared to that recoded through an 
established national system. Errors in reporting immunization data have been attributed to poor supervision 
and the inaccurate use of denominators. In other instances, countries fabricate reports in order to appear to 
meet immunization targets (Shen et al. 2014). This significantly impedes the appropriate use of immunization 
data in improving the performance of NIPs in these countries (Shen et al. 2014). 
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In an effort to strengthen immunization data generation and use in all member states, WHO and the United 
Nations Children's Fund encourage reporting national data through a joint reporting process (Shen et al. 2014). 
Home-based immunization records and immunization registries have proven to be useful in ensuring reliable 
data collection at the country level (Kriss et al. 2016; Novaes et al. 2015; Shen et al. 2014). In addition, disease 
surveillance systems such as the Global Measles and Rubella Laboratory Network support active surveillance 
in several LMICs (Xu et al. 2017; Shen et al. 2014).  
 
Financing NIPs in LMICs 
There is much in the published literature about the cost-effectiveness of delivering effective routine 
immunization services in LMICs (Menzies et al. 2017; Aljunid et al. 2016; Mogasale et al. 2016; Ahanhanzo et 
al. 2015; Portnoy et al. 2015; Alkoshi et al. 2014; Castañeda-Orjuela et al. 2013; Bakır et al. 2012; Babigumira 
et al. 2011; Bishai et al. 2011). The available evidence demonstrates rising costs of financing NIPs in LMICs as 
programs expand to include new vaccines, and reach larger populations and extended age groups (Ozawa, 
Grewal et al. 2016; Brenzel 2015; Portnoy et al. 2015). It is reported that the bulk of funding for NIPs is often 
required to finance vaccine service delivery, procurement of vaccines, and maintenance of cold chain and 
logistics systems (Geng et al. 2017; Ozawa, Grewal et al. 2016). Historically, financing NIPs has been challenging 
in LMICs on account of budget constraints (Brenzel 2015). National governments face mounting pressure with 
allocating limited resources to both health and non-health sectors. Without appropriate financing mechanisms 
dedicated to NIPs, large populations in LMICs may not be able to access lifesaving vaccines (Ozawa, Grewal et 
al. 2016; Brenzel 2015).  
 
The Pan American Health Organization’s (PAHO) revolving fund was established in 1977 to assist the 41 
countries and territories in the Americas to finance their NIPs (PAHO 2015). Through the PAHO revolving fund, 
member states pool their limited resources to procure high quality vaccines at discounted prices (PAHO 2015). 
More recently in 2000, an innovative financing mechanism known as GAVI10 was established to assist 73 of the 
most dependent LMICs worldwide to finance procurement, and introduction of new and underused vaccines 
into their NIPs (Kallenberg et al. 2016; Brenzel 2015). The establishment of GAVI has been a watershed 
moment in the history of the EPI. According to Kallenberg et al. (2016) the period since its inception has seen 
rapid uptake of vaccines in GAVI-funded LMICs, a significant contribution to the control of vaccine preventable 
diseases worldwide. 
 
                                                          
10 The GAVI alliance includes the World Bank, WHO, the United Nations Children's Fund, and the Bill and Melinda Gates 
Foundation. 
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To maximize the reach of GAVI funds and ensure that the poorest countries have access to the assistance they 
need, GAVI has set an eligibility threshold (gross national income of US$1,000 per capita) beyond which 
countries will have to transition out of GAVI support. In 2015, the first 20 LMICs11 entered the transition phase 
of GAVI funding (Kallenberg et al. 2016). By the end of the GAVI funding period, these countries are expected 
to self-finance all their vaccines and will join some 40 middle-income countries who were never eligible for 
GAVI support (Kallenberg et al. 2016).  
 
Ghana is a prime example of a GAVI-funded country that experienced a rapid increase in its gross national 
income (estimated at $1 480 in 2015) and crossed the GAVI eligibility threshold 15 years earlier than predicted 
by the International Monetary Fund (Kallenberg et al. 2016). During its time as a GAVI funded country, Ghana 
has been able to introduce eight new vaccines into its NIP. After 2019, Ghana will have to come to terms with 
a rapid decline in GAVI support and will have to take necessary steps towards self-financing its NIP (Kallenberg 
et al. 2016). 
 
Health systems in LMICs 
It has been suggested that health programs like NIPs, are only as effective as the health systems in which they 
are embedded (Atun et al. 2008; Kruk and Freedman 2008; WHO 2007; Mills et al. 2006). According to the 
WHO (2007) the term health systems refers to a collective of “all organizations, people and actions whose 
primary intent is to promote, restore or maintain health”. The dimensions and overall goals of health systems 
are presented in Figure 2. 
 
                                                          
11 Countries that entered the transition phase of GAVI funding I 2015 are Cameroon, Côte d’Ivoire, Djibouti, Ghana, 
India, Kyrgyzstan, The Lao People’s Democratic Republic, Lesotho, Mauritania, Nicaragua, Nigeria, Pakistan, Papua New 
Guinea, Sao Tome and Principe, Senegal, The Solomon Islands, South Sudan, Sudan, Yemen, and Zambia. 
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Figure 2: The WHO health systems framework [Source; Author, (drawing on WHO 2007)] 
 
These dimensions are not mutually exclusive, but exist in a constant dynamic interaction to achieve optimal 
health systems functioning (WHO 2007). De Savigny and Adam (2009) describe this dynamic interaction among 
the six health systems dimensions as, “how one [dimension] affects and influences the others, and is in turn 
affected by them”. Essentially, this dynamic interaction is non-linear, but rather a complex relationship among 
the six dimensions, giving rise to a system (Sheikh et al. 2011; de Savigny and Adam 2009).  It is important to 
note however that the determinants of a well-performing health system go beyond these six dimensions to 
include the broader context within which they are situated (van Olmen et al. 2012; WHO 2007). 
 
The dynamism of health systems is such that even countries with similar levels of income, education and health 
expenditure differ in their ability to attain key health goals (Papanicolas and Jha 2017; WHO 2007). As such, 
health systems contexts matter in how the performance of national and international health sectors are 
assessed (WHO 2009b; WHO 2007). The evidence-base is in agreement that there is no single blueprint of 
ideal health systems performance that cuts across all country-contexts (Papanicolas and Jha 2017; Atun 2012; 
WHO 2009b; WHO 2007). However, well-performing health systems have shared characteristics, and these 
may include, 
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Procurement and distribution systems that actually deliver interventions to those in need. They are 
staffed with sufficient health workers having the right skills and motivation. And they operate with 
financing systems that are sustainable, inclusive, and fair (WHO 2007). 
 
While these characteristics may be true of most health systems in high-income countries, this is not always 
the case in LMICs. Historically, the health systems of some LMICs have been characterized by poor governance, 
weak organizational and institutional capacity, and fragile health infrastructure (including financial, physical 
and human resources) (WHO 2018c; Swanson et al. 2015; Mills 2014; Olafsdottir et al. 2011; Mills et al. 2006). 
Health systems in LMICs are further challenged by a disproportionate burden of diseases like malaria, 
HIV/AIDS, tuberculosis, and other vaccine preventable diseases (WHO 2018c). Altogether, these systems 
weaknesses mean that the quality of health service delivery has been less than desirable, and key health 
targets12 are often difficult to achieve (Phillips et al. 2015; WHO 2009c; Mills et al. 2006; Ranson et al. 2003; 
Hanson et al. 2003).  
 
Within the past three decades, growing concerns for the state of health systems in LMICs have spurred an 
expansion in research and interventions aimed at strengthening health systems (Phillips et al. 2015; Mills 2014; 
Atun 2012; Adam et al. 2012; Mills et al. 2006). Innovative approaches to strengthening health systems in 
LMICs have become even more imperative considering the substantial technical and financial investments 
directed at disease-specific health programs13 (Mills 2014; Atun 2012; Balabanova et al. 2010). Accordingly, 
major development partners like GAVI, the Global Fund to Fight AIDS, Tuberculosis and Malaria (The Global 
Fund), and the United States President’s Emergency Plan for AIDS Relief, increasingly encourage the inclusion 
of health systems strengthening proposals as part of countries’ funding applications (Mills 2014; WHO 2009c).  
 
Health systems strengthening is often targeted at sustained improvements to performance drivers such as 
governance, organizational, and institutional structures in order to achieve and sustain better health services 
and health outcomes (Swanson et al. 2015; Chee et al. 2013; WHO 2007). Ultimately, comprehensive health 
systems strengthening initiatives are those that continuously improve on all six dimensions of the health 
system while managing the dynamic interactions among them (WHO 2011; WHO 2007). While major 
development partners aim for this level of health systems strengthening within the LMICs they support, there 
has been some criticism that disease-specific investments only achieve incomplete success because wider 
                                                          
12 According to the WHO, global health targets may be grouped into seven thematic areas; (i) reproductive, maternal, 
new born and child health; (ii) infectious diseases; (iii) non-communicable diseases and mental health; (iv) injuries and 
violence; (v) universal health coverage and health systems; (vi) environmental risks; (vii) health risks and disease 
outbreaks. 
13 These are often vertical health programs targeted at priority disease conditions like malaria, HIV/AIDS, tuberculosis, 
and vaccine preventable diseases. 
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health services often remain underfunded and weakly supported (Mills 2014; Chee et al. 2013). Additionally, 
it has been suggested that the plurality of disease-specific health programs places further demands on already 
fragile health systems in LMICs (Balabanova et al. 2010; WHO 2009c; Marchal et al. 2009; Kallings 2008).  
 
It is undeniable that sustained investments in disease-specific health programs have significantly improved 
health systems and health outcomes in most LMICs (Balabanova et al. 2010; WHO 2009c; Marchal et al. 2009). 
However, it has been argued that investments in these disease-specific programs have largely achieved health 
systems support more than systems-wide strengthening (Chee et al. 2013; Marchal et al. 2009). The long-term 
goal is to yield maximum health returns on the investments made in disease-specific health programs in LMICs. 
This is most likely to be achieved by continuously strengthening health systems to be effective, efficient and 
responsive (Marchal et al. 2009; Mills et al. 2006). Taken together, it is not surprising that there is great interest 
in the interaction between disease-specific health programs and the health systems that deliver them, and 
how this interaction impacts on health systems performance (WHO 2009c). 
 
The interface between NIPs and health systems in LMICs  
By reviewing the existing evidence-base it is clear that NIPs are not restricted to the Medical Products, Vaccines 
and Technologies dimension of the health system. Instead, the eight components of NIPs continuously operate 
and interact across all six dimensions of the health system. Where this interaction between NIPs and health 
systems is concerned, some studies have shown that NIP services such as new vaccine introductions and 
supplementary immunization activities like mass immunization campaigns, may have both positive and 
negative impacts on health systems in LMICs (Postolovska et al. 2018; Andrus et al. 2016; Wang et al. 2013; 
Hyde et al. 2012).  
 
Over and above the established public health impact of immunization, Lahariya et al. (2016) found that new 
vaccine introductions into the Indian NIP improved health equity, as well as the efficiency and utilization of 
wider health services. Hyde et al. (2012) also reports that introducing new vaccines into country NIPs facilitates 
the widespread use of new technologies like auto-disable syringes and state-of-the-art cold chain systems, 
within the broader health system. Furthermore, reports of capacity development for health care workers and 
expansion of health services as a consequence of introducing new vaccines in LMICs have also been sufficiently 
documented in the literature (Torres-Rueda et al. 2015; Nyirenda et al. 2014; Burchett et al. 2014). In the case 
of supplementary immunization activities, there have been significant opportunities to strengthen political 
support for national and international health targets, scale-up disease surveillance systems, and improve 
health communication and social mobilization (Andrus et al. 2016; Mounier-Jack et al. 2014; Closser et al. 
2014). 
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Where negative influences on the health system have been reported, these have been moderate and often 
short-lived (Postolovska et al. 2018; Torres-Rueda et al. 2015). For example, it has been reported that intensive 
immunization campaigns sometimes disrupt routine health services by diverting limited financial, technical 
and human resources from them. This negatively impacts health access and contributes to reduced volumes 
of consultations in primary health care facilities for the duration of the campaigns (Bonenberger et al. 2015; 
Mounier-Jack et al. 2014; Verguet et al. 2013; Loevinsohn et al. 2002). Over the long term however, such 
moderate negative impacts could have substantial cumulative system-wide effects, some of which may be 
unintended (Mounier-Jack et al. 2014). In their investigation of the interaction between polio eradication 
campaigns and the health system, Closser et al. (2015) found increased public distrust in the Pakistani health 
system. This is because the national government appeared willing to provide door-to-door polio immunization 
while other basic needs remained unmet (Closser et al. 2015). It has been suggested that distrust in the health 
system eventually spills over into immunization systems and negatively influence NIP performance (Ozawa, 
Paina et al. 2016). It is important to caution however, that most negative effects are observed in countries 
with unstable health systems, while developed health systems are able to withstand disruptions or avoid them 
altogether (Wang et al. 2013; Hanvoravongchai et al. 2011).  
 
Very limited systematic evidence comprehensively explores the interface between NIPs and health systems 
from a health systems perspective. Where evidence is available, the focus is narrow, and key aspects such as 
the governance and information systems dimensions are not fully explored (Bosch-Capblanch et al. 2011). 
Given the interaction between NIPs and their health systems, it can be expected that certain health systems 
facilitators or barriers could have a knock-on effect on the performance of NIPs. For example, it has been 
reported that strengthening wider health services increases vaccine uptake in LMICs (Vélez et al. 2014). 
Additionally, health systems barriers to well-performing NIPs have been identified, and include weak health 
infrastructure, inequitable financing mechanisms and unresponsive health services (Nishtar et al. 2013; 
Grundy and Moodie 2009). It may be worth conducting an in-depth exploration of these health systems 
facilitators and barriers. Such evidence could expand our understanding of the challenges experienced in 
scaling-up NIPs in some LMICs.  
 
This scoping review does not suggest that empirical research studies exploring the interface between NIPs and 
their health systems should always examine all six dimensions of the health system. However, by adopting a 
comprehensive health systems approach that factors in all six dimensions, it is possible to identify potential 
health systems constraints or facilitators which impact on the performance of NIPs in LMICs (Lahariya 2015; 
Adam et al. 2012). In relation to this, Bosch-Capblanch et al. (2011) suggest that high quality systematic 
evidence on health systems in LMICs is generally scarce. Additionally, the limited evidence that is available 
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does not adequately meet the needs of immunization managers and key decision-makers (Bosch-Capblanch 
et al. 2011). Generating evidence on the performance of health systems for stakeholders involved in NIPs 
would require some guidance from an appropriate framework. While there are several analytical and strategic 
frameworks proposed for assessing the performance of health systems, these frameworks differ in their 
starting points, operationalization, as well as process and outcome measures (Mounier-Jack et al. 2014; WHO 
2011; Kruk and Freedman 2008; Arah et al. 2003; Murray and Evans 2003; Murray and Frenk, 2000). It is also 
established that no single framework can holistically evaluate the interaction between disease control 
interventions and the health system (Mounier-Jack et al. 2014). It is for these reasons that we propose the 
logic model shown in Figure 3 for an in-depth assessment of the interface between NIPs and health systems. 
This logic model takes into full consideration, the eight components of NIPs as described by Shen et al. (2014) 
and all six dimensions of the health system (WHO 2007) which gives rise to six cross-cutting themes, namely; 
(i) the governance and policy landscape, (ii) the capacity of the health workforce, (iii) the availability of potent 
vaccines, cold chain, and logistics systems, (iv) the quality of health service delivery, (v) the state of health 
information systems and community partnerships, and (vi) the availability of equitable and sustainable health 
financing. In addition to this, unique regional and country-level contexts have been factored into the logic 
model. The reasoning behind this logic model is that the interaction among the six cross-cutting themes – 
which are influenced by underlying contextual factors – will determine whether key NIP targets (like optimal 
immunization coverage and improved population health) are attained. 
  
PART B: Scoping Review 
 
19 
 
 
Figure 3: A logic model for in-depth assessment of the interface between NIPs and health systems [Source; Author] 
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Theme 1: The governance and policy landscape 
Theme 2: The capacity of the health workforce 
Theme 3: The availability of potent vaccines, cold chain, and logistics systems 
Theme 6: The availability of equitable and sustainable health financing 
Theme 5: The state of health information systems and community partnerships 
Theme 4: The quality of health service delivery 
Health systems dimension: leadership, governance, and stewardship 
NIP component: vaccine policy, standards, and guidelines 
Health systems dimension: overall health workforce 
NIP component: NIP human resource capacity 
Health systems dimension: medical products, vaccines and technologies 
NIP component: vaccines, cold chain, and logistics management 
Health systems dimension: health (and other health-related) service delivery 
NIP component: vaccine service delivery 
Health systems dimension: health information 
NIP component: data generation and use, communication and community partnership 
Health systems dimension: health financing 
NIP component: sustainable NIP financing 
Overall NIP Outcomes / Goals 
  
Optimal Immunization coverage 
• Universal access to safe, 
potent vaccines; increase 
access, extend reach and 
expand target age groups 
where necessary 
• Efficient, equitable, 
responsive and acceptable 
vaccine service delivery 
  
Improved population health 
• Improved population 
immunity to vaccine 
preventable diseases  
• Reduced incidence of vaccine 
preventable diseases 
• Decline in rates of morbidity, 
disability and mortality 
associated with vaccine 
preventable diseases 
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Conclusion 
The positive public health impact of NIPs in LMICs, at least over the past four decades (1974 – 2018) of the 
EPI, is irrefutable. It is evident that in order to sustain and improve on the gains achieved thus far, there is a 
need for robust evidence to inform ongoing health systems strengthening initiatives in LMICs. This much 
needed evidence includes information on how health systems constraints and facilitators impact on the 
performance of NIPs in LMICs. This scoping review therefore argues for a systematic and comprehensive 
assessment of the interaction between NIPs and health systems in LMICs, with a focus on how health systems 
functioning impacts on the performance of NIPs.  
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Abstract 
Given the vast investments made in national immunization programs (NIPs) and the significance of NIPs to 
public health, it is important to understand what influences the optimal performance of NIPs. It has been 
established that well-performing NIPs require enabling health systems. However, systematic evidence on how 
the performance of health systems impacts on NIPs is lacking, especially from sub-Saharan Africa. We 
conducted a qualitative systematic review to synthesize the available evidence on health systems constraints 
and facilitators of NIPs in sub-Saharan Africa, using human papillomavirus (HPV) immunization programs as a 
proxy. Fifty-four articles published between 2008 and 2018 were found to be eligible. Data extraction was 
guided by a logic model on the interface between NIPs and health systems. A cross-cutting thematic analysis 
of the extracted data was performed. This systematic review provides evidence necessary for informing 
ongoing health systems strengthening initiatives in sub-Saharan Africa. There is evidence to suggest that NIPs 
in sub-Saharan Africa have surmounted significant health systems constraints and have achieved notable 
public health success. This success can be attributed to strong political endorsement for vaccines, clear 
governance structures and effective collaboration with global partners. Despite this, significant health systems 
constraints persist in service delivery, vaccine communication, community engagement, the capacity of the 
health workforce and sustainable financing. These constraints could derail further progress if not addressed 
through health systems strengthening efforts. There is a need to expand the research agenda to include 
comprehensive evaluation of health systems constraints and facilitators of NIPs within sub-Saharan Africa. 
 
Keywords 
Africa; Cervical cancer; Health systems; Human papillomavirus; HPV vaccine; Immunization; National 
Immunization Programs  
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Introduction 
It has become increasingly apparent that some of the major challenges experienced in scaling-up the 
performance of national immunization programs (NIPs) in low- and middle- income countries (LMICs) are not 
necessarily program-specific, but rather challenges in wider health systems functioning (SAGE 2016). This is in 
line with the notion that NIPs exist in a continuous interaction with the health systems that deliver them (SAGE 
2016; Shen et al. 2014; Samb et al. 2009). As such, major health systems constraints could have a significant 
impact on how NIPs perform. For example, financial, technical, logistical, political and socioeconomic 
constraints have all been cited as negatively impacting on the overall performance of NIPs in LMICs (SAGE 
2016). Unfortunately, these health systems constraints on effective NIP performance appear to be even more 
prevalent within the sub-Saharan Africa region (SAGE 2016).  
 
In sub-Saharan Africa, NIPs have undergone steady advancements since the establishment of the Expanded 
Program on Immunization in 1974 (WHO 2013a). Tremendous progress has been made in increasing access to 
lifesaving vaccines and reducing the burden of vaccine preventable diseases in the region (Machingaidze et al. 
2013; Arevshatian et al. 2007). Despite this, sub-Saharan Africa continues to lag in meeting global 
• National immunization programs (NIPs) are embedded within health systems. However, the 
interactions between NIPs and health systems are poorly understood. 
• This systematic review provides evidence of how NIPs and health systems interact by reporting on 
the health systems constraints and facilitators of NIPs in sub-Saharan Africa. 
• Strong political will, clear governance structures and effective collaboration with global partners 
have been major facilitators of NIPs in sub-Saharan Africa. 
• Despite this, significant health systems constraints persist in service delivery, vaccine 
communication, community engagement, the capacity of the health workforce and sustainable 
financing.  
• The findings of this review have relevance for ongoing health systems strengthening initiatives in 
sub-Saharan Africa, especially where NIPs are concerned. By providing a better understanding of 
what works – and does not work – for NIPs, health systems strengthening initiatives could be better 
designed to adequately respond to the burden of vaccine preventable diseases in sub-Saharan 
Africa. 
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immunization targets (Mihigo et al. 2017; SAGE 2016). Although substantial investments have been dedicated 
to NIPs in sub-Saharan Africa, this has not been enough to improve their performance to the levels required 
to significantly reduce the disproportionate burden of vaccine preventable diseases in the region. In this 
regard, global actors have recognized the harrowing state of health systems within sub-Saharan Africa as a 
major barrier to achieving further progress in improving the performance of NIPs (SAGE 2016). This has 
contributed to making health systems strengthening in sub-Saharan Africa a matter of global public health 
priority (SAGE 2016). It has been argued however, that while ongoing health systems strengthening efforts are 
absolutely vital, they have not been able to achieve their intended outcomes (Chee et al. 2013; Marchal et al. 
2009). Some of the challenges faced have been attributed to the fact that health systems constraints are not 
adequately defined and as such interventions are often poorly designed and weakly targeted in the long term 
(Chee et al. 2013; Goeman et al. 2010; Marchal et al. 2009). Systematic evidence on how health systems 
constraints (and facilitators) impact on the performance of NIPs in sub-Saharan African could be very useful in 
better informing health systems strengthening efforts in the region. Unfortunately, such evidence is lacking. 
We report on a systematic review study which sought to determine how health systems constraints and 
facilitators impact on the performance of NIPs in sub-Saharan Africa. Given that NIPs serve as a platform for 
the delivery of several immunization services (these include routine childhood immunization programs, 
adolescent immunization programs, mass immunization campaigns, emergency vaccination services and 
introduction of new, improved or underused vaccines into existing NIPs), an in-depth review incorporating the 
mass of these services would not be appropriate. As such, a single immunization program – the human 
papillomavirus (HPV) immunization program – was selected as a proxy or tracer immunization program for the 
purpose of this systematic review. Our interests in HPV immunization programs stem from the fact they 
present a unique challenge to health systems in sub-Saharan Africa compared to routine childhood 
immunization programs. Foremost is the fact that HPV vaccines are not widely accessible through NIPs in most 
sub-Saharan Africa countries as compared to other regions of the world (see Figure 1 and Appendix 1 for 
further details). 
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Figure 1: Global progress in the implementation of nationwide HPV immunization programs 
Note: Data from countries with planned or partial HPV vaccine introduction, or HPV vaccine demonstration 
projects are not represented here [Source; Author, (drawing on data from http://www.hpvcentre.net, WHO 
2018a; Gallagher et al. 2018; LaMontagne et al. 2017; Herrero et al. 2015)]  
 
Three HPV vaccines are currently licensed for use; the four-valent3 vaccine was licensed in 2006, the bivalent 
vaccine in 2007 and the nine-valent vaccine in 2014 (WHO 2017a; Herrero et al. 2015). All three prophylactic 
HPV vaccines have been proven to be safe and effective against persistent HPV infections which lead to a 
broad spectrum of diseases and cancers (Garland et al. 2016; Herrero et al. 2015; Lu et al. 2011). In addition 
to this, all three vaccines confer immune protection against the HPV oncogenic types 16 and 18 which are 
implicated in 70% of all cervical cancers. Cervical cancer in turn, accounts for 84% of all HPV-associated cancers 
(WHO 2017b; WHO 2017a). Given the burden of the disease, the World Health Organization (WHO) recognizes 
prevention of cervical cancer as priority and recommends that member states introduce the HPV vaccine into 
their NIPs (WHO 2017b). The schedule recommended by WHO is two doses of the HPV vaccine, administered 
six months apart and prioritizing adolescent girls between the ages of nine and 14 years, prior to sexual debut 
(WHO 2017b). 
 
                                                          
3 This refers to the number of strains (or types) of HPV that are targeted in the vaccine. 
HPV vaccine introduced into NIP 
HPV vaccine not introduced into NIP 
Data unavailable 
PART C: Manuscript 
 
5 
 
As at November 2018, about 102 countries and overseas territories had established nationwide HPV 
immunization programs (WHO 2018b; WHO 2018a; Gallagher et al. 2018; LaMontagne et al. 2017; Herrero et 
al. 2015). Of this total, only 12 countries4 are in sub-Saharan Africa (Gallagher et al. 2018; LaMontagne et al. 
2017). Another major challenge is the fact that HPV immunization coverage rates in sub-Saharan Africa are 
reported to be among the lowest (1.2% among 10 – 20-year-old females) in the world (Bruni et al. 2016). This 
implies that a substantial proportion of adolescent girls are excluded from the full benefits of the HPV vaccine. 
This is most concerning, considering that cervical cancer incidence rates in the region are among the highest 
(31.0 per 100 000 women) in the world (de Martel et al. 2017; Louie et al. 2009). In addition, cervical cancer 
is one of the most common causes of cancer-related deaths among women in sub-Saharan Africa (De Vuyst et 
al. 2013). Evidently, the status of HPV immunization programs in sub-Saharan Africa is a matter of major public 
health concern. Expanding access to lifesaving HPV vaccines is a significant challenge for NIPs and health 
systems in the region (Wigle et al. 2013; Denny et al. 2012; Sankaranarayanan et al. 2012). There is an obvious 
need for intervention informed by evidence on the health systems constraints and facilitators of HPV 
immunization programs in sub-Saharan Africa. Such evidence is currently lacking and is worth exploring 
through systematic review methods. 
 
Methods 
A systematic review study was conducted to assess how health systems constraints and facilitators impact on 
the performance of NIPs in sub-Saharan Africa. For this purpose, an initial scoping review was performed to 
gain an in-depth understanding of the interaction between NIPs and health systems (see Part B). One of the 
primary outcomes of the scoping review was a logic model, describing the interface between NIPs and health 
systems, which addresses six cross-cutting themes, namely; (i) the governance and policy landscape, (ii) the 
capacity of the health workforce, (iii) the availability of potent vaccines, cold chain and logistics systems, (iv) 
the quality of health service delivery, (v) the state of health information systems and community partnerships 
and (vi) the availability of equitable and sustainable health financing. Drawing on the themes emanating from 
this logic model, a qualitative systematic review was conducted to address the following research question; 
How do health systems constraints and facilitators impact on the performance of HPV immunization programs 
in sub-Saharan Africa?  
  
A search strategy was developed using key search terms and search term synonyms which focused on three 
thematic areas; NIPs, health systems and HPV immunization programs. The full search strategy is available in 
Appendix 2. Using this search strategy, peer-reviewed and grey literature sources were sought through 
                                                          
4 Countries that have introduced the HPV vaccine into their NIPs are Angola, Botswana, Lesotho, Mauritius, Rwanda, 
São Tomé and Principe, Senegal, Seychelles, South Africa, Tanzania, Uganda, Zimbabwe. 
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electronic databases such as PubMed, Web of Science, Scopus and EBSCOhost. In addition, supplementary 
searches for literature sources which may have been missed during the initial electronic search were 
conducted through internet searches in Google Scholar as well as organizational websites like WHO 
(http://www.who.int/en/), GAVI, the Vaccine Alliance (https://www.gavi.org/) and the HPV Information 
Centre (http://www.hpvcentre.net/). The last date of the literature search was August 2018. 
 
With regards to the eligibility of studies for this review, only the full texts of empirical studies conducted and 
published between 2008 and 2018 were considered eligible for inclusion. This is because the past 10 years has 
been characterized by intensified global efforts to implement HPV immunization programs, especially in sub-
Saharan Africa (LaMontagne et al. 2017; Sankaranarayanan et al. 2012). Reviewing studies conducted within 
this period therefore enhanced the relevance of the review findings. Eligible studies also included those which 
used qualitative, quantitative and mixed method study designs. However, modelling studies, reviews, 
descriptive reports and commentaries reporting on secondary research findings were excluded from review. 
In addition, studies published in languages other than English were excluded because of the time and resource 
constraints on the thesis from which this systematic review emanated. Finally, studies reporting on 
interventions other than HPV immunization programs were excluded from the review. 
 
After selection, full texts of eligible studies were critically appraised for the appropriateness of the methods 
used and the findings reported. Ethical considerations and rigour were also assessed. Evidence of reflexivity, 
where appropriate, was assessed throughout the texts including authors’ affiliations, research funding and 
declaration of potential conflict of interest. The quality appraisal was conducted with the assistance of 
published appraisal tools (see Appendix 3 for an example) developed for multiple study designs by the Critical 
Appraisal Skills Programme (http://www.casp-uk.net/). These appraisal tools have been used previously in 
other qualitative systematic reviews (Chan 2013; Kane et al. 2007; Walter et al. 2004).  
 
The analytical approach for this systematic review was guided by the logic model developed as part of the 
preliminary scoping review (see Part B). Study findings related to health systems constraints and facilitators of 
HPV immunization programs were extracted and organized according to the six themes of the model. During 
the first stage of the analysis process, full texts were imported into Rayyan, a web-based application for 
systematic reviews, where they were screened for eligibility (Ouzzani et al. 2016). Eligible studies were then 
coded using inductive and deductive approaches. The codes used were related to the types of health systems 
constraints and facilitators reported in the study findings. Relevant findings from each study were then 
extracted and recorded in a database (see Appendix 4 for a summary of the data extracted for this review). 
The extracted data set was then subjected to rigorous thematic analysis with careful consideration for 
prevailing contextual factors reported for the relevant countries. 
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Given that majority of sub-Saharan African countries are yet to implement nationwide HPV immunization 
programs through their NIPs, we explored outcomes on health systems constraints to implementation. Where 
studies investigated potential or anticipated health systems constraints and facilitators to the performance of 
nationwide HPV immunization programs should they be implemented, these outcomes were also considered 
for this review. Where HPV immunization programs have been introduced in sub-Saharan African countries as 
part of their NIPs or through demonstration projects5, it was also worth exploring study findings related to 
health systems constraints and facilitators to the acceptance and uptake of the HPV vaccine. 
 
Results 
Characteristics of studies included in this review 
The literature search yielded a total of 356 published records. Overall, 355 of these records were retrieved 
from electronic databases, while a search in Google Scholar yielded an additional record. No additional unique 
records were found through organizational websites. Of the total output, 54 full text articles were found to be 
eligible for inclusion in the systematic review. Figure 1 shows the screening and selection process for this 
systematic review. 
 
                                                          
5 Vaccine demonstration projects are pilot campaigns conducted in advance of nationwide roll-out of a vaccine. They 
are targeted at a subset of the population with the aim of building capacity to inform nationwide vaccine introduction. 
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Figure 2: Flowchart of the literature search and selection process for the systematic review 
 
The 54 full text articles included in this review reported on studies conducted in 20 countries in SSA, namely; 
Botswana, Burundi, Cameroon, Côte d’Ivoire, Gambia, Ghana, Kenya, Lesotho, Madagascar, Malawi, Mali, 
Mozambique, Niger, Nigeria, Rwanda, Senegal, South Africa, Tanzania, Uganda and Zambia. The majority of 
articles focused on South Africa (10), Nigeria (8), Kenya (6) and Uganda (6). Where articles reported on findings 
from multiple countries, only those findings relating to sub-Saharan African countries were extracted. The 
majority (31) of studies made use of qualitative study designs, while others adopted mixed method (10), or 
quantitative (10) study designs. A population-based intervention study and a project evaluation were also 
included in this review (see Table 1). 
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Table 1: Characteristics of studies included in the systematic review  
No. Author, year Title Country Study design Availability of 
HPV vaccine* 
1 Audu et al, 
2015 
Awareness and perception of human papilloma 
virus vaccine among healthcare professionals in 
Nigeria 
Nigeria Cross-sectional, 
questionnaire-
based 
Not available 
2 Ayissi et al, 
2012 
Awareness, acceptability and uptake of human 
papilloma virus vaccine among Cameroonian 
school-attending female adolescents 
Cameroon Cross-sectional, 
questionnaire-
based 
Demonstration 
project 
3 Bardají et al, 
2018 
Awareness of cervical cancer and willingness to be 
vaccinated against human papillomavirus in 
Mozambican adolescent girls 
Mozambique Quantitative, 
cross-sectional 
Demonstration 
project 
4 Botha et al, 
2015 
The Vaccine and Cervical Cancer Screen (VACCS) 
project: acceptance of human papillomavirus 
vaccination in a school-based programme in two 
provinces of South Africa 
South Africa Quantitative Demonstration 
project 
5 Botwright et 
al, 2017 
Experiences of operational costs of HPV vaccine 
delivery strategies in Gavi-supported 
demonstration projects 
African 
Countries 
Quantitative Demonstration 
project 
6 Chigbu et al, 
2017 
The impact of community health educators on 
uptake of cervical and breast cancer prevention 
services in Nigeria 
Nigeria Prospective 
population-
based 
intervention  
Demonstration 
project 
7 Coleman et al, 
2011 
HPV vaccine acceptability in Ghana, West Africa Ghana Qualitative, 
questionnaire-
based 
Available in the 
private sector 
only 
8 De Groot et al, 
2017 
Knowledge, attitudes, practices and willingness to 
vaccinate in preparation for the introduction of 
HPV vaccines in Bamako, Mali 
Mali Qualitative, 
household 
survey 
Demonstration 
project 
9 DiAngi et al, 
2011 
A cross-sectional study of HPV vaccine 
acceptability in Gaborone, Botswana 
Botswana Cross-sectional, 
survey 
Available in the 
private sector 
only 
10 Francis et al, 
2011 
A qualitative analysis of South African women's 
knowledge, attitudes, and beliefs about HPV and 
cervical cancer prevention, vaccine awareness 
and acceptance, and maternal-child 
communication about sexual health 
South Africa Qualitative Available in the 
private sector 
only 
11 Francis et al, 
2010 
Examining attitudes and knowledge about HPV 
and cervical cancer risk among female clinic 
attendees in Johannesburg, South Africa 
South Africa Quantitative Not available 
12 Friedman et al, 
2014 
Preparing for human papillomavirus vaccine 
introduction in Kenya: implications from focus-
group and interview discussions with caregivers 
and opinion leaders in Western Kenya 
Kenya Qualitative Not available 
13 Harries et al, 
2009 
Preparing for HPV vaccination in South Africa: key 
challenges and opinions 
South Africa Qualitative Available in the 
private sector 
only 
14 Hoque, 2015 Acceptability of human papillomavirus vaccination 
among academics at the University of KwaZulu-
Natal, South Africa 
South Africa Qualitative, 
cross-sectional 
Available 
through NIP 
15 Hoque, 2016 Factors influencing the recommendation of the 
Human Papillomavirus vaccine by South African 
doctors working in a tertiary hospital 
South Africa Quantitative, 
cross-sectional 
Available 
through NIP 
16 Hoque et al, 
2013 
Human Papillomavirus vaccination acceptability 
among female university students in South Africa 
South Africa Qualitative, 
cross-sectional 
Available in the 
private sector 
only 
17 Hutubessy et 
al, 2012 
A case study using the United Republic of 
Tanzania: costing nationwide HPV vaccine delivery 
using the WHO Cervical Cancer Prevention and 
Control Costing Tool 
Tanzania Quantitative Not available 
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18 Kamya et al, 
2017 
Evaluating global health partnerships: a case 
study of a Gavi HPV vaccine application process in 
Uganda 
Uganda Mixed-methods 
case study 
Available 
through NIP 
19 Katz et al, 2013 A qualitative analysis of factors influencing HPV 
vaccine uptake in Soweto, South Africa among 
adolescents and their caregivers 
South Africa Qualitative Available in the 
private sector 
only 
20 Ladner et al, 
2012 
Assessment of eight HPV vaccination programs 
implemented in lowest income countries 
Lesotho and 
Cameroon 
(non-African 
countries 
included) 
Mixed-methods  Demonstration 
project 
21 Ladner et al, 
2014 
Performance of 21 HPV vaccination programs 
implemented in low and middle-income 
countries, 2009-2013 
African 
countries 
(non-African 
LMICs 
included) 
Quantitative  Demonstration 
project 
22 LaMontagne et 
al, 2011 
Human papillomavirus vaccine delivery strategies 
that achieved high coverage in low- and middle-
income countries 
Uganda 
(non-African 
LMICs 
included) 
Mixed-
methods, cross-
sectional 
Demonstration 
project 
23 Levin et al, 
2013 
Delivery cost of human papillomavirus vaccination 
of young adolescent girls in Peru, Uganda and Viet 
Nam 
Uganda 
(non-African 
LMICs 
included) 
Mixed-method Demonstration 
project 
24 Mabeya et al, 
2018 
Uptake of three doses of HPV vaccine by primary 
school girls in Eldoret, Kenya; a prospective 
cohort study in a malaria endemic setting 
Kenya Cross-sectional, 
questionnaire-
based 
Demonstration 
project 
25 MacPhail et al, 
2013 
Using HPV vaccination for promotion of an 
adolescent package of care: opportunity and 
perspectives 
South Africa Qualitative, 
cross-sectional 
Available in the 
private sector 
only 
26 Makwe and 
Anorlu, 2011 
Knowledge of and attitude toward human 
papillomavirus infection and vaccines among 
female nurses at a tertiary hospital in Nigeria 
Nigeria Qualitative, 
cross-sectional 
Not available 
27 Masika et al, 
2015 
Knowledge on HPV vaccine and cervical cancer 
facilitates vaccine acceptability among school 
teachers in Kitui County, Kenya 
Kenya Mixed-
methods, cross-
sectional, 
Demonstration 
project 
28 Massey et al, 
2017 
Human papillomavirus (HPV) awareness and 
vaccine receptivity among Senegalese adolescents 
Senegal Quantitative, 
questionnaire-
based 
Demonstration 
project 
29 Moodley et al, 
2013 
High uptake of Gardasil vaccine among 9-12-year-
old schoolgirls participating in an HPV vaccination 
demonstration project in KwaZulu-Natal Province, 
South Africa 
South Africa Mixed-methods Available in the 
private sector 
only 
30 Morhason-
Bello et al, 
2015 
Willingness of reproductive-aged women in a 
Nigerian community to accept human 
papillomavirus vaccination for their children 
Nigeria Quantitative, 
multi-stage 
household 
survey 
Available in the 
private sector 
only 
31 Msyamboza et 
al, 2017 
Implementation of a human papillomavirus 
vaccination demonstration project in Malawi: 
successes and challenges 
Malawi Mixed-method, 
cross-sectional 
Demonstration 
project 
32 Mugisha et al, 
2015 
Feasibility of delivering HPV vaccine to girls aged 
10 to 15 years in Uganda 
Uganda Qualitative Demonstration 
project 
33 Ndizeye et al, 
2018 
Knowledge and practices of general practitioners 
at district hospitals towards cervical cancer 
prevention in Burundi, 2015: a cross-sectional 
study 
Burundi Descriptive, 
cross-sectional 
Not available 
34 Ngabo et al, 
2017 
A cost comparison of introducing and delivering 
pneumococcal, rotavirus and human 
papillomavirus vaccines in Rwanda 
Rwanda Quantitative Available 
through NIP 
35 Odunyemi et 
al, 2018 
Effect of nursing intervention on mothers' 
knowledge of cervical cancer and acceptance of 
Nigeria Quasi-
experimental 
study 
Available in the 
private sector 
only 
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human papillomavirus vaccination for their 
adolescent daughters in Abuja - Nigeria 
36 Ogembo et al, 
2014 
Achieving high uptake of human papillomavirus 
vaccine in Cameroon: lessons learned in 
overcoming challenges 
Cameroon Project 
evaluation 
Demonstration 
project 
37 Okunade et al, 
2017 
Knowledge and acceptability of human 
papillomavirus vaccination among women 
attending the gynaecological outpatient clinics of 
a university teaching hospital in Lagos, Nigeria 
Nigeria Descriptive, 
cross-sectional 
Available in the 
private sector 
only 
38 Poole et al, 
2013 
A cross-sectional study to assess HPV knowledge 
and HPV vaccine acceptability in Mali 
Mali Qualitative, 
cross-sectional 
Not available 
39 Ports et al, 
2013 
Barriers and facilitators to HPV vaccination: 
perspectives from Malawian women 
Malawi Qualitative Not available 
40 Quentin et al, 
2012 
Costs of delivering human papillomavirus 
vaccination to schoolgirls in Mwanza Region, 
Tanzania 
Tanzania Mixed-methods Demonstration 
project 
41 Remes et al, 
2012 
A qualitative study of HPV vaccine acceptability 
among health workers, teachers, parents, female 
pupils, and religious leaders in northwest 
Tanzania 
Tanzania Qualitative Not available 
42 Tchounga et al 
2012 
Cervical cancer prevention in reproductive health 
services: knowledge, attitudes and practices of 
midwives in Côte d'Ivoire, West Africa 
Cote d'Ivoire Qualitative, 
cross-sectional 
Available in the 
private sector 
only 
43 Torres-Rueda 
et al, 2016 
HPV vaccine introduction in Rwanda: impacts on 
the broader health system 
Rwanda Mixed-methods  Available 
through NIP 
44 Tuhiro et al, 
2014 
Effect of school-based human papillomavirus 
(HPV) vaccination on adolescent girls' knowledge 
and acceptability of the HPV vaccine in Ibanda 
District in Uganda 
Uganda Cross-sectional, 
mixed-methods 
Demonstration 
project 
45 Tuhiro et al, 
2017 
Perceptions of human papillomavirus vaccination 
of adolescent schoolgirls in western Uganda and 
their implications for acceptability of HPV 
vaccination: a qualitative study 
Uganda  Qualitative Demonstration 
project 
46 Ugwu et al, 
2013 
Acceptability of human papilloma virus vaccine 
and cervical cancer screening among female 
health-care workers in Enugu, Southeast Nigeria 
Nigeria Cross-sectional, 
questionnaire-
based 
Available in the 
private sector 
only 
47 Umeh et al, 
2016 
Mothers' willingness to pay for HPV vaccines in 
Anambra state, Nigeria: a cross sectional 
contingent valuation study 
Nigeria Cross-sectional, 
survey 
Available in the 
private sector 
only 
48 Urasa and Darj, 
2011 
Knowledge of cervical cancer and screening 
practices of nurses at a regional hospital in 
Tanzania 
Tanzania Descriptive, 
cross-sectional 
Available in the 
private sector 
only 
49 Venturas and 
Umeh, 2017 
Health professional feedback on HPV vaccination 
roll-out in a developing country 
Zambia Qualitative Demonstration 
project 
50 Vermandere et 
al, 2015 
Implementation of an HPV vaccination program in 
Eldoret, Kenya: results from a qualitative 
assessment by key stakeholders 
Kenya Qualitative Demonstration 
project 
51 Vermandere et 
al, 2014 
Determinants of acceptance and subsequent 
uptake of the HPV vaccine in a cohort in Eldoret, 
Kenya 
Kenya Qualitative, 
longitudinal 
study 
Demonstration 
project 
52 Wamai et al, 
2013 
Awareness, knowledge and beliefs about HPV, 
cervical cancer and HPV vaccines among nurses in 
Cameroon: an exploratory study 
Cameroon Qualitative, 
questionnaire-
based 
Demonstration 
project 
53 Watson-Jones 
et al, 2015 
Access and attitudes to HPV vaccination amongst 
hard-to-reach populations in Kenya 
Kenya Qualitative Demonstration 
project 
54 Watson-Jones 
et al, 2012 
Reasons for receiving or not receiving HPV 
vaccination in primary schoolgirls in Tanzania: a 
case control study 
Tanzania Qualitative Demonstration 
project 
Source; Author 
Note: *Availability of the HPV vaccine at the time the studies were conducted 
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Most studies (33/54) were primarily concerned with assessing knowledge, awareness, and acceptability of the 
HPV vaccine among key populations such as adolescents, parents and caregivers, health workers, teachers and 
religious leaders (see Table 1). The articles also reported on the availability of the HPV vaccine in the relevant 
countries at the time each study was conducted. This information tended to change in some countries 
overtime and presented a unique opportunity to assess the evolution of health systems constraints and 
facilitators to HPV immunization programs in these countries. Overall, the HPV vaccine was reported to be 
available through the NIPs of South Africa, Rwanda and Uganda. In most countries where the studies were 
conducted, the HPV vaccine was only available through demonstration projects (see Table 1). Nine articles 
reported on studies which were conducted at a time when the HPV vaccine was not available, either through 
NIPs, demonstration projects or in private health facilities. These studies were mainly focused on determining 
the feasibility of implementing HPV immunization programs in the relevant countries by assessing potential 
health systems constraints and facilitators. 
 
Health systems constraints and facilitators of HPV immunization programs in sub-Saharan Africa 
We synthesized the available evidence on health systems constraints and facilitators of HPV immunization 
programs in sub-Saharan Africa. Findings pertaining to health systems constraints to HPV vaccine introduction 
into NIPs, as well as health systems constraints and facilitators of HPV vaccine acceptance and uptake, and the 
overall performance of HPV immunization programs (include existing nationwide programs or demonstration 
projects, and future HPV immunization programs) in sub-Saharan Africa were all considered during this review. 
The findings of this review have been organized and reported under the six cross-cutting themes of the logic 
model on the interface between NIPs and health systems as described previously (see Part B). 
 
The governance and policy landscape 
This theme explored findings related to leadership, management and stewardship throughout the HPV vaccine 
policy- and decision-making cascade. The evidence highlights the importance of clear governance6 and 
management structures, the involvement of political champions, the support of policy influencers (including 
governmental and non-governmental organizations), and the role of strong and inclusive partnerships to the 
optimal performance of HPV immunization programs in sub-Saharan Africa (see Table 3) (Kamya et al. 2017; 
Torres-Rueda et al. 2015; Mugisha et al. 2015; Ladner et al. 2014; Harries et al. 2008). For example, prior to 
the implementation of an HPV immunization program in South Africa, Harries et al. (2008) sought to identify 
potential barriers and facilitators of such a program. It was reported that strong collaboration between the 
                                                          
6 Where NIPs are concerned, governance functions include the decision- and policy-making that goes into developing of 
immunization program-related standards and guidelines, overall program organization, as well as training and 
supervision. These functions cut across global, national, sub-national and local or facility levels. 
PART C: Manuscript 
 
13 
 
national Departments of Health and Education, as well as between the private and public health sectors were 
necessary to support and sustain an HPV immunization program (Harries et al. 2008). These findings were 
echoed in studies conducted in Rwanda and Uganda where the HPV vaccine had been introduced as part of 
NIPs (Kamya et al. 2017; Torres-Rueda et al. 2015). In addition, Kamya et al. (2017) recognized the role of the 
First Lady of Uganda as a champion of the HPV vaccine. This level of endorsement ensured that the HPV 
immunization program remained a priority in the national policy agenda. It was also reported that a diverse 
and inclusive network of stakeholders from governmental and non-governmental agencies, having past 
immunization partnership experience and assigned clear roles and responsibilities, were invaluable to a GAVI 
HPV vaccine application process in Uganda (Kamya et al. 2017). Apart from the national level, the role of 
governance structures and processes at the health facility level were also identified as critical to HPV 
immunization programs. In a study that assessed how HPV vaccine introduction impacted on the Rwandan 
health system, it was reported that extensive planning and supervision at the health facility level contributed 
to the successful integration of the HPV vaccine into the NIP (Torres-Rueda et al. 2015). 
 
Table 2: Summary of health systems constraints and facilitators of HPV immunization programs in sub-Saharan 
Africa 
Theme (n*) Health Systems Constraints Health Systems Facilitators 
The 
governance 
and policy 
landscape (5) 
• Weak involvement of Ministries of Education and 
Finance 
• Clear governance and management structures 
• Political champions steering and endorsing the 
agenda for introduction of HPV immunization 
nationwide 
• Partnerships between all stakeholders – 
Departments of Health, Finance and Education, 
private and public health sectors 
• Participation of actors with past immunization 
partnership experience 
• Appropriate supervision, training and planning at 
the facility level 
• Non-governmental partners playing advocacy and 
management roles 
• Support of policy influencers 
The capacity of 
the health 
workforce (17) 
• Inadequate training of health workers leading to low 
level of knowledge about HPV infection, cervical 
cancer and the HPV vaccine 
• Fragile health worker capacity  
• Adequately trained health workers who can provide 
sound recommendations to clients about the HPV 
vaccine 
• Availability of a well-trained school health team 
• Community health workers as source of information 
and serving as community mobilizers  
The availability 
of potent 
vaccines, cold 
chain and 
logistics 
systems (3) 
• Limited availability and accessibility of the HPV 
vaccine 
• Conducting national cold chain inventory and 
ensuring adequate capacity of the cold chain prior 
to introduction of the HPV vaccine in NIPs 
The quality of 
health service 
delivery (16) 
• Adopting age-based, or health facility-based 
community outreach vaccine delivery strategies 
• Health resource constraints 
• Greater resource requirements associated with 
creating new vaccine delivery infrastructure 
• Implementing mixed vaccine delivery models 
comprising both grade-based and health facility-
based outreach strategies 
• Availability of well-functioning NIPs instilling trust in 
immunization and improving acceptance and 
uptake 
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• Logistical challenges of HPV vaccine delivery given 
the underdevelopment of adolescent health 
services 
• Long distance to health facilities delivering HPV 
vaccine 
• Physical barriers to accessing schools, e.g. long 
distance, unsafe and poor terrain during rainy 
seasons 
• Poor accessibility of schools and communities for 
vaccinators due to poor road networks 
The state of 
health 
information 
systems and 
community 
partnerships 
(33) 
• Inadequate sensitization campaigns leading to low 
level of awareness about the HPV vaccine and the 
vaccination program 
• Inadequate engagement with fathers and male 
teachers 
• Poor access to information about HPV, cervical 
cancer and HPV vaccine, for individuals living in 
hard-to-reach communities, and among 
populations with low literacy levels 
• Low level of knowledge about safety and 
effectiveness of the HPV vaccine 
• Misinformation about the side-effects, safety and 
benefits of the HPV vaccine 
• Misconceptions about other vaccines 
• Negative media reports and interference  
• Exclusive reliance on paper-based vaccine records 
• Evidence-based health promotion strategies 
involving intensive community mobilization and 
sensitization 
• Effective community engagement involving key 
stakeholders; adolescents, parents (including 
fathers), teachers, municipal and religious leaders 
• Adequate information, education and 
communication, especially on vaccine safety and 
efficacy issues. Prioritizing hard-to-reach 
communities  
• Consideration for culturally appropriate 
communication about HPV, cervical cancer and HPV 
vaccination 
• Adequate communication about all vaccines  
• Strengthening surveillance of adverse events 
following immunization 
The availability 
of equitable 
and sustainable 
health 
financing (8) 
• Non-integration of HPV vaccination programs 
within existing NIP 
• High financial costs of social mobilization and HPV 
vaccine delivery as adolescents are not “typical” 
clients of the health system 
• Adopting an age-based vaccine delivery strategy – 
less cost effective 
• High cost of the HPV vaccine 
• Cost of delivering vaccines to adolescents is higher 
than that of routine childhood immunization 
• Planning appropriate delivery strategies based on 
local context – country specific strategies 
• Intensive investments in community mobilization 
and sensitization increases vaccine acceptance and 
uptake 
• Implementing a grade-based delivery strategy – 
more cost-effective 
• GAVI funding and support 
• Adopting free HPV immunization services 
Source; Author 
Note: *Numbers in parenthesis represent the number of articles which reported findings related to each 
theme. Some articles reported on findings pertaining to more than one theme. A detailed description of each 
of the studies used and the themes they relate to is presented in Appendix 4. 
 
The capacity of the health workforce 
The size and competency of the health workforce emerged from the evidence-base as priority issues where 
HPV immunization programs were concerned. Majority of studies relating to health workers were conducted 
at a time when the HPV vaccine was not widely available to the general population, either because it was yet 
to be introduced in the country or was only available through the private health sector. In a study conducted 
by Remes et al. (2012) health workers identified staff shortages as a potential constraint to an HPV 
immunization program, were it to be introduced in Tanzania. The major health systems constraint identified 
in other studies however, was the inadequate training of the existing workforce in sub-Saharan Africa. Several 
studies reported that health workers (including doctors, nurses and midwives) exhibited suboptimal levels of 
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knowledge on HPV infection, the pathogenesis and prevention of cervical cancer, the availability, safety and 
effectiveness of the HPV vaccine and the HPV immunization schedule (Ndizeye et al. 2018; Venturas and Umeh 
2017; Hoque 2016; Audu et al. 2014; Tchounga et al. 2014; Wamai et al. 2013; Remes et al. 2012; Makwe and 
Anorlu 2011; Urasa and Darj 2011). When the HPV vaccine was not widely available, the proportion of health 
workers with optimal knowledge about the safety and effectiveness of the HPV vaccine ranged from 13% 
among nurses in Nigeria (Makwe and Anorlu 2011) to 55% among general practitioners in Burundi (Ndizeye et 
al. 2018). However, this increased to 78.9% when the HPV vaccine was available through demonstration 
projects (Wamai et al. 2013). Health workers’ limited knowledge about the safety of the HPV vaccine was 
reported to negatively impact on their acceptance of the vaccine for their adolescent daughters as well as 
their ability to recommend the vaccine to their clients (Venturas and Umeh 2017; Hoque 2016; Audu et al. 
2014; Wamai et al. 2013; Makwe and Anorlu 2011). In a study conducted in Cameroon where an HPV vaccine 
demonstration project was ongoing, 69.7% of nurses surveyed, indicated that they often recommended the 
vaccine to their clients. However, 63.9% of these nurses remained concerned about the potential side effects 
of the vaccine (Wamai et al. 2013). Poor access to appropriate training was cited as the primary reason for the 
suboptimal level of knowledge about HPV infection, cervical cancer and HPV immunization, among health 
workers in sub-Saharan African countries (Venturas and Umeh 2017; Tchounga et al. 2014; Urasa and Darj 
2011). 
 
Where health workers received adequate training, it was reported that they were capable of providing sound 
recommendations about the HPV vaccine to clients, thereby positively influencing acceptance and uptake of 
the vaccine (Odunyemi et al. 2018; Chigbu et al. 2017; Katz et al. 2013). Additional facilitators of HPV 
immunization programs included the involvement of well-trained school health teams as well as community 
health workers who were reported to play a key role in health promotion and social mobilization for HPV 
immunization (Watson-Jones et al. 2015; Moodley et al. 2013). 
 
The availability of potent vaccines, cold chain and logistics systems 
Research evidence on how the availability of the HPV vaccine, and the capacity of cold chain and logistics 
systems (for vaccine delivery, transport, and storage), impact on the performance of HPV immunization 
programs in sub-Saharan Africa was rather limited. Studies conducted by Okunade et al. (2017) and Ugwu et 
al. (2013) addressed the limited availability of the HPV vaccine and how this served as a barrier to acceptance 
and uptake of the vaccine in Nigeria. At the time both studies were conducted, the HPV vaccine was not widely 
available to the general population but was provided through the private health sector at a cost (Okunade et 
al. 2017; Ugwu et al. 2013). With regards to cold chain and logistics systems, Torress-Reuda et al. (2015) 
reported that the Rwandan NIP conducted a cold chain inventory to access the capacity of the system prior to 
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the introduction of the HPV vaccine. This formed part of the planning and training implemented in advance of 
introducing the HPV vaccine into the NIP. 
 
The quality of health service delivery 
There was much in the literature about the health systems constraints and facilitators to accessing quality 
health services that are safe, people-centred, integrated and efficient, and how this impacts on the 
performance of HPV immunization programs in sub-Saharan Africa (see Table 3). Studies exploring the most 
efficient and effective HPV vaccine delivery models were well represented in the evidence-base (Msyamboza 
et al. 2017; Botwright et al. 2017; Watson-Jones et al. 2015; Ladner et al. 2014; Ogembo et al. 2014; Moodley 
et al. 2013; Levin et al. 2013; Ladner et al. 2012; Hutubessy et al. 2012; Quentin et al. 2012; LaMontagne et al. 
2011). Two main HPV vaccine delivery models, namely, the school-based and the health facility-based vaccine 
delivery strategies were explored. Overall, the findings were consistent, suggesting that adopting a school-
based vaccine delivery strategy where eligibility to receive the vaccine was based on school grade or class and 
not on the age of the recipient, was the most effective model (Msyamboza et al. 2017; Mugisha et al. 2015; 
Ladner et al. 2014; Moodley et al. 2013; Ladner et al. 2012; LaMontagne et al. 2011). This is because, the 
school-based strategy was reported to achieve higher HPV immunization coverage rates compared to the 
health facility-based strategy (Mugisha et al. 2015; Ladner et al. 2014; Ladner et al. 2012; LaMontagne et al. 
2011).  
 
Several challenges to delivering the HPV vaccine through the school-based strategy in sub-Saharan Africa have 
been documented however, and these include, absenteeism, high school dropout rates among girls, and girls 
transferring out of the district at the time of the immunization programs (Msyamboza et al. 2017). Physical 
barriers to accessing the HPV vaccine through schools have also been reported in some hard-to-reach 
communities in Kenya. These barriers have been associated with non-attendance or delayed enrolment in 
schools because of long distances (up to 10km) and safety concerns with possibly encountering wildlife on the 
way to school (Watson-Jones et al. 2015). In areas like this, where road networks are poorly developed or 
unsafe, vaccinators have been reported to experience difficulty in accessing schools in order to provide HPV 
immunization (Masika et al. 2015). To mitigate these challenges, a mixed vaccine delivery model is highly 
recommended in the literature and involves coupling the school-based strategy with community outreach 
immunization campaigns. This mixed vaccine delivery model has been shown to be feasible in sub-Saharan 
Africa, expanding the reach of HPV immunization programs, improving adherence to the immunization 
schedule, and scaling-up immunization coverage rates (Msyamboza et al. 2017; Ogembo et al. 2014; Ladner 
et al. 2012). 
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It was evident from the studies reviewed that the introduction of the HPV vaccine has exposed gaps in the 
development of adolescent and school health services in sub-Saharan Africa. This has been considered in the 
evidence-base as a constraint to HPV immunization programs because of the logistical challenges to providing 
health services to a previously underserved adolescent population and the greater resource requirements 
associated with creating new vaccine delivery infrastructure (Ngabo et al. 2015; Remes et al. 2012; Harries et 
al. 2008). A study conducted in South Africa by McPhail et al. (2013) also identified gaps in the appropriate 
integration of the HPV immunization program with other adolescent health services such as sex education, 
screening and preventive services, assistance with substance abuse and provision of other adolescent 
vaccines. 
 
The state of health information systems and community partnerships 
Three main dimensions were explored under this theme; (i) health information, education and communication 
about HPV infection, cervical cancer and HPV immunization, (ii) community partnerships during HPV 
immunization programs, and (iii) the generation and use of surveillance and immunization data. After 
reviewing the evidence-base, the state of health information systems and community partnerships emerged 
as the most researched theme where HPV immunization programs in sub-Saharan Africa are concerned (see 
Table 2).  
 
Several studies were conducted to assess the level of awareness about HPV infection, cervical cancer and HPV 
immunization among general populations in sub-Saharan Africa. Study participants included key stakeholders 
like adolescents, women of reproductive age, parents or caregivers, teachers, opinion leaders, religious 
leaders, and university students and academics (Bardají et al. 2018; De Groot et al. 2017; Massey et al. 2017; 
Okunade et al. 2017; Turiho et al. 2017; Botha et al. 2015; Hoque 2015; Masika et al. 2015; Morhason-Bello et 
al. 2015; Vermandere et al. 2015; Turiho et al. 2014; Vermandere et al. 2014; Hoque et al. 2013; MacPhail et 
al. 2013; Poole et al. 2013; Ports et al. 2013; Ayissi et al. 2012; Remes et al. 2012; Watson-Jones et al. 2012; 
Coleman et al. 2011; Francis et al. 2011; DiAngi et al. 2011; Francis et al. 2010). Majority of these studies found 
that the level of awareness among the general population was rather limited. With the exception of university 
academics, the proportion of the general population found to be aware of HPV infection, cervical cancer, and 
the HPV vaccine was generally low, and ranged from 8.6% to 36.5%, 61% to 87%, and 0% to 40%, respectively 
(Okunade et al. 2017; De Groot et al. 2017; Massey et al. 2017; Friedman et al. 2014; Ports et al. 2013; Remes 
et al. 2012; Coleman et al. 2011; DiAngi et al. 2011; Francis et al. 2010). In comparison, the highest level of 
awareness about HPV (100%) and cervical cancer (96%) was recoded among university academics (Hoque 
2015). 
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The low level of awareness demonstrated among the general population was reported to fuel misconceptions 
about the safety and benefits of the HPV vaccine. Some misconceptions about the potential side effects of the 
vaccine included infertility and death, while some feared that introduction of the vaccine would promote 
promiscuity and early sexual debut among adolescent girls (Morhason-Bello et al. 2015; Ogembo et al. 2014; 
Watson-Jones et al. 2012). Other studies also reported that some participants believed that the HPV vaccine 
would prevent HIV and pregnancy, or even safeguard the fertility of adolescent girls (Turiho et al. 2017; 
Vermandere et al. 2015). Ultimately, low level of awareness was a major constraint to the acceptance and 
uptake of the HPV vaccine in sub-Saharan Africa (Vermandere et al. 2014). When intensive social mobilization 
and community sensitization interventions were implemented to provide culturally appropriate information 
about the risks of cervical cancer and the safety and effectiveness of the HPV vaccine (often as part of vaccine 
demonstration projects; see Figure 3), an increase in vaccine acceptance and uptake was reported (Bardají et 
al. 2018; De Groot et al. 2017; Botha et al. 2015; Hoque 2015; Masika et al. 2015; Vermandere et al. 2015; 
Turiho et al. 2014; Ports et al. 2013; Ayissi et al. 2012; Coleman et al. 2011; DiAngi et al. 2011). Participants 
also identified health workers as their most trusted source of information about the HPV vaccine (Massey et 
al. 2017; Ports et al. 2013; Ayissi et al. 2012). Engaging key stakeholders like adolescents (both males and 
females), parents (including fathers) or caregivers, municipal and religious leaders, and school teachers, at the 
onset of HPV immunization programs was considered as a major facilitator to vaccine acceptance and uptake 
(Masika et al. 2015; Vermandere et al. 2015; Ogembo et al. 2014; Ports et al. 2013). 
 
Very few studies reported on how the generation and use of surveillance and immunization data (including 
immunization coverage data) impacted on the performance of HPV immunization programs in sub-Saharan 
Africa. Where studies explored this dimension, the evidence found was rather limited. For example, a study 
conducted to assess the capacity of school health teams to carry out future HPV immunization in schools 
within the KwaZulu Natal province of South Africa, found that the reliance on paper-based vaccine records 
would be a major constraint to real-time monitoring and evaluation of the immunization program. To mitigate 
this challenge, the use of electronic data capturing methods was recommended (Moodley et al. 2013). In 
addition to this, Torres-Rueda et al. (2015) highlighted the importance of strengthening the surveillance of 
adverse events following immunization in Rwanda where a nationwide HPV immunization program was 
already in existence (see Figure 3). 
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KENYA 
Constraints: Access barriers to information 
about HPV, cervical cancer and HPV vaccine 
Facilitators: Culturally appropriate social 
mobilization and communication strategies 
TANZANIA 
Facilitators: Grade-
based delivery model 
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Constraints: High cost of vaccine delivery strategies; 
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sensitization about HPV vaccine 
Facilitators: Use of mixed vaccine delivery approaches; 
appropriate communication and sensitization 
strategies, and community engagement 
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Facilitators: Use of mixed 
vaccine delivery models; school- 
and health-facility- based 
 
SOUTH AFRICA 
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communication and sensitization  
Key: The colours represent the varied availability of HPV 
immunization program at the time of each study; 
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about HPV vaccine 
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social mobilization and 
vaccine delivery strategy 
Facilitators: Planning and 
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appropriate delivery 
strategies 
MADAGASCAR 
Constraints: High cost of social 
mobilization and vaccine delivery 
strategy 
Côte d’Ivoire 
Constraints: Inadequate 
community sensitization about HPV 
vaccine 
Facilitators: Adequate training of 
health workers on cervical cancer 
and cancer prevention 
GAMBIA 
Constraints: High cost of 
vaccine delivery strategies 
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health facility-based vaccine delivery strategies 
Facilitators: Adoption of school-based vaccine delivery 
models; Engaging teachers early in the campaign 
 
MALAWI 
Constraints: Long 
distance to health facility 
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Constraints: Inadequate community 
sensitization about HPV vaccine 
 
MALI 
Facilitators: Health promotion and 
education about HPV and cervical 
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Constraints: High cost of 
vaccine delivery strategies 
cancer 
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Facilitators: Sufficient 
training for health workers  
 
NIGERIA 
Constraints: Inadequate training for 
health workers 
 
RWANDA 
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strengthened surveillance systems 
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training for health workers 
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Constraints: Fragile health 
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BURUNDI 
Constraints: Inadequate 
training of health workers 
  
Figure 3: Summary of health systems constraints and facilitators of HPV immunization programs in sub-Saharan Africa [Source; Author, (drawing on studies included in the systematic review)] 
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The availability of equitable and sustainable health financing 
The final theme examined national health financing mechanisms in sub-Saharan Africa, including the 
availability of equitable and sustainable financing mechanisms for HPV immunization programs. Research 
evidence on this theme was found to be limited. None of the studies included in the review addressed any 
dedicated financing mechanisms earmarked for the introduction and sustainable delivery of the HPV vaccine. 
Instead, the available evidence on financing was mainly focussed on determining the economic and financial 
costs of social mobilization campaigns and HPV vaccine delivery models (Botwright et al. 2017; Ngabo et al. 
2015; Levin et al. 2013; Hutubessy et al. 2012; Quentin et al. 2012). 
  
With the exception of South Africa, HPV vaccine procurement costs were largely covered by external funding 
sources (from organizations like GAVI, Program for Appropriate Technology in Health, and the Gardasil Access 
Program), in countries where the HPV immunization program had been implemented as part of demonstration 
projects or NIPs (Botwright et al. 2017; Ngabo et al. 2015; Mugisha et al. 2015; Ladner et al. 2014). In most 
cases, national governments are expected to co-finance the cost of delivering the vaccine. However, this was 
a major constraint to implementing HPV immunization programs, given that the financial cost of introducing 
and delivering the HPV vaccine was significantly higher than that of routine childhood vaccines (Ngabo et al. 
2015; Levin et al. 2013). Reasons given for this included the fact that the infrastructure for delivering vaccines 
to adolescents was largely underdeveloped prior to the introduction of the HPV vaccine in sub-Saharan Africa. 
As such financial costs were reported to be higher in countries that could not leverage existing immunization 
infrastructure and had greater resource requirements (Botwright et al. 2017; Ngabo et al. 2015).  
 
It was reported that a substantial cost component was required to train health workers, cover per diems, 
organize effective social mobilization and community sensitization campaigns, and deliver the vaccine through 
the school-based strategy (Botwright et al. 2017; Ngabo et al. 2015; Levin et al. 2013; Hutubessy et al. 2012). 
With regards to the school-based vaccine delivery strategy, adopting an age-based eligibility approach was 
found to be a constraint to HPV immunization programs as it was less cost-effective compared to the grade-
based approach (Quentin et al. 2012). However, delivering the HPV vaccine through health facilities incurred 
lower economic costs compared to the school-based strategy, but achieved lower immunization coverage 
rates (Levin et al. 2013). To offset the cost of delivering the HPV vaccine, some countries charged a fee for 
immunization, while in other countries, the vaccine was only available through the private health sector at 
unaffordable costs (Odunyemi et al. 2018; Okunade et al. 2017; Umeh et al. 2016; Ogembo et al. 2014; Ugwu 
et al. 2013). In these countries, socioeconomic constraints to accessing the HPV vaccine negatively impacted 
on vaccine acceptance and uptake.  
PART C: Manuscript 
 
21 
 
Discussion 
There is growing consensus that the success of key health programs in achieving improved population health 
is highly dependent on the performance of their health systems (Balabanova et al. 2010; Travis et al. 2004). In 
this regard, previous systematic reviews have assessed the health systems constraints and facilitators to the 
effective performance of several health programs, such as those targeted at HIV anti-retroviral treatment, 
prevention of mother-to-child transmission of HIV, and the prevention and control of breast cancer, as well as 
other chronic diseases (Bowser et al. 2017; Watt et al. 2017; Colvin et al. 2014). The primary intent of these 
reviews is to build up the evidence-base required to inform health systems strengthening efforts. This has 
been spurred by the realization that strong health systems are able to withstand acute shocks or avoid them 
altogether, in order to provide health programs with the support they require to be effective (Wang et al. 
2013; Hanvoravongchai et al. 2011; Balabanova et al. 2010; Travis et al. 2004). To date, no rigorous systematic 
evidence exists on the health systems constraints and facilitators of NIPs, especially from the sub-Saharan 
African region. 
 
At the World Health Assembly held in May 2012, 194 member states endorsed the Global Vaccine Action Plan. 
One of the visions of the Global Vaccine Action Plan is to advance universal access to immunization between 
2011 and 2020 (WHO 2015; WHO 2013b). To date, regional efforts have been heavily focussed on routine 
childhood immunization programs which have achieved remarkable public health success within the 
subcontinent (Machingaidze et al. 2013; Arevshatian et al. 2007). However, if sub-Saharan Africa is to have a 
chance of achieving the vision of the Global Vaccine Action Plan, countries will have to scale-up the 
performance of existing immunization programs, introduce and improve the uptake of underused vaccines 
and extend access to lifesaving vaccines to underserved and hard-to-reach populations (Bonner et al. 2018; 
Nanni et al. 2017; WHO 2013b). Scaling-up HPV immunization programs, which target the adolescent 
population, presents a unique opportunity to contribute to attaining the vision of the Global Vaccine Action 
Plan. In this regard, Nanni et al. (2017) advocate for “global consensus, political will, policies, global and 
country infrastructure, and financing mechanisms” in order to accelerate universal access to the HPV vaccine 
for adolescent populations in low- and middle- income regions like sub-Saharan Africa. To facilitate this, it is 
important to provide decision-makers with robust systematic evidence of what works (and what does not 
work) for HPV immunization programs in sub-Saharan Africa, especially where health systems are concerned.  
 
The findings of this systematic review are in agreement with the recommendations made by Nanni et al. 
(2017). In sub-Saharan African countries like Uganda where national governments have strongly endorsed the 
HPV vaccine and have made concerted efforts through national policy to ensure that the vaccine is widely 
available to the population, HPV immunization programs have been successfully implemented as part of NIPs, 
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and vaccine acceptance and uptake has significantly improved (Kamya et al. 2017; Mugisha et al. 2015). Global 
infrastructure for HPV immunization programs have typically come in the form of external funding, and expert 
and technical support from organizations like GAVI, Program for Appropriate Technology in Health, and the 
Gardasil Access Program (Botwright et al. 2017; Mugisha et al. 2015; Ngabo et al. 2015; Ladner et al. 2014). 
The support of these global partners has been instrumental in facilitating the introduction of HPV 
immunization programs in sub-Saharan Africa, either through demonstration projects or NIPs (Gallagher et al. 
2018; Gallagher et al. 2017b; Ladner et al. 2014; Oluwole and Kraemer 2013). While these health systems 
facilitators have achieved some progress for HPV immunization programs in sub-Saharan Africa, the region 
continues to fall short in meeting global targets for implementing HPV immunization programs. In addition to 
this, HPV immunization coverage rates in sub-Saharan Africa are recorded among the lowest in the world 
(Gallagher et al. 2018; LaMontagne et al. 2017; Gallagher et al. 2017a; Bruni et al. 2016). These persistent 
challenges may be the result of significant health systems constraints in sub-Saharan Africa, as has been 
suggested previously (SAGE 2016; Wigle et al. 2013; Bello et al. 2011). 
  
The most recurrent health systems constraint identified by this systematic review was the low level of 
knowledge and awareness on HPV infection, risk of cervical cancer, and the safety and effectiveness of the 
HPV vaccine, among general populations in sub-Saharan Africa. This finding is highly relevant given the well-
established link between levels of knowledge, awareness and attitudes towards the HPV vaccine, and vaccine 
acceptance and uptake (Maseko et al. 2015; Hopkins and Wood 2013; Garcini et al. 2012; Kessels et al. 2012). 
The gap identified in the level of knowledge and awareness among the general population is not unique to the 
sub-Saharan Africa context and has been reported in other parts of the world where HPV immunization 
programs have long been in existence (Cartmell et al. 2018; Hendry et al. 2013). Nonetheless, this calls into 
question the effectiveness of existing HPV vaccine communication strategies in sub-Saharan Africa. Key 
stakeholders, including adolescents and their caregivers, depend on reliable communication in order to make 
informed decisions about lifesaving HPV vaccines and take ownership of their health (Bonner et al. 2018). 
Evidently, there is a need to strengthen health systems in sub-Saharan Africa by reinforcing the role of health 
promotion activities, especially where HPV immunization programs are concerned. Where intensified social 
mobilization and community sensitization campaigns have been implemented, this was shown to increase the 
demand for the HPV vaccine. In addition to this, the importance of designing culturally appropriate 
communication strategies which are also accessible to populations living in hard-to-reach communities, was 
emphasized in the literature (Watson-Jones et al. 2015; Friedman et al. 2014). 
 
The limited capacity of health workers was identified as another major health systems constraint to the 
performance of HPV immunization programs in sub-Saharan Africa. Overall, health workers demonstrated 
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suboptimal levels of knowledge and awareness about HPV infection, risk of cervical cancer, and the safety and 
effectiveness of the HPV vaccine. These findings are consistent with those reported in other resource limited 
settings (Chawla et al. 2016; Ali et al. 2010; Nganwai et al. 2008). In contrast, reports from some high resource 
settings indicate high levels of knowledge and awareness about HPV infection, cervical cancer and the HPV 
vaccine, among health workers (Rosen et al. 2018). This is a matter of major public health concern in sub-
Saharan Africa, given that cadres like nurses and community health workers are at the frontline of HPV 
immunization programs and have been identified as the most trusted source of information on HPV 
immunization (Massey et al. 2017; Watson-Jones et al. 2015; Ports et al. 2013; Ayissi et al. 2012). There is a 
need, therefore, to reinforce the capacity of health workers in sub-Saharan Africa. This can be achieved 
through continued training and education to ensure that health workers can provide sound vaccine 
recommendations to their clients.  
 
Historically, adolescents have not been the ‘typical’ client-base of most health systems. However, with the 
introduction of HPV immunization programs, this notion is beginning to change (Nanni et al. 2017; MacPhail 
et al. 2013; Ladner et al. 2012). This systematic review has found that poorly developed adolescent and school 
health services present a significant challenge to effectively delivering HPV vaccines in sub-Saharan Africa. This 
is further compounded by weak country infrastructure, including underdeveloped and unsafe road networks, 
as well as geographically inaccessible schools and health facilities, which create physical barriers to reaching 
target populations with the HPV vaccine (Msyamboza et al. 2017; Watson-Jones et al. 2015; Masika et al. 
2015). A review by Sankaranarayanan et al. (2012) which sought to address the infrastructure requirements 
for HPV immunization programs in sub-Saharan Africa found that although leveraging existing NIP resources 
(for example human resources and cold chain and logistics systems) could improve the performance of HPV 
immunization programs, greater investments in infrastructure are still needed. This calls for intersectoral 
collaboration within national governments, involving relevant Ministries like Health, Education and Finance. 
Improving adolescent and school health services to support HPV immunization programs and administration 
of other adolescent vaccines also deserves particular attention in the health policy agenda in sub-Saharan 
Africa (Nanni et al. 2017). 
 
Finally, this review found that significant financial constraints impact on the introduction of HPV immunization 
programs and the delivery of the vaccine to adolescents in sub-Saharan Africa. The HPV vaccine is more costly 
than other routine childhood vaccines. In addition, the HPV vaccine delivery models incur higher financial and 
economic costs when compared to routine childhood immunization programs (Ngabo et al. 2015; Levin et al. 
2013). These financial barriers are intensified when considered in light of unique sub-Saharan African 
contextual issues, such as the limited health budgets of some national governments and the high burden of 
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diseases which has given rise to multiple health programs (such as those targeting malaria, HIV, and other 
vaccine preventable diseases) competing for the limited resources (Bello et al. 2011). Altogether, these 
financial constraints significantly obstruct the widespread implementation of HPV immunization programs in 
sub-Saharan Africa (Gallagher et al. 2018). While substantial investments have been made by global partners, 
co-financing commitments make HPV vaccine introduction unaffordable for some national governments in 
sub-Saharan Africa (Gallagher et al. 2018). Increasing national investments in HPV immunization programs will 
require reforms in health policy, although this will have to be informed by country-specific evidence on the 
resources need and the most effective financing mechanisms to be adopted. 
 
In 2019, other sub-Saharan African countries like Ethiopia, Kenya, Malawi and Nigeria will be looking to 
introduce HPV immunization programs nationwide (see Appendix 1). While this will be an impressive move 
towards expanding access to lifesaving HPV vaccines within the region, it is important that key decision-makers 
take into consideration the health systems constraints and facilitators presented in this review. Countries 
could draw on the health systems facilitators to well-performing HPV immunization programs in developing 
country-specific standards and guidelines for their immunization programs. The findings on health systems 
constraints also serve as a set of ‘lessons learned’ for HPV immunization programs in sub-Saharan Africa so 
far, and could be used to inform interventions to scale-up the performance of existing immunization programs 
or to guide the implementation of new HPV immunization programs where necessary. 
 
Although this systematic review assessed health systems constraints and facilitators to HPV immunization 
programs, the findings have significant relevance for scaling-up NIPs in general. The major health systems 
constraints and facilitators pertaining to service delivery, the health workforce, vaccine communication and 
community partnerships, as well as governance and policy are applicable to almost all services delivered 
through NIPs. For example, barriers to accessing vaccines due to ineffective service delivery, staff shortages, 
lack of awareness about vaccines, weak engagement with key populations, as well as poor governance and 
policy structures have all been suggested to negatively impact on the performance of NIPs in most LMICs, and 
the findings of this review are in support of this (Mihigo et al. 2017; SAGE, 2016; Shen et al. 2014). What has 
not been sufficiently addressed in the existing literature is how to overcome these constraints and strengthen 
broader health systems to support NIPs in performing their functions. In addition to this, detailed 
considerations of the cost effectiveness of strengthening the broader health system in anticipation of scaling-
up NIP performance is scarce. This systematic review provides evidence on health systems facilitators which 
can be leveraged in developing interventions to mitigate some of the system-wide barriers to scaling-up NIPs. 
It is important to caution, however, that HPV immunization programs have some unique characteristics when 
compared with other NIP activities. First, HPV immunization programs are targeted at the adolescent 
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population while most NIP services have typically been focused on infants and children. Secondly, the vaccine 
delivery models for HPV immunization programs are also different from those typically used in other NIP 
services. As such certain variations exist in terms of some of the health systems functions needed to support 
HPV immunization programs compared to routine childhood immunization services, as discussed previously. 
Despite this, NIPs are beginning to evolve towards a ‘life-course approach’ to immunization by expanding 
target age groups and extending immunization services to adolescents and adults who have been previously 
underserved (Langley 2015; Mehta 2014). In this regard, the findings of this systematic review could be useful 
for informing health systems strengthening initiatives to support the expanding scope of NIPs, especially in 
sub-Saharan Africa. 
   
This review has some limitations which include the geographical restriction to countries within the sub-
Saharan African region. The findings and recommendations of the review may not be generalizable to parts of 
the world that do not share similar contexts with sub-Saharan Africa. The language restriction applied during 
the search strategy is another limitation as relevant studies conducted and published from non-Anglophone 
countries may have been missed. It is also worth noting that most studies on knowledge and awareness were 
based on self-reporting and might be subject to reporting bias. Finally, the use of HPV immunization programs 
as a proxy for NIPs may not give a comprehensive assessment given some of the programmatic differences 
with other routine childhood immunization programs. The generalizability of the findings of this systematic 
review for other NIP services may therefore require further investigation, adapting and using the logic model 
on the interface between NIPs and health systems.   
 
Conclusion 
This systematic review provides evidence of how NIPs and health systems interact by reporting on the health 
systems constraints and facilitators of NIPs in sub-Saharan Africa. In addition, the findings show how these 
system-wide constraints and facilitators impact on the performance of NIPs. There is evidence to suggest that 
NIPs in sub-Saharan Africa have surmounted significant health systems constraints and have achieved notable 
public health success. This success can be attributed to strong political endorsement for vaccines, clear 
governance structures and effective collaboration with global partners. Despite this, important health systems 
constraints persist and could derail further progress if not addressed through health systems strengthening 
efforts. Gaps in the evidence-base pertaining to cold chain and logistics systems, data generation and use, as 
well as national financing mechanisms needed to sustain NIPs in sub-Saharan Africa were also identified. This 
calls for an expansion of the research agenda, not only to address these gaps, but to also continuously evaluate 
health systems constraints and facilitators of NIPs in sub-Saharan Africa. 
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The findings of this review are relevant to ongoing health systems strengthening initiatives in sub-Saharan 
Africa. By enhancing our understanding of what works – and does not work – for NIPs, health systems 
strengthening initiatives could be better designed to adequately respond to the burden of vaccine preventable 
diseases in sub-Saharan Africa.  
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Appendix 1: Human Papillomavirus Vaccine Introduction Worldwide 
Country / Territory Income 
Introduction of HPV 
vaccine in NIP 
Year of 
Introduction 
Comment 
East Asia and Pacific 
American Samoa UMIC No   
Partial introduction in parts of the 
country in 2013 
Australia HIC Yes 2007   
Brunei Darussalam HIC Yes 2012   
Cambodia LMIC No   
HPV vaccine demonstration project 
launched in January 2017 with intent to 
scale-up to a national program in 2019 
China UMIC No   
Approved for use by the Chinese Food 
and Drug Administration in 2016 
Cook Islands   Yes 2011   
Fiji UMIC Yes 2013   
French Polynesia HIC     
No data found on HPV immunization 
program 
Guam HIC Yes 2012   
Hong Kong SAR, China HIC No   
HPV vaccine demonstration project 
launched in October 2016 for 3 years 
Indonesia LMIC No   
HPV vaccine demonstration project 
launched in 2016 
Japan HIC No   
HPV vaccine introduced nationwide in 
2011, but suspended in 2013 
Kiribati LMIC Yes 2011   
Korea, Democratic 
People's Republic 
LIC No   
No nationwide HPV immunization 
program 
Korea, Republic HIC Yes 2016   
Lao PDR LMIC No   
HPV demonstration project launched in 
October 2013 
Macao SAR, China HIC Yes 2013   
Malaysia UMIC Yes 2010   
Marshall Islands UMIC Yes 2008   
Micronesia, 
Federated States 
LMIC Yes 2009   
Mongolia LMIC No   
HPV vaccine demonstration project rolled 
out between 2009 to 2013 
Myanmar LMIC No   
No nationwide HPV immunization 
program  
Nauru UMIC No   
No nationwide HPV immunization 
program 
New Caledonia HIC Yes 2011   
New Zealand HIC Yes 2008   
Niue   Yes   
No data found on year of HPV vaccine 
introduction 
Northern Mariana 
Islands 
HIC Yes 2008   
Palau HIC Yes 2009   
Papua New Guinea LMIC No   
HPV vaccine demonstration project 
launched in 2017 
Philippines LMIC Yes 2016   
Samoa UMIC No   
No nationwide HPV immunization 
program 
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Singapore HIC Yes 2010   
Solomon Islands LMIC No   
HPV vaccine demonstration project 
launched in 2015 
Taiwan, China HIC No   
HPV vaccine demonstration project 
launched in 2008. Introduction 
announced for November 2018 
Thailand UMIC Yes 2017 Introduced in August 2017 
Timor-Leste LMIC No   
No nationwide HPV immunization 
program 
Tonga UMIC No   
No nationwide HPV immunization 
program 
Tuvalu UMIC No   
No nationwide HPV immunization 
program 
Vanuatu LMIC Yes 2015   
Vietnam LMIC No   
HPV vaccine demonstration project 
rolled-out between in 2008 to 2010 
Wallis and Futuna    No   
No nationwide HPV immunization 
program 
Europe and Central Asia 
Albania UMIC No   
No nationwide HPV immunization 
program 
Andorra HIC Yes 2014   
Armenia UMIC No   
HPV vaccine demonstration project 
launched in 2017 for 2 years 
Austria HIC Yes 2014   
Azerbaijan UMIC No   
No nationwide HPV immunization 
program 
Belarus UMIC No   
No nationwide HPV immunization 
program 
Belgium HIC Yes 2007   
Bosnia and 
Herzegovina 
UMIC No   
No nationwide HPV immunization 
program 
Bulgaria UMIC Yes 2012   
Croatia HIC Yes 2016   
Cyprus HIC Yes 2016   
Czech Republic HIC Yes 2012   
Denmark HIC Yes 2009   
Estonia HIC No   
No nationwide HPV immunization 
program 
Faroe Islands HIC     
No data found on HPV immunization 
program 
Finland, Republic HIC Yes 2013   
France HIC Yes 2007   
French Guiana       
Commercialized since 2007 following 
recommendation in France 
Georgia LMIC No   
HPV vaccine demonstration project was 
launched 
Germany HIC Yes 2007   
Gibraltar HIC Yes 2008   
Greece HIC Yes 2008   
Greenland HIC Yes 2008   
Guernsey   Yes 2015 May have been introduced in 2015 
Hungary HIC Yes 2014   
Appendices 
3 
 
Iceland HIC Yes 2011   
Ireland HIC Yes 2010   
Isle of Man HIC Yes 2009   
Italy HIC Yes 2007   
Bailiwick of Jersey    Yes 2008   
Kazakhstan UMIC Yes 2013   
Kosovo LMIC     
No data found on HPV immunization 
program 
Kyrgyz Republic LMIC No   
No nationwide HPV immunization 
program 
Latvia HIC Yes 2010   
Liechtenstein HIC Yes 2007 Approved for use in 2007 
Lithuania HIC Yes 2016   
Luxembourg HIC Yes 2008   
Macedonia, FYR UMIC Yes 2009   
Moldova LMIC Yes 2012 Introduced in November 2017 
Monaco HIC Yes 2011   
Montenegro UMIC No   
No nationwide HPV immunization 
program. The HPV vaccine not been 
registered for use as at March 2018 
Netherlands HIC Yes 2010   
Norway HIC Yes 2009   
Poland HIC No   
No nationwide HPV immunization 
Program. The vaccine has been 
introduced in some territorial self-
government Units 
Portugal HIC Yes 2008   
Romania UMIC No   
No nationwide HPV immunization 
program. Voluntary immunization 
campaigns held in 2008 to 2010, but 
campaigns were discontinued due to low 
acceptance and uptake 
Russian Federation UMIC Yes 2009   
San Marino HIC Yes 2008   
Serbia UMIC No   
No nationwide HPV immunization 
program 
Slovak Republic HIC Yes 2014   
Slovenia HIC Yes 2009   
Spain HIC Yes 2007   
Sweden HIC Yes 2010   
Switzerland HIC Yes 2008   
Tajikistan LIC No   
No nationwide HPV immunization 
program 
Turkey UMIC No   
No nationwide HPV immunization 
program 
Turkmenistan UMIC Yes 2016   
Ukraine LMIC No   
No nationwide HPV immunization 
program 
United Kingdom HIC Yes 2008   
Uzbekistan LMIC Yes 2015   
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Latin America and the Caribbean 
Anguilla HIC Yes 2016 Introduced in April 2016 
Antigua and Barbuda HIC Yes 2018 
Nationwide HPV immunization begun in 
July 2018 
Argentina HIC Yes 2011   
Aruba HIC No   No nationwide HPV immunization program 
Bahamas, The HIC Yes 2015   
Barbados HIC Yes 2014   
Belize UMIC Yes 2016   
Bolivia LMIC No   
HPV vaccine demonstration projects rolled-
out between 2009 - 2011 
Brazil UMIC Yes 2014   
British Virgin Islands HIC     
No data found on HPV immunization 
program 
Cayman Islands HIC Yes 2012   
Chile HIC Yes 2014   
Colombia UMIC Yes 2012   
Costa Rica UMIC No   No nationwide HPV immunization program 
Cuba UMIC No   No nationwide HPV immunization program 
Dominica UMIC No   No nationwide HPV immunization program 
Dominican Republic UMIC No   
HPV immunization campaign rolled-out in 
April 2017 
Ecuador UMIC Yes 2015   
El Salvador LMIC No   No nationwide HPV immunization program 
Grenada UMIC No   No nationwide HPV immunization program 
Guatemala UMIC No   No nationwide HPV immunization program 
Guyana UMIC Yes 2011   
Haiti LIC No   
HPV vaccine demonstration projects rolled-
out in 2009 - 2010 and 2018 
Honduras LMIC Yes 2016   
Jamaica UMIC Yes 2017 Introduced in October 2017 
Mexico UMIC Yes 2012   
Netherlands Antilles        
No data found on HPV immunization 
program 
Nicaragua LMIC No   No nationwide HPV immunization program 
Panama HIC Yes 2008   
Paraguay UMIC Yes 2013   
Peru UMIC Yes 2011   
Puerto Rico HIC Yes 2006   
Sint Maarten (Dutch 
part) 
HIC Yes 2013   
St. Kitts and Nevis HIC No   
No nationwide HPV immunization 
program. Introduction announced for 2018 
St. Lucia UMIC No   No nationwide HPV immunization program 
St. Martin (French 
part) 
HIC       
St. Vincent and the 
Grenadines 
UMIC No   No nationwide HPV immunization program 
Suriname UMIC Yes 2013   
Trinidad and Tobago HIC Yes 2013   
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Turks and Caicos 
Islands 
HIC     
No data found on HPV immunization 
program 
Uruguay HIC Yes 2013   
Venezuela, RB UMIC No   
No nationwide HPV immunization 
program. Included in national 
immunization policy in 2015 but remains 
available through the NIP 
Virgin Islands (U.S.) HIC Yes 2006   
Middle East and North Africa 
Algeria UMIC No   No nationwide HPV immunization program 
Bahrain HIC No   No nationwide HPV immunization program 
Djibouti LMIC No   No nationwide HPV immunization program 
Egypt, Arab Republic LMIC No   No nationwide HPV immunization program 
Iran, Islamic Rep. UMIC No   No nationwide HPV immunization program 
Iraq UMIC No   No nationwide HPV immunization program 
Israel HIC Yes 2013   
Jordan UMIC No   No nationwide HPV immunization program 
Kuwait HIC No   No nationwide HPV immunization program 
Gaza Strip LMIC     
No data found on HPV immunization 
program 
Lebanon UMIC No   No nationwide HPV immunization program 
Libya UMIC Yes 2013   
Malta HIC Yes 2012   
Morocco LMIC No   No nationwide HPV immunization program 
Oman HIC No   No nationwide HPV immunization program 
Qatar HIC Yes 2018 Introduced in April 2018 
Saudi Arabia HIC No   No nationwide HPV immunization program 
Syrian Arab Republic LIC No   No nationwide HPV immunization program 
Tunisia LMIC No   No nationwide HPV immunization program 
United Arab Emirates HIC Yes 2008   
West Bank LMIC No   No nationwide HPV immunization program 
Western Sahara       
No data found on HPV immunization 
program 
Yemen, Rep. LIC No   No nationwide HPV immunization program 
North America 
Bermuda HIC Yes 2016   
Canada HIC Yes 2007   
Guadeloupe       
No data found on HPV immunization 
program 
Martinique       
No data found on HPV immunization 
program 
Montserrat       
No data found on HPV immunization 
program 
St Pierre & Miquelon        
No data found on HPV immunization 
program 
United States HIC Yes 2006   
South East Asia 
Afghanistan LIC No   No nationwide HPV immunization program 
Bangladesh LMIC No   
HPV vaccine demonstration project 
launched in 2016 for 2 years 
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Bhutan LMIC Yes 2010   
India LMIC No   
HPV vaccine demonstration project 
launched in 2009 
Maldives UMIC No   No nationwide HPV immunization program 
Nepal LIC No   
HPV vaccine demonstration program was 
launched 
Pakistan LMIC No   No nationwide HPV immunization program 
Sri Lanka LMIC Yes 2017 Introduced in July 2017 
Sub-Saharan Africa 
Angola LMIC Yes 2015 
Announced for nationwide introduction in 
2015 
Benin LIC No   
HPV vaccine demonstration project was 
launched 
Botswana UMIC Yes 2015   
Burkina Faso LIC No   
HPV vaccine demonstration project 
launched in 2015 
Burundi LIC No   
HPV vaccine demonstration project was 
launched 
Cameroon LMIC No   
HPV vaccine demonstration project 
launched between March 2010 - 
November 2012 
Cape Verde LMIC No   No nationwide HPV immunization program 
Central African 
Republic 
LIC No   No nationwide HPV immunization program 
Chad LIC No   No nationwide HPV immunization program 
Comoros LIC No   No nationwide HPV immunization program 
Congo, Democratic 
Republic 
LIC No   No nationwide HPV immunization program 
Congo Republic LMIC No   No nationwide HPV immunization program 
Côte d'Ivoire LMIC No   
HPV vaccine demonstration project 
launched in 2015 
Equatorial Guinea UMIC No   No nationwide HPV immunization program 
Eritrea LIC No   No nationwide HPV immunization program 
Ethiopia LIC No   
HPV vaccine demonstration project 
launched in December 2015 for 2 years. 
Nationwide introduction announced for 
2019 
Gabon UMIC No   No nationwide HPV immunization program 
Gambia, The LIC No   
HPV vaccine demonstration project 
launched in November 2014 
Ghana LMIC No   
HPV vaccine demonstration project 
launched in November 2013 for 2 years 
Guinea LIC No   No nationwide HPV immunization program 
Guinea-Bissau LIC No   No nationwide HPV immunization program 
Kenya LMIC No   
HPV vaccine demonstration project 
launched in 2013. Nationwide introduction 
announced for 2019 
Lesotho LMIC Yes 2012   
Liberia LIC No   
HPV vaccine demonstration project 
launched in April 2016 
Madagascar LIC No   
HPV vaccine demonstration project rolled-
out between 2013 to 2015 
Malawi LIC No   
HPV vaccine demonstration project rolled-
out between 2013 to 2016. Nationwide 
introduction announced for January 2019 
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Mali LIC No   
HPV vaccine demonstration project was 
launched 
Mauritania LMIC No   
HPV vaccine demonstration project was 
launched 
Mauritius UMIC Yes 2016 Announced in August 2016 
Mayotte       
No data found on HPV immunization 
program 
Mozambique LIC No   
HPV vaccine demonstration project 
launched in 2014 
Namibia UMIC No   No nationwide HPV immunization program 
Niger LIC No   
HPV vaccine demonstration project rolled-
out between 2013 to 2015 
Nigeria LMIC No   
HPV vaccine demonstration project was 
launched. Nationwide introduction 
planned for 2019 
Réunion       
No data found on HPV immunization 
program 
Rwanda LIC Yes 2011   
Saint Helena       
No data found on HPV immunization 
program 
São Tomé and 
Principe 
LMIC Yes 2016   
Senegal LIC Yes 2016   
Seychelles HIC Yes 2014   
Sierra Leone LIC No   
HPV vaccine demonstration project 
launched in 2012 for 2 years 
Somalia LIC No   No nationwide HPV immunization program 
South Africa UMIC Yes 2014   
South Sudan LIC No   No nationwide HPV immunization program 
Sudan LMIC No   No nationwide HPV immunization program 
Swaziland LMIC No   No nationwide HPV immunization program 
Tanzania LIC Yes 2018   
Togo LIC No   
HPV vaccine demonstration project was 
launched 
Uganda LIC Yes 2012   
Zambia LMIC No   
HPV vaccine demonstration project 
launched in 2013 
Zimbabwe LIC Yes 2018 Introduced in May 2018 
Source; Author, (drawing on data from http://www.hpvcentre.net, WHO 2018a; Gallagher et al. 2018; 
LaMontagne et al. 2017; Herrero et al. 2015)  
Notes: NIP = National Immunization Program; LIC = Low-Income Country; LMIC = Lower Middle-Income 
Country; UMIC = Upper Middle-Income Country; HIC = High-income Country.  
Country income ranking as defined by the World Bank (http://data.worldbank.org/about/country-
and-lending-groups). Where the income ranking is not indicated, the information could not be 
confirmed. 
Where nationwide HPV immunization programs have not been identified, it may be that the vaccine 
is available in the private health sector.  
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Appendix 2: Literature Search Strategy  
Query # Search Term 
#1 “Immuni* Program”  
#2 “National Immuni* Program” OR NIP OR “Expanded Program on Immuni*” OR EPI OR “Universal Immuni* Program” OR UIP OR Immuni* OR “Vaccination” OR “Vaccine Administration” OR 
Vaccine OR “Vaccine/Introduction” OR “Immuni*/Pilot*” OR “Immuni*/Demonstration Project” OR “Immuni* Program/Communication” OR “Immuni* Program/Community and Partnership” OR 
“Immuni* Program/Economics” OR “Immuni* Program/Finance” OR “Immuni* Program/Instrumentation” OR “Immuni* Program/Legislation” OR “Immuni* Program/Workforce” OR “Immuni* 
Program/Organization and Administration” OR “Immuni* Program/Management” OR “Immuni* Program/Supply and Distribution” OR “Immuni* Program/Performance” OR “Immuni* 
Program/Strengthen*” 
#3 #1 OR #2 
#4 “Health System”  
#5 “Global Health” OR “Health Service” OR Hospital OR Clinic OR “School Health” OR “Adolescent Health” OR “Health Policy” OR “Health Governance” OR “Health Workforce” OR “Health Worker” 
OR “Health Care Worker” OR “Health Provider” OR Nurse OR “Medical Products” OR “Medical Technologies” OR “Service Delivery” OR “Health Care” OR “Health Care Delivery” OR “Health 
Information” OR “Health Financing” OR “Health System/Constraints” OR “Health System/Limitations” OR “Health System/Restrictions” OR “Health System/Barriers” OR “Health 
System/Challenges” OR “Health System/Facilitators” OR “Health System/Enablers” OR “Health System/Drivers” OR “Health System/Building Blocks” OR “Health System/Strengthen*” OR “Health 
System/Function*” OR “Health System/Capacity” 
#6 #4 OR #5 
#7 #3 AND #6 
#8 “Sub-Saharan Africa” OR “West Africa” OR “East Africa” OR “Central Africa” OR “Southern Africa” 
#9 Algeria OR Angola OR Benin OR Botswana OR “Burkina Faso” OR Burundi OR Cameroon OR “Cape Verde” OR “Cabo Verde” OR “Central African Republic” OR Chad OR Comoros OR Comores OR 
Comoro OR Congo OR “Congo-Brazzaville” OR “Congo Republic” OR “Republic of the Congo” “Côte d'Ivoire” OR “Democratic Republic of the Congo” OR “DR Congo” OR DRC OR “Congo-Kinshasa” 
OR Djibouti OR “Equatorial Guinea” OR Eritrea OR Ethiopia OR Gabon OR Gambia OR “The Gambia” OR Ghana OR Guinea OR Guinea-Bissau OR Kenya OR Lesotho OR Liberia OR Madagascar OR 
Malawi OR Mali OR Mauritania OR Mauritius OR Mozambique OR Namibia OR Niger OR Nigeria OR Rwanda OR “Sao Tome and Principe” OR “São Tomé and Príncipe” OR Senegal OR Seychelles 
OR “Sierra Leone” OR Somalia OR “South Africa” OR “South Sudan” OR Sudan OR Swaziland OR Togo OR Uganda OR “United Republic of Tanzania” OR Tanzania OR Zambia OR Zimbabwe 
#10 #8 OR #9  
#11 “Human Papillomavirus/Vaccine” OR “HPV/Vaccine” OR “Cervical Cancer/Vaccine” OR Gardasil OR Cervarix OR “Human Papillomavirus/Vaccination” “Human Papillomavirus/Immuni*” OR “HPV 
Vaccination” OR “HPV/Immuni*”  
#12 #7 AND #10 AND #11 
Filters Abstract (Available); Full text (Available); published in last 10 years; Humans; English 
Source; Author 
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Appendix 3: Critical Appraisal Skills Programme (CASP) Appraisal Tool  
 
 
 
 
 
 
 
 
 
 
 
10 questions to help you make sense of qualitative research 
 
 
 
 
How to use this appraisal tool 
 
Three broad issues need to be considered when appraising a qualitative study: 
 
Are the results of the study valid? 
What are the results? 
Will the results help locally? 
 
 
(Section A) 
(Section B) 
(Section C) 
 
 
The 10 questions on the following pages are designed to help you think about these issues systematically. The first 
two questions are screening questions and can be answered quickly. If the answer to both is “yes”, it is worth 
proceeding with the remaining questions. 
 
There is some degree of overlap between the questions, you are asked to record a “yes”, “no” or “can’t tell” to 
most of the questions. A number of italicised prompts are given after each question. These are designed to remind 
you why the question is important. Record your reasons for your answers in the spaces provided. 
 
These checklists were designed to be used as educational pedagogic tools, as part of a workshop setting, therefore 
we do not suggest a scoring system. The core CASP checklists (randomised controlled trial & systematic review) 
were based on JAMA 'Users’ guides to the medical literature 1994 (adapted from Guyatt GH, Sackett DL, and Cook 
DJ), and piloted with health care practitioners. 
 
For each new checklist a group of experts were assembled to develop and pilot the checklist and the workshop 
format with which it would be used. Over the years overall adjustments have been made to the format, but a 
recent survey of checklist users reiterated that the basic format continues to be useful and appropriate. 
 
Referencing: we recommend using the Harvard style citation, i.e.: 
 
Critical Appraisal Skills Programme (2017). CASP (insert name of checklist i.e. Qualitative Research) Checklist. 
[online] Available at: URL. Accessed: Date Accessed. 
 
©CASP this work is licensed under the Creative Commons Attribution – Non Commercial-Share A like. To view 
a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ www.casp-uk.net  
 
 
 
 
 
 
 
 
 
 
©Critical Appraisal Skills Programme (CASP) Qualitative Research Checklist 13.03.17 1 
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 Screening Questions 
 
1. Was there a clear statement of the aims Yes   Can’t tell  No 
 
of the research? 
 
HINT: Consider  
What was the goal of the research? 
Why it was thought important? 
 
Its relevance  
 
 
 
 
 
 
 
2. Is a qualitative methodology appropriate? Yes   Can’t tell  No 
 
 
HINT: Consider  
If the research seeks to interpret or illuminate the 
actions and/or subjective experiences of research 
 
participants  
Is qualitative research the right methodology for 
addressing the research goal?  
 
 
 
 
 
 
 
 
Is it worth continuing? 
 
 
Detailed questions    
3. Was the research design appropriate to 

Yes 

Can’t tell 

 No 
address the aims of the research?   
 
HINT: Consider  
If the researcher has justified the research design 
(E.g. have they discussed how they decided 
which method to use)?  
 
 
 
 
 
 
 
 
©Critical Appraisal Skills Programme (CASP) Qualitative Research Checklist 13.03.17 2 
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4. Was the recruitment strategy appropriate to the 
 
Yes 
 
Can’t tell 
 
No 
 
aims of the research? 
 
HINT: Consider 
If the researcher has explained how the participants 
 
were selected  
If they explained why the participants they selected were 
the most appropriate to provide access to the type of 
 
knowledge sought by the study  
If there are any discussions around recruitment (e.g. why 
some people chose not to take part)  
 
 
 
 
 
 
5. Was the data collected in a way that addressed 
 
 
 
 
 
 
Yes 
 
 
 
 
 
 
Can’t tell 
 
 
 
 
 
 
No 
 
the research issue? 
 
HINT: Consider 
 
  If the setting for data collection was justified 
 
  If it is clear how data were collected (e.g. focus group,  
semi-structured interview etc.) 
 
  If the researcher has justified the methods chosen 
 
  If the researcher has made the methods explicit (e.g.  
for interview method, is there an indication of how  
interviews were conducted, or did they use a topic guide)? 
 
  If methods were modified during the study. If so, has  
the researcher explained how and why? 
 
  If the form of data is clear (e.g. tape recordings, video  
material, notes etc) 
 
  If the researcher has discussed saturation of data  
 
 
 
6. Has the relationship between researcher and 
 
 
 
Yes 
 
 
 
Can’t tell 
 
 
 
No 
 
participants been adequately considered? 
HINT: Consider  
If the researcher critically examined their own 
role, potential bias and influence during 
 
(a) Formulation of the research questions  
(b) Data collection, including sample recruitment and  
choice of location  
How the researcher responded to events during the 
study and whether they considered the implications of 
any changes in the research design  
 
 
©Critical Appraisal Skills Programme (CASP) Qualitative Research Checklist 13.03.17 3 
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7. Have ethical issues been taken into consideration? Yes   Can’t tell  No 
 
 
HINT: Consider  
If there are sufficient details of how the research was explained to 
participants for the reader to assess whether ethical standards 
 
were maintained  
If the researcher has discussed issues raised by the study (e.g. 
issues around informed consent or confidentiality or how they 
have handled the effects of the study on the participants during 
 
and after the study) 
If approval has been sought from the ethics committee  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. Was the data analysis sufficiently rigorous? Yes   Can’t tell  No 
 
 
HINT: Consider 
 
If there is an in-depth description of the analysis process If 
thematic analysis is used. If so, is it clear how the 
 
categories/themes were derived from the data?  
Whether the researcher explains how the data presented 
were selected from the original sample to demonstrate 
 
the analysis process 
If sufficient data are presented to support the findings 
 
To what extent contradictory data are taken into account 
Whether the researcher critically examined their own role, 
 
potential bias and influence during analysis and selection 
of data for presentation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©Critical Appraisal Skills Programme (CASP) Qualitative Research Checklist 13.03.17 4 
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9. Is there a clear statement of findings? Yes   Can’t tell  No 
 
 
HINT: Consider 
 
If the findings are explicit 
 
If there is adequate discussion of the evidence both for 
 
and against the researchers arguments  
If the researcher has discussed the credibility of their 
findings (e.g. triangulation, respondent validation, 
 
more than one analyst)  
If the findings are discussed in relation to the original 
research question  
 
 
 
 
 
 
 
 
 
 
 
 
 
10. How valuable is the research? 
 
HINT: Consider 
 
If the researcher discusses the contribution the study 
makes to existing knowledge or understanding e.g. do 
they consider the findings in relation to current 
 
practice or policy?, or relevant research-based literature? 
If they identify new areas where research is necessary  
If the researchers have discussed whether or how the 
findings can be transferred to other populations or 
considered other ways the research may be used  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©Critical Appraisal Skills Programme (CASP) Qualitative Research Checklist 13.03.17 5 
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Appendix 4: Data Extraction Table 
Study 
No. 
  
Study Details Context Data Extraction 
Author 
and Year 
Title Country Underlying 
Context 
Availability / Type 
of HPV 
Immunization 
Program 
Main 
Theme 
Health 
Systems 
Constraint 
Health Systems 
Facilitator 
Comment 1 Comment 2 Comment 3 
1 Audu et 
al. 2015 
Awareness and 
perception of human 
papilloma virus vaccine 
among healthcare 
professionals in Nigeria 
Nigeria Not 
Applicable 
Not Available Health 
Workers 
Inadequate 
training of 
health 
workers 
  91.0% were aware 
of HPV while 
44.0% knew about 
the HPV vaccine. 
81.0% would allow 
their teenage 
daughters to be 
vaccinated 
Reasons given 
for refusing HPV 
vaccination: lack 
of knowledge 
about the safety 
of the vaccine, 
immorality, 
doubt about 
vaccine potency 
Nurses and 
midwives were 
the least aware 
about the HPV 
vaccine (p = 
0.001) 
2 Ayissi et 
al. 2012 
Awareness, 
acceptability and 
uptake of human 
papilloma virus vaccine 
among Cameroonian 
school-attending 
female adolescents 
Cameroon Socio-
demographic 
Demonstration 
Project 
Information 
/ 
Community 
Engagement 
  Appropriate 
communication 
and 
sensitization 
strategies 
34.2% of the 
respondents had 
been vaccinated 
against HPV 
infection 
75.9% were 
aware that that 
HPV vaccine is 
important in 
preventing HPV 
infections and 
cervical cancer 
62.9% heard 
about HPV from 
a nurse. There 
was a high 
acceptability of 
HPV vaccination 
3 Bardají et 
al. 2018 
Awareness of cervical 
cancer and willingness 
to be vaccinated 
against human 
papillomavirus in 
Mozambican 
adolescent girls 
Mozambique Not 
Applicable 
Demonstration 
Project 
Information 
/ 
Community 
Engagement 
  Appropriate 
health 
education and 
sensitization 
about HPV 
vaccine 
Increased 
acceptability of 
HPV vaccine 
among adolescent 
girls was 
associated with 
level of education 
  
4 Botha et 
al. 2015 
The Vaccine and 
Cervical Cancer Screen 
(VACCS) project: 
Acceptance of human 
papillomavirus 
vaccination in a school-
based programme in 
two provinces of South 
Africa 
South Africa Socio-
economic 
Demonstration 
Project 
Information 
/ 
Community 
Engagement 
  Appropriate 
communication 
and 
sensitization 
strategies 
High acceptance 
rate following 
better information 
underlines the 
importance of 
clear, direct 
communication 
with parents 
Parents who 
received 
complete 
information on 
the HPV vaccine 
demonstrated a 
very high 
acceptance rate 
Appropriate 
information 
contributed 
significantly to 
vaccine uptake 
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5 Botwright 
et al. 2017 
Experiences of 
operational costs of 
HPV vaccine delivery 
strategies in Gavi-
supported 
demonstration projects 
African 
Countries 
Socio-
economic 
Demonstration 
Project 
Health 
Financing 
Non-
integration of 
HPV 
immunization 
programs 
within 
existing 
routine 
immunization 
programs  
Planning 
appropriate 
delivery 
strategies based 
on local 
context. 
Evidence-based 
social 
mobilization 
Social 
mobilization, 
information, 
education, and 
communication 
(IEC) and service 
delivery each 
comprised the 
greatest financial 
cost 
Countries 
incurring the 
greatest 
financial costs 
also had the 
highest social 
mobilization/IEC 
costs 
School-based 
delivery had the 
highest service 
delivery cost per 
dose due to 
transportation 
costs and health 
worker per 
diems 
6 Chigbu et 
al. 2017 
The impact of 
community health 
educators on uptake of 
cervical and breast 
cancer prevention 
services in Nigeria 
Nigeria Socio-
economic 
Demonstration 
Project 
Health 
Workers 
  Educating and 
training nurses 
on the HPV 
vaccination 
schedule and 
technique 
The intervention 
was house-to-
house cervical and 
breast cancer 
prevention 
education by 
trained health 
workers 
At baseline, 
only 2 (0.9%) 
children had 
received HPV 
vaccination. 
This increased 
to 33.2% after 
the intervention 
(p<0.001) 
Education of 
mothers 
improves the 
uptake of HPV 
vaccination of 
children 
7 Coleman 
et al. 2011 
HPV vaccine 
acceptability in Ghana, 
West Africa 
Ghana Socio-
economic 
Available in 
Private Sector 
Only 
Information 
/ 
Community 
Engagement 
Lack of 
awareness, 
poor 
knowledge 
about cervical 
cancer and 
HPV vaccine 
Education, 
social 
mobilization, 
communication 
about HPV and 
the vaccine 
Although majority 
of the women had 
heard about 
cervical cancer 
(87%) and Pap test 
(63%) before the 
survey, fewer 
women had heard 
about the HPV 
vaccine (40%) 
Participants 
proved very 
accepting of the 
HPV vaccine, 
both for 
themselves and 
their daughters 
(94% each) 
Those less likely 
to accept the 
vaccine had 
significantly 
lower level of 
income  
8 De Groot 
et al. 2017 
Knowledge, attitudes, 
practices and 
willingness to vaccinate 
in preparation for the 
introduction of HPV 
vaccines in Bamako, 
Mali 
Mali Socio-
economic 
Demonstration 
Project 
Information 
/ 
Community 
Engagement 
  Education and 
communication 
about HPV, 
cervical cancer 
and HPV 
vaccination 
Before the 
educational 
session, awareness 
about HPV was 
low; 8.6% knew 
that HPV was 
transmitted by 
sexual contact 
Knowledge of 
the participants 
significantly 
increased after 
the education 
session.  
The education 
session 
increased the 
HPV vaccine 
acceptance in all 
groups, 
especially among 
adolescents  
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9 DiAngi et 
al. 2011 
A cross-sectional study 
of HPV vaccine 
acceptability in 
Gaborone, Botswana 
Botswana Socio-
economic 
Available in 
Private Sector 
Only 
Information 
/ 
Community 
Engagement 
  Education and 
communication 
about HPV, 
cervical cancer 
and HPV 
vaccination 
Prior to the survey, 
few (9%) 
respondents had 
heard of HPV 
vaccine, and most 
(75%) wanted 
more information 
about it  
80% percent of 
respondents 
said they would 
obtain the HPV 
vaccine for their 
adolescent 
daughters 
  
10 Francis et 
al. 2011 
A qualitative analysis of 
South African women's 
knowledge, attitudes, 
and beliefs about HPV 
and cervical cancer 
prevention, vaccine 
awareness and 
acceptance, and 
maternal-child 
communication about 
sexual health 
South Africa Socio-
economic 
Available in 
Private Sector 
Only 
Information 
/ 
Community 
Engagement 
Poor access to 
information 
about HPV, 
cervical 
cancer and 
HPV vaccine 
  Majority of 
participants knew 
little about HPV, 
cervical cancer, 
and the HPV 
vaccine, and they 
expressed interest 
in learning more 
about these topics 
Participants 
agreed that 
vaccinations 
would keep 
their children 
healthy, but 
they worried 
about long-term 
side effects 
Most 
participants 
thought the 
government 
should offer the 
vaccine for free 
as part of the 
country’s 
immunization 
program 
11 Francis et 
al. 2010 
Examining attitudes and 
knowledge about HPV 
and cervical cancer risk 
among female clinic 
attendees in 
Johannesburg, South 
Africa 
South Africa Socio-
economic 
Not Available Information 
/ 
Community 
Engagement 
Poor access to 
information 
about HPV, 
cervical 
cancer and 
HPV vaccine 
  39% of 
participants had 
not heard of 
cervical cancer 
while 71% had 
never heard of 
HPV 
Almost half of 
participants 
were very likely 
to vaccinate if 
their health 
provider 
recommended 
it  
Commonly cited 
barriers to 
vaccinating 
included 
inadequate 
information, fear 
of side effects, 
cost of vaccine. 
12 Friedman 
et al. 2014 
Preparing for human 
papillomavirus vaccine 
introduction in Kenya: 
implications from 
focus-group and 
interview discussions 
with caregivers and 
opinion leaders in 
Western Kenya 
Kenya Socio-cultural Not Available Information 
/ 
Community 
Engagement 
Poor access to 
information 
about HPV, 
cervical 
cancer and 
HPV vaccine 
Effective 
Community 
sensitization 
about HPV 
vaccination 
through 
culturally 
appropriate 
strategies 
Majority of 
caregivers and 
opinion leaders 
had not previously 
heard of cervical 
cancer 
Apart from 
health and 
media experts 
(n = 3), none of 
the participants 
had heard of 
the HPV vaccine 
Participants 
identified 
cultural beliefs 
as potential 
barriers to 
vaccination  
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13 Harries et 
al. 2009 
Preparing for HPV 
vaccination in South 
Africa: key challenges 
and opinions 
South Africa Not 
Applicable 
Available in 
Private Sector 
Only 
Service 
Delivery 
Health 
resource 
constraints. 
Logistical 
challenges 
with vaccine 
delivery  
Appropriate 
health 
promotion 
strategies. 
Partnerships 
between 
Departments of 
Education + 
Health, private 
+ public health 
sectors  
Policy influencers 
and health 
providers 
expressed strong 
support for the 
HPV vaccine  
Participants 
acknowledged 
the difficulties 
of introducing a 
new technology 
in a health 
system with 
limited capacity 
and resources - 
especially 
where school 
health is 
concerned 
Opposition could 
be countered by 
providing 
comprehensive 
information and 
communication 
with all 
stakeholders 
about the 
benefits of the 
HPV 
immunization 
14 Hoque 
2015 
Acceptability of human 
papillomavirus 
vaccination among 
academics at the 
University of KwaZulu-
Natal, South Africa 
South Africa Socio-
economic 
Available through 
NIP 
Information 
/ 
Community 
Engagement 
Poor 
knowledge 
about safety 
and 
effectiveness 
of the vaccine 
Adequate 
knowledge 
about HPV, 
cervical cancer 
and HPV 
vaccine 
Almost all (96%) 
the academics had 
heard of cervical 
cancer and all had 
heard about HPV 
After reading 
information on 
cervical cancer 
and HPV, the 
vaccine 
acceptability 
rate increased 
from 80% to 
89% 
Those who still 
did not want to 
vaccinate their 
daughters cited 
the “newness” of 
the vaccine and 
fear of side-
effects. 
15 Hoque 
2016 
Factors influencing the 
recommendation of the 
Human Papillomavirus 
vaccine by South 
African doctors working 
in a tertiary hospital 
South Africa Not 
Applicable 
Available through 
NIP 
Health 
Workers 
Low level of 
knowledge on 
HPV infection 
and 
vaccination 
among 
Doctors 
  75.3% of Doctors 
indicated not 
knowing the 
effectiveness of 
the HPV vaccine 
Only one doctor 
(of 320) agreed 
that the 
vaccines should 
be given to girls 
before sexual 
debut 
96.3% of the 
Doctors 
indicated 
willingness to 
recommend the 
vaccines to their 
patients 
16 Hoque et 
al 2013 
Human Papillomavirus 
vaccination 
acceptability among 
female university 
students in South Africa 
South Africa Not 
Applicable 
Available in 
Private Sector 
Only 
Information 
/ 
Community 
Engagement 
Low level of 
knowledge on 
HPV infection, 
cervical 
cancer, and 
HPV vaccine 
  Overall, awareness 
of cervical cancer 
and HPV was low 
Of the 163 
students who 
reported never 
having had sex, 
127 (77.3%) 
were willing to 
accept HPV 
vaccination 
Reasons for non-
acceptance, 
included fear of 
injection 
(78.9%), side-
effects (15.8%), 
and pain (5.3%) 
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17 Hutubessy 
et al. 2012 
A case study using the 
United Republic of 
Tanzania: Costing 
nationwide 
HPV vaccine delivery 
using the WHO Cervical 
Cancer Prevention and 
Control Costing Tool 
Tanzania Not 
Applicable 
Not Available Health 
Financing 
Financial costs 
of social 
mobilization 
and HPV 
vaccine 
delivery 
  Excluding vaccine 
procurement, 
social mobilization 
and IEC 
contributed to the 
largest share of 
costs, followed by 
service delivery 
Substantial 
funding is 
required to 
facilitate HPV 
vaccine delivery 
Recurrent costs 
per dose would 
be higher for a 
school-based 
compared to 
health facility-
based delivery 
because of 
transportation 
costs and health 
worker per 
diems 
18 Kamya et 
al. 2017 
Evaluating global health 
partnerships: A case 
study of a Gavi HPV 
vaccine application 
process in Uganda 
Uganda Political Available through 
NIP 
Governance 
/ Policy 
Weak 
involvement 
Ministries of 
Education and 
Finance  
Clear 
governance and 
management 
structures and 
processes. 
Political 
champions 
(First Lady). 
Advocacy by 
NGOs (PATH) 
Respondents 
agreed that 
partnerships 
increased country 
ownership and 
improved the 
effectiveness and 
efficiency of the 
GAVI application 
process 
Potential 
drawbacks of 
the partnership, 
included an 
unnecessary 
management 
burden on 
organization 
Network 
mapping 
identified the 
absence of the 
Ministries of 
education and 
Finance 
19 Katz et al. 
2013 
A qualitative analysis of 
factors influencing HPV 
vaccine uptake in 
Soweto, South Africa 
among adolescents and 
their caregivers 
South Africa Socio-
economic 
Available in 
Private Sector 
Only 
Health 
Workers 
  The influence of 
health workers 
Health workers at 
the adolescent 
clinic were serves 
as “adult proxies” 
and positively 
influenced HPV 
vaccine uptake 
High HIV 
endemicity, 
sexual violence, 
poverty, and an 
abundance of 
female-headed 
households 
influenced 
vaccine uptake 
  
20 Ladner et 
al. 2012 
Assessment of eight 
HPV vaccination 
programs implemented 
in lowest income 
countries 
Lesotho and 
Cameroon 
(non-African 
countries 
included) 
Socio-
economic 
Demonstration 
Project 
Service 
Delivery 
  Use of mixed 
vaccine delivery 
models; school 
and health 
facility -based 
strategies 
Health-facility 
model had a lower 
vaccine coverage 
(77.1%) compared 
to the school-
based (93.0%) or 
mixed model 
(93.8%) (p = 0.74)  
With regards to 
adherence to 
the vaccine 
doses, the 
mixed model 
was the most 
effective 
In Cameroon, 
intensive IEC 
strategies were 
facilitators to the 
success of HPV 
vaccination 
campaigns 
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21 Ladner et 
al. 2014 
Performance of 21 HPV 
vaccination programs 
implemented in low 
and middle-income 
countries, 2009-2013 
Cameroon, 
Kenya, 
Lesotho, 
Tanzania and 
Uganda (non-
African LMICs 
included) 
Socio-
economic 
Demonstration 
Project 
Service 
Delivery 
  Use of school-
based delivery 
models. 
Community 
engagement. 
Adequate 
communication, 
especially on 
vaccine safety 
and efficacy  
School-based 
vaccine delivery 
and program 
management by 
an NGO (vs MoH) 
each had a positive 
and statistically 
significant impact 
on vaccine uptake 
rates 
Community 
involvement 
appeared to 
have a positive 
impact on the 
vaccine uptake 
rate 
Inclusion of key 
messages 
regarding the 
safety and 
efficacy of the 
vaccine had a 
positive impact 
on vaccine 
uptake 
22 LaMontag
ne et al. 
2011 
Human papillomavirus 
vaccine delivery 
strategies that achieved 
high coverage in low- 
and middle-income 
countries 
Uganda (non-
African LMICs 
included) 
Socio-
economic 
Demonstration 
Project 
Service 
Delivery 
Use of age-
based vaccine 
delivery 
models. Low 
level of 
awareness 
about HPV 
vaccine and 
vaccination 
program 
Use of grade-
based vaccine 
delivery models 
Parents' 
perceived 
benefits of HPV 
vaccine due to 
sensitization 
and trust in 
existing NIP 
High HPV 
vaccination 
coverage was 
achieved with the 
grade-based 
compared to the 
age-based vaccine 
delivery strategy in 
Uganda 
The most 
frequently cited 
reasons for non-
vaccination was 
a lack of 
awareness of 
the 
immunization 
programme  
Difficulty in 
determining 
girl’s eligibility 
was the mainly 
challenge with 
the age-based 
vaccine delivery 
model 
23 Levin et 
al. 2013 
Delivery cost of human 
papillomavirus 
vaccination of young 
adolescent girls in Peru, 
Uganda and Viet Nam 
Uganda (non-
African LMICs 
included) 
Socio-
economic 
Demonstration 
Project 
Health 
Financing 
Cost of 
delivering 
vaccines to 
adolescents is 
higher than 
that of 
routine 
childhood 
immunization 
Investments in 
community 
mobilization 
and 
sensitization 
increases 
vaccine 
acceptance and 
uptake 
School-based 
vaccine delivery 
incurred a higher 
economic cost 
than the health 
facility-based or 
integrated 
outreach models 
The average 
incremental 
economic cost 
per fully 
immunized girl 
was highest 
with school-
based delivery 
model 
Community 
mobilization and 
IEC activities 
accounted for 
approximately 
40% of start-up 
costs 
24 Mabeya 
et al. 2018 
Uptake of three doses 
of HPV vaccine by 
primary school girls in 
Eldoret, Kenya; a 
prospective cohort 
study in a malaria 
endemic setting 
Kenya Disease 
Epidemiology 
Demonstration 
Project 
Service 
Delivery 
Low level of 
awareness 
about HPV. 
Distance to 
health facility. 
  Of those who 
received the first 
dose of HPV 
vaccine (3026), 
63.8% returned for 
the second dose, 
and 39.1% for the 
third dose  
Administration 
of the 2nd dose 
and caregiver's 
knowledge of 
HPV were 
predictors of 
uptake of the 
3rd dose  
Distance to the 
health facility 
was a significant 
barrier to uptake 
of subsequent 
doses of the HPV 
vaccine 
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25 MacPhail 
et al. 2013 
Using HPV vaccination 
for promotion of an 
adolescent package of 
care: Opportunity and 
perspectives 
South Africa Socio-
economic 
Available in 
Private Sector 
Only 
Information 
/ 
Community 
Engagement 
Poor access to 
information 
about HPV, 
cervical 
cancer and 
HPV vaccine 
  Participants 
expressed demand 
for information 
about the HPV 
vaccine  
Community 
members 
echoed 
adolescents’ 
demands for 
information 
about the HPV 
vaccine 
There was an 
expressed need 
for integrating 
other adolescent 
health programs 
with HPV 
immunization  
26 Makwe 
and 
Anorlu 
2011 
Knowledge of and 
attitude toward human 
papillomavirus infection 
and vaccines among 
female nurses at a 
tertiary hospital in 
Nigeria 
Nigeria Not 
Applicable 
Not Available Health 
Workers 
Low level of 
knowledge on 
HPV, cervical 
cancer 
prevention 
and HPV 
vaccine 
  99.4% had heard 
of cervical cancer 
and 84.8% had 
heard of HPV 
infection. Only 
13% knew it could 
be prevented 
through 
vaccination 
Most (74.7%) of 
the respondents 
had never heard 
of the HPV 
vaccines 
Reasons for not 
recommending 
HPV vaccination 
included: young 
age, poor 
knowledge of 
risk factors and 
vaccine safety  
27 Masika et 
al. 2015 
Knowledge on HPV 
vaccine and cervical 
cancer facilitates 
vaccine acceptability 
among school teachers 
in Kitui County, Kenya 
Kenya Socio-
economic 
Demonstration 
Project 
Information 
/ 
Community 
Engagement 
Lack of 
information 
about HPV 
and HPV 
vaccine. poor 
road 
networks to 
schools 
Effective social 
mobilization. 
Engaging 
teachers at the 
outset of the 
HPV 
immunization 
program 
95% of 
participants knew 
that the HPV 
vaccine prevents 
cervical cancer, 
but they had very 
little information 
about HPV 
infection and 
cervical cancer 
89% would 
allow their 
daughter or 
close relative to 
receive the 
vaccine.  
Vaccine refusal 
was mainly 
associated with 
concerns about 
vaccine safety 
28 Massey et 
al. 2017 
Human papillomavirus 
(HPV) awareness and 
vaccine receptivity 
among Senegalese 
adolescents 
Senegal Socio-
economic 
Demonstration 
Project 
Information 
/ 
Community 
Engagement 
Low level of 
awareness 
about HPV 
and HPV 
vaccine. Poor 
socio-
economic 
status 
Appropriate 
health worker 
re-
commendation 
on HPV vaccine  
27% of 
participants had 
heard of HPV. Only 
28% of those who 
had heard about 
HPV indicated 
willingness to 
vaccinate 
Health 
providers’ re-
commendations 
were strongly 
associated with 
willingness to 
vaccinate 
As socio-
economic status 
increased, the 
odds of having 
heard of HPV 
also increased 
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29 Moodley 
et al. 2013 
High uptake of Gardasil 
vaccine among 9 – 12-
year-old schoolgirls 
participating in an HPV 
vaccination 
demonstration project 
in KwaZulu-Natal 
Province, South Africa 
South Africa Not 
Applicable 
Available in 
Private Sector 
Only 
Service 
Delivery 
Use of paper-
based vaccine 
records 
School-based 
vaccine delivery 
strategy. Well-
trained school 
health team. 
Intensive 
community 
mobilization 
and 
sensitization 
99.7% received 
their first dose of 
vaccine, 97.9% 
received their 
second dose, and 
97.8% received 
their third dose.  
High uptake of 
the vaccine 
depends on 
parental or 
caregiver 
consent  
Using 
predominantly 
paper-based 
vaccine records 
was cited as a 
barrier to real-
time monitoring 
and evaluation 
of the program 
30 Morhason
-Bello et 
al. 2015 
Willingness of 
reproductive-aged 
women in a Nigerian 
community to accept 
human papillomavirus 
vaccination for their 
children 
Nigeria Not 
Applicable 
Available in 
Private Sector 
Only 
Information 
/ 
Community 
Engagement 
Low level of 
awareness 
about HPV 
and HPV 
vaccine 
Free, universal 
HPV vaccination 
64.3% strongly 
agreed that HPV 
vaccination should 
be made 
mandatory to all 
female children 
Concerns about 
the vaccine 
included: cost 
(10.2%) and fear 
of encouraging 
promiscuity 
(9.9%), early 
sexual debut 
(6.7%), 
infertility 
(6.3%), and 
side-effects 
(6.0%) 
88.6% women 
were willing to 
vaccinate their 
children 
31 Msyambo
za et al. 
2017 
Implementation of a 
human papillomavirus 
vaccination 
demonstration project 
in Malawi: successes 
and challenges 
Malawi Not 
Applicable 
Demonstration 
Project 
Service 
Delivery 
Use of health 
facility-based 
or community 
outreach 
delivery 
models. Low 
level 
awareness 
about the 
safety of the 
vaccine 
Using a school-
based vaccine 
delivery 
strategy 
23,831 (89.0%) of 
school girls and 
403 (52.7%) out-
of-school girls 
aged 9–13 years 
were fully 
vaccinated 
Reasons cited 
for no or partial 
vaccination 
included girls 
transferring out 
of the district, 
dropping out of, 
and absence 
from school, 
and caregivers’ 
dissent 
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32 Mugisha 
et al. 2015 
Feasibility of delivering 
HPV vaccine to girls 
aged 10 to 15 years in 
Uganda 
Uganda Not 
Applicable 
Demonstration 
Project 
Service 
Delivery 
Use of age-
based vaccine 
delivery 
strategy 
Use of grade-
based vaccine 
delivery 
strategy. Active 
participation by 
teachers. 
Government 
endorsement of 
the vaccine 
Use of the grade-
based strategy 
achieved higher 
vaccination 
coverage 
compared to the 
age-based strategy 
Establishing 
eligibility was 
easier with the 
grade-based 
compared to 
the age-based 
strategy 
The dropout rate 
between the 1st 
and 3rd dose was 
higher using the 
age-based model  
33 Ndizeye 
et al. 2018 
Knowledge and 
practices of general 
practitioners at district 
hospitals towards 
cervical cancer 
prevention in Burundi, 
2015: A cross-sectional 
study 
Burundi Not 
Applicable 
Not Available Health 
Workers 
Low level of 
knowledge 
about HPV 
vaccination 
among 
General 
Practitioners 
(GPs) 
  Of 131 GPs, 89% 
knew that HPV 
infection is 
associated with 
most cervical 
cancer cases 
55% of GPs 
were aware that 
the HPV vaccine 
can prevent 
invasive cervical 
cancer 
Only 10.7% knew 
the target age 
group for HPV 
immunization 
and 3.1% knew 
the required 
doses 
34 Ngabo et 
al. 2017 
A cost comparison of 
introducing and 
delivering 
pneumococcal, 
rotavirus and human 
papillomavirus vaccines 
in Rwanda 
Rwanda Socio-
economic 
Available through 
NIP 
Health 
Financing 
High financial 
cost of HPV 
vaccine 
delivery due 
to greater 
resource 
requirements  
  The financial cost 
of delivering the 
HPV vaccine was 
significantly higher 
compared to other 
routine childhood 
vaccines  
HPV vaccine 
introduction 
costs were 
higher due to 
greater social 
mobilization 
and training 
requirements 
Recurrent costs 
were greater for 
the HPV vaccine 
than for routine 
childhood 
vaccines 
35 Odunyemi 
et al. 2018 
Effect of nursing 
intervention on 
mothers' knowledge of 
cervical cancer and 
acceptance of human 
papillomavirus 
vaccination for their 
adolescent daughters in 
Abuja - Nigeria 
Nigeria Not 
Applicable 
Available in 
Private Sector 
Only 
Health 
Workers 
Lack of 
education on 
HPV, cervical 
cancer and 
HPV 
vaccination. 
Cost of 
vaccination 
Adequate 
education and 
communication 
from nurses 
about HPV, 
cervical cancer 
and HPV 
vaccination 
Prior to the 
intervention 74% 
in the 
experimental arm 
and 83.1% in the 
control group had 
heard about 
cervical cancer 
85.5% of the 
respondents 
cited lack of 
information as a 
deterrent to 
vaccinating 
their daughters  
HPV vaccine 
acceptance 
increased after 
the intervention  
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36 Ogembo 
et al. 2014 
Achieving high uptake 
of human 
papillomavirus vaccine 
in Cameroon: Lessons 
learned in overcoming 
challenges 
Cameroon Socio-
economic 
Demonstration 
Project 
Service 
Delivery 
Negative 
media reports 
about the 
side-effects 
and 
interference 
in HPV 
immunization 
program 
Use of mixed 
vaccine delivery 
models. 
Adequate 
community 
sensitization. 
Community 
engagement, 
especially with 
municipal and 
religious leaders 
Low vaccine 
uptake despite 
adequate social 
mobilization was 
linked with false 
reports by a 
newspaper article 
claiming the 
vaccine had 
serious side effects 
including death  
The use of 
mixed vaccine 
delivery models 
involving 
school-based 
and community 
outreach 
approaches was 
feasible 
Wealthy 
community 
members 
subsidized the 
cost of 
immunization for 
those who could 
not afford to pay 
37 Okunade 
et al. 2017 
Knowledge and 
acceptability of human 
papillomavirus 
vaccination among 
women attending the 
gynaecological 
outpatient clinics of a 
university teaching 
hospital in Lagos, 
Nigeria 
Nigeria Socio-
demographic 
Available in 
Private Sector 
Only 
Information 
/ 
Community 
Engagement 
High cost of 
vaccination. 
Poor 
knowledge of 
the safety of 
the vaccine. 
Limited access 
to the HPV 
vaccine 
  36.5% of the 
respondents had 
heard about 
genital HPV 
infection and 
18.9% were aware 
of the existence of 
HPV vaccines 
81.8% of the 
respondents 
expressed their 
willingness to 
vaccinate their 
daughters 
Reasons 
unwillingness to 
vaccinate were 
high cost (55.6%) 
concerns about 
side-effects 
(48.1%), and 
poor availability 
(25.9%) of the 
vaccine 
38 Poole et 
al. 2013 
A cross-sectional study 
to assess HPV 
knowledge and HPV 
vaccine acceptability in 
Mali 
Mali Socio-cultural Not Available Information 
/ 
Community 
Engagement 
Low level of 
knowledge 
about HPV 
and cervical 
cancer 
  Participants 
exhibited low level 
of knowledge 
about HPV and 
cervical cancer 
100% of 
participants said 
they would like 
the HPV vaccine 
to be available 
in Mali 
There was a high 
level of 
willingness to 
vaccinate 
39 Ports et 
al. 2013 
Barriers and facilitators 
to HPV vaccination: 
Perspectives from 
Malawian women 
Malawi Socio-cultural Not Available Information 
/ 
Community 
Engagement 
Long distance 
to health 
facilities. 
Inadequate 
IEC strategies 
about HPV, 
cervical 
cancer and 
HPV vaccine 
Health worker 
re-
commendation 
on HPV vaccine. 
Adequate IEC 
and community 
engagement 
Participants’ 
knowledge about 
HPV and cervical 
cancer was 
limited. None of 
the women had 
heard of the HPV 
vaccine 
Long distance to 
health facilities 
negatively 
influenced 
women’s ability 
to access health 
services and 
their decision to 
vaccinate 
All participants 
were accepting 
of the vaccine 
once informed 
about it and 
were willing to 
recommend the 
vaccine to others 
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40 Quentin 
et al. 2012 
Costs of delivering 
human papillomavirus 
vaccination to 
schoolgirls in Mwanza 
Region, Tanzania 
Tanzania Socio-
economic 
Demonstration 
Project 
Health 
Financing 
Using an age-
based vaccine 
delivery 
strategy – less 
cost effective 
Using a class or 
grade-based 
vaccine delivery 
strategy – more 
cost-effective 
Marked difference 
in the costs of 
delivering HPV 
vaccines to girls 
between age-
based and class-
based deliver 
The cost per 
fully-immunized 
schoolgirl using 
a class-based 
delivery 
strategy was 
lower 
  
41 Remes et 
al. 2012 
A qualitative study of 
HPV vaccine 
acceptability among 
health workers, 
teachers, parents, 
female pupils, and 
religious leaders in 
northwest Tanzania 
Tanzania Not 
Applicable 
Not Available Information 
/ 
Community 
Engagement 
Low level of 
awareness 
about HPV, 
cervical 
cancer and 
HPV vaccine. 
Fragile health 
worker 
capacity and 
limited health 
resources 
Appropriate 
community 
sensitization 
Nurses' knowledge 
was limited. None 
of the parents, 
teachers, religious 
leaders or the girls 
had heard about 
HPV or the 
vaccine.  
Most 
respondents 
welcomed the 
vaccine. Almost 
all parents 
indicated they 
would vaccinate 
their daughters. 
All the girls 
wanted to be 
vaccinated 
Health workers 
were concerned 
about staff 
shortages and 
lack of transport 
if the HPV 
immunization 
program was to 
be introduced in 
the country 
42 Tchounga 
et al. 2012 
Cervical cancer 
prevention in 
reproductive health 
services: Knowledge, 
attitudes and practices 
of midwives in Côte 
d'Ivoire, West Africa 
Côte d'Ivoire Socio-
demographic 
Available in 
Private Sector 
Only 
Health 
Workers 
Low level of 
knowledge 
about cervical 
cancer and 
HPV vaccine 
Appropriate 
training of 
health workers 
on cervical 
cancer and 
cervical cancer 
prevention 
Only 298 midwives 
(50.3%) were 
aware of the HPV 
vaccine and knew 
that it protects 
against cervical 
cancer 
38.5% of the 
midwives knew 
that the vaccine 
was already 
available in Côte 
d’Ivoire 
Factors 
associated with 
appropriate 
knowledge were 
professional 
experience, 
training 
43 Torres-
Rueda et 
al. 2016 
HPV vaccine 
introduction in Rwanda: 
Impacts on the broader 
health system 
Rwanda Socio-
economic 
Available through 
NIP 
Service 
Delivery 
  Appropriate 
training, 
supervision, 
planning, 
partnerships, 
and political 
will. 
Strengthening 
surveillance 
HPV vaccine-
specific 
supervision was 
reported by 10/27 
health facilities 
and were said to 
have taken place 
before and during 
immunizations 
Surveillance of 
adverse events 
following 
immunization 
was emphasised 
during planning 
and formed part 
of training of 
health workers 
A cold chain 
inventory was 
carried out 
before the 
introduction of 
the HPV vaccine  
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44 Tuhiro et 
al. 2014 
Effect of school-based 
human papillomavirus 
(HPV) vaccination on 
adolescent girls' 
knowledge and 
acceptability of the HPV 
vaccine in Ibanda 
District in Uganda 
Uganda Socio-
demographic 
Demonstration 
Project 
Information 
/ 
Community 
Engagement 
Mis-
information 
about the 
side-effects of 
the HPV 
vaccine 
Pre-
immunization 
sensitization 
Vaccinated girls 
who were 
sensitized during 
the demonstration 
project had a 
higher level of 
knowledge about 
cervical cancer and 
the HPV vaccine 
Motivation for 
HPV vaccine 
acceptability 
was related to 
appreciation of 
its preventive 
role against 
cervical cancer 
Introduction of 
the HPV vaccine 
triggered several 
rumours which 
threatened 
acceptability of 
the vaccine 
45 Tuhiro et 
al. 2017 
Perceptions of human 
papillomavirus 
vaccination of 
adolescent schoolgirls 
in western Uganda and 
their implications for 
acceptability of HPV 
vaccination: A 
qualitative study 
Uganda  Socio-cultural Demonstration 
Project 
Information 
/ 
Community 
Engagement 
Mis-
information 
about the 
benefits of 
the HPV 
vaccine 
Existing 
perceptions 
that vaccination 
in general 
prevents 
disease due to 
the availability 
of a well-
functioning NIP 
Following IEC and 
community 
mobilization, 
respondents 
perceived the HPV 
vaccine to be 
beneficial 
Misconceptions 
potentially 
threatened 
acceptance; 
Some believed 
that the vaccine 
prevented HIV 
and pregnancy  
Misconceptions 
about safety of 
the HPV vaccine 
persisted despite 
dissemination of 
information 
about vaccine 
safety 
46 Ugwu et 
al. 2013 
Acceptability of human 
papilloma virus vaccine 
and cervical cancer 
screening among 
female health-care 
workers in Enugu, 
Southeast Nigeria 
Nigeria Socio-
demographic 
Available in 
Private Sector 
Only 
Health 
Workers 
Non-
availability of 
the vaccine in 
the NIP and 
high cost of 
the vaccine 
  85.9% were aware 
of cervical cancer 
and 84.2% knew 
that HPV was the 
causative agent 
62.7% 
respondents 
were aware of 
the HPV vaccine 
and 91% of 
them were 
willing to 
recommend it 
Reasons for non-
vaccination 
included cost 
(92%) and 
limited access to 
the vaccine 
(76%) 
47 Umeh et 
al. 2016 
Mothers' willingness to 
pay for HPV vaccines in 
Anambra state, Nigeria: 
A cross sectional 
contingent valuation 
study 
Nigeria Socio-
economic 
Available in 
Private Sector 
Only 
Health 
financing 
High cost of 
the HPV 
vaccine 
Availability of 
GAVI funding 
and support 
Demand for HPV 
vaccine was high. 
A total of 91.6% of 
mothers were 
willing to pay for 
the HPV vaccine 
Majority of the 
mothers were 
willing to pay an 
average of US$ 
11.68 to get 
their daughters 
fully vaccinated 
At the GAVI 
vaccine price, up 
to US$ 7.58 is 
needed to 
augment the 
cost of the 
vaccine  
48 Urasa and 
Darj 2011 
Knowledge of cervical 
cancer and screening 
practices of nurses at a 
regional hospital in 
Tanzania 
Tanzania Socio-
demographic 
Available in 
Private Sector 
Only 
Health 
Workers 
Inadequate 
knowledge on 
HPV 
vaccination. 
Inadequate 
training 
  Only 31 (22.6%) of 
the respondents 
were aware of the 
HPV vaccine 
Of these, 7 
(22.6%) knew 
that vaccination 
should be done 
before sexual 
debut 
Only 2.9% and 
8% had attended 
relevant training 
seminars 
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49 Venturas 
and Umeh 
2017 
Health professional 
feedback on HPV 
vaccination roll-out in a 
developing country 
Zambia Socio-
economic 
Demonstration 
Project 
Health 
Workers 
Inadequate 
training of 
health 
workers 
Disparities in 
education 
levels of 
urban vs rural 
communities. 
High cost of 
the vaccine 
  Misconceptions 
and myths 
surrounding the 
vaccine translated 
into a fear of the 
HPV vaccine within 
the community 
Health workers 
who were not 
directly involved 
in the pilot 
program were 
not given HPV 
vaccine training 
Low level of 
education was 
reported as a 
barrier to 
effective vaccine 
communication 
50 Vermande
re et al. 
2015 
Implementation of an 
HPV vaccination 
program in Eldoret, 
Kenya: Results from a 
qualitative assessment 
by key stakeholders 
Kenya Socio-cultural Demonstration 
Project 
Information 
/ 
Community 
Engagement 
Inadequate 
IEC and 
engagement 
with fathers 
and male 
teachers. Mis-
conceptions 
about 
vaccines. 
Health 
facility-based 
vaccine 
delivery 
Appropriate 
communication 
about cervical 
cancer and HPV 
vaccination as a 
preventive 
measure 
Few fathers had 
heard about the 
past HPV 
vaccination 
program and when 
they had, it was 
mostly through 
their children and 
wives. Health care 
providers failed to 
sensitize all 
teachers 
There was a 
general low 
level of 
understanding 
about the 
potential side 
effects of the 
vaccine which 
negatively 
impacted on 
promotional 
activities 
Once 
participants 
were fully 
informed about 
cervical cancer 
and the HPV 
vaccine, they 
were accepting 
the vaccine 
51 Vermande
re et al. 
2014 
Determinants of 
acceptance and 
subsequent uptake of 
the HPV vaccine in a 
cohort in Eldoret, Kenya 
Kenya Socio-
demographic 
Demonstration 
Project 
Information 
/ 
Community 
Engagement 
Weak IEC 
strategies on 
the HPV 
vaccine 
  Up to 59.4% 
considered a lack 
of information as 
potentially 
preventing them 
from vaccinating 
their daughter. 
Older mothers 
were more likely 
to accept the 
vaccine 
Baseline 
acceptance was 
associated with 
subsequent 
uptake of the 
vaccine. Being 
well-informed 
increased the 
odds of 
immunization 
Barriers-faced 
leading to non-
uptake: poorly 
informed 
regarding where 
and when 
immunization 
was to take 
place; fear of 
side effects  
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52 Wamai et 
al. 2013 
Awareness, knowledge 
and beliefs about HPV, 
cervical cancer and HPV 
vaccines among nurses 
in Cameroon: An 
exploratory study 
Cameroon Socio-
economic 
Demonstration 
Project 
Health 
Workers 
Low level of 
knowledge 
about the 
safety of the 
vaccine 
among health 
workers 
  90.8% of the 
nursing staff 
surveyed 
acknowledged that 
cervical cancer is 
caused by HPV 
infection 
78.9% 
recognized HPV 
vaccine as an 
important 
means of 
prevention 
against HPV 
infections and 
78.9% believed 
the vaccine is 
safe 
69.7% of the 
nurses stated 
that they would 
often 
recommend the 
HPV vaccine 
although, 63.9% 
of them said 
they were 
concerned about 
the side-effects 
53 Watson-
Jones et 
al. 2015 
Access and attitudes to 
HPV vaccination 
amongst hard-to-reach 
populations in Kenya 
Kenya Socio-
economic 
Demonstration 
Project 
Service 
Delivery 
Poor physical 
access to 
schools and 
health 
facilities. 
Inadequate 
information 
about HPV 
vaccine 
Community 
health workers 
as source of 
information and 
drivers of social 
mobilization. 
Adequate and 
appropriate 
sensitization for 
hard-to-reach 
communities 
Barriers to school-
based delivery: 
long distances (up 
to 10km) and 
concerns about 
encountering 
wildlife on the way 
were cited as non- 
or delayed 
enrolment or 
absence from 
school  
Barriers to 
health facility-
based delivery: 
physical 
inaccessibility, 
complaints 
about the 
quality of care, 
a preference for 
traditional 
medicine 
Most parents 
were willing for 
their daughters 
to be vaccinated 
after being 
sensitized 
54 Watson-
Jones et 
al. 2012 
Reasons for receiving or 
not receiving HPV 
vaccination in primary 
schoolgirls in Tanzania: 
A case control study 
Tanzania Socio-
economic 
Demonstration 
Project 
Information 
/ 
Community 
Engagement 
Inadequate 
IEC about the 
HPV vaccine, 
its safety and 
efficacy 
  Reasons for 
refusing to 
vaccinate: absence 
from school, 
caregivers’ dissent, 
girls’ dissent  
Vaccine 
acceptance was 
associated with 
an 
understanding 
of the benefits 
of the vaccine in 
preventing 
cervical cancer 
Fear of side 
effects, infertility 
and insufficient 
knowledge about 
the vaccine was 
associated with 
vaccine refusal 
Source; Author
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Appendix 5: Health Policy and Planning Journal Guidelines 
Instructions for Authors 
Health Policy and Planning improves the design, implementation and evaluation of health policies in low- and middle-
income countries through providing a forum for publishing high quality research and original ideas, for an audience of 
policy and public health researchers and practitioners. HPP is published 10 times a year. 
HPP has a double-blinded peer-review policy. All types of papers are peer reviewed and all article abstracts from each 
issue are translated into French, Spanish and Chinese. 
Before you submit please make sure you have followed all the relevant instructions. A checklist for authors is 
available here. 
Not sure which section to submit to? Read our Section Summaries here. 
• Guidance 
i. Improving chances of publication 
ii. Manuscript format and style for all articles 
• Types of papers 
• Submission process 
Guidance 
Improving chances of publication 
As well as the high overall quality required for publication in an international journal, authors should take into 
consideration: 
• Addressing HPP's readership: national and international policy makers, practitioners, academics and general 
readers with a particular interest in health policy issues and debates. 
• Manuscripts that fail to set out the international debates to which the paper contributes, and to draw out policy 
lessons and conclusions, are more likely to be rejected, returned to the authors for redrafting prior to being 
reviewed, or undergo a slower acceptance process. 
• Economists should note that papers accepted for publication in HPP will consider the broad policy implications 
of an economic analysis rather than focusing primarily on the methodological or theoretical aspects of the 
study. 
• Public health specialists writing about a specific health problem or service should discuss the relevance of the 
analysis for the broader health system. Those submitting health policy analyses should draw on relevant bodies 
of theory in their analysis, or justify why they have not, rather than only presenting a narrative based on 
empirical data. 
• Primarily focus on one or more low- or middle-income countries. 
The editors cannot enter into correspondence about papers considered unsuitable for publication and their decision is 
final. Neither the editors nor the publishers accept responsibility for the views of authors expressed in their 
contributions. The editors reserve the right to make amendments to the papers submitted although, whenever possible, 
they will seek the authors' consent to any significant changes made. The manuscript will not be returned to authors 
following submission unless specifically requested. 
Should you require any assistance in submitting your article or have any queries, please do not hesitate to contact the 
editorial office at hpp.editorialoffice@oup.com. 
Manuscript format and style for all articles 
Only articles in English are considered for publication. 
Prepare your manuscript, including tables, using a word processing program and save it as a .doc, .rtf or .ps file. Use a 
minimum font size of 11, double-spaced and paginated throughout including references and tables, with margins of at 
least 2.5 cm. The text should be left justified and not hyphenated. 
The title page should contain: 
• Title - please keep as concise as possible and ensure it reflects the subject matter 
• Corresponding author's name, address, telephone/fax numbers and e-mail address 
• Each author's affiliation and qualifications 
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• Keywords and an abbreviated running title 
• 2-4 Key Messages, detailing concisely the main points made in the paper 
• Acknowledgements 
• A word count of the full article 
In the acknowledgements, all sources of funding for research must be explicitly stated, including grant numbers if 
appropriate. Other financial and material support, specifying the nature of the support, should be acknowledged as well. 
Figures should be designed using a well-known software package for standard personal computers. If a figure has been 
published earlier, acknowledge the original source and submit written permission from the copyright holder to 
reproduce the material. Colour figures are permitted but authors will be required to pay the cost of reproduction. 
Please be aware that the requirements for online submission and for reproduction in the journal are different: (i) for 
online submission and peer review, please upload your figures separately as low-resolution images (.jpg, .tif, .gif or. eps); 
(ii) for reproduction in the journal, you will be required after acceptance to supply high-resolution .tif files. Minimum 
resolutions are 300 d.p.i. for colour or tone images, and 600 d.p.i. for line drawings. We advise that you create your high-
resolution images first as these can be easily converted into low-resolution images for online submission.    
Figures will not be relettered by the publisher. The journal reserves the right to reduce the size of illustrative material. 
Any photomicrographs, electron micrographs or radiographs must be of high quality. Wherever possible, photographs 
should fit within the print area or within a column width. Photomicrographs should provide details of staining technique 
and a scale bar. Patients shown in photographs should have their identity concealed or should have given their written 
consent to publication. When creating figures, please make sure any embedded text is large enough to read. Many 
figures contain miniscule characters such as numbers on a chart or graph. If these characters are not easily readable, 
they will most likely be illegible in the final version. 
Certain image formats such as .jpg and .gif do not have high resolutions, so you may elect to save your figures and insert 
them as .tif instead. 
For useful information on preparing your figures for publication, go to http://cpc.cadmus.com/da. 
All measures should be reported in SI units, followed (where necessary) by the traditional units in parentheses. There are 
two exceptions: blood pressure should be expressed in mmHg and haemoglobin in g/dl. For general guidance on the 
International System of Units, and some useful conversion factors, see 'The SI for the Health Professions' (WHO 1977). 
Manuscript file must include text body. Title Page, Figures and Tables should be uploaded separately. 
Manuscript Preparation 
Page 1: Title Page – as above. 
Page 2: Abstract. The abstract should be prepared in one paragraph, no headings are required. It should describe the 
purpose, materials and methods, results, and conclusion in a single paragraph no longer than 300 words without line 
feeds.  
Page 3: Introduction. The Introduction should state the purpose of the investigation and give a short review of the 
pertinent literature, and be followed by:  
Materials and methods. The Materials and methods section should follow the Introduction and should provide enough 
information to permit repetition of the experimental work. For particular chemicals or equipment, the name and location 
of the supplier should be given in parentheses.  
Results. The Results section should describe the outcome of the study. Data should be presented as concisely as possible, 
if appropriate in the form of tables or figures, although very large tables should be avoided. 
Discussion. The Discussion should be an interpretation of the results and their significance with reference to work by 
other authors. 
Abbreviations. Non-standard abbreviations should be defined at the first occurrence and introduced only where multiple 
use is made. Authors should not use abbreviations in headings. 
All measures should be reported in SI units, followed (where necessary) by the traditional units in parentheses. There are 
two exceptions: blood pressure should be expressed in mmHg and haemoglobin in g/dl. For general guidance on the 
International System of Units, and some useful conversion factors, see 'The SI for the Health Professions' (WHO 1977). 
References. References must follow the Harvard system and must be cited as follows:  
Baker and Watts (1993) found...  
In an earlier study (Baker and Watts 1993), it...  
Where works by more than two authors are cited, only the first author is named followed by 'et al.' and the year. The 
reference list must be typed double-spaced in alphabetical order and include the full title of both paper (or chapter) and 
APPENDICES 
30 
  
journal (or book), thus:  
Baker S, Watts P. 1993. Paper/chapter title in normal script. Journal/book title in italics Volume number in bold : page 
numbers.  
Baker S, Watts P. 1993. Chapter title in normal script. In: Smith B (ed). Book title in italics. 2nd edn. Place of publication: 
Publisher's name, page numbers.  
 
Tables All tables should be on separate pages and accompanied by a title - and footnotes where necessary. The tables 
should be numbered consecutively using Arabic numerals. Units in which results are expressed should be given in 
parentheses at the top of each column and not repeated in each line of the table. Ditto signs are not used. Avoid 
overcrowding the tables and the excessive use of words. The format of tables should be in keeping with that normally 
used by the journal; in particular, vertical lines, coloured text and shading should not be used. Please be certain that the 
data given in tables are correct. Tables should be provided as Word or Excel files. 
Types of papers 
Health Policy and Planning welcomes submissions of the following article types: 
• Original research 
• Review articles 
• Methodological musings 
• Innovation and practice reports 
• Commentaries 
• 'How to do (or not to do)...' [for example, see Hutton & Baltussen, HPP, 20(4): 252-9] and 
• '10 best resources' [for example, see David & Haberlen, HPP, 20(4): 260-3]. 
ORIGINAL RESEARCH 
Manuscripts should preferably be a maximum of 6,000 words, excluding tables and figures/diagrams. 
The manuscript will generally follow through sections: Title page (as above), Abstract (no more than 300 words), 
Introduction, Methods, Results, Discussion, Conclusion, Acknowledgements, References. However, it may be appropriate 
to combine the results and discussion sections in some papers. Tables and Figures should not be placed within the text, 
rather provided in separate file/s. 
For the reporting of statistical analyses please consider the following additional points: 
• Focus the statistical analysis at the research question. 
• Provide information about participation and missing data. 
• As much as possible, describe results using meaningful phrases (e.g., do not say "beta" or "regression 
coefficient", but "mean change in Y per unit of X"). Provide 95% confidence intervals for estimates. 
• Report the proportions as N (%), not just %. 
• Report P values with 2 digits after the decimal, 3 if <0.01 or near 0.05 (e.g., 0.54, 0.03, 0.007, <0.001, 0.048). Do 
not report P values greater than 0.05 as "NS". 
• Always include a leading zero before the decimal point (e.g., 0.32 not .32). 
• Do not report tests statistics (such as chi-2, T, F, etc.)." 
For acknowledgements, figures and measures see above. 
REVIEW ARTICLES 
Manuscripts should preferably be a maximum of 10,000 words, excluding tables, figures/diagrams and references. 
Reviews may be invited. They generally address recent advances in health policy, health systems and 
implementation. Systematic reviews are particularly welcomed, but may not be appropriate for every topic. If authors are 
submitting a review article that is not a systematic review then the paper should explain why a systematic review was not 
feasible/desirable, and the review methods should be described in a way that is as clear and as replicable as possible. 
The manuscript will generally follow through sections: Abstract (no more than 300 words), Introduction, Methods, 
Results, Discussion, Conclusion, References. However, it may be appropriate to combine the results and discussion 
sections in some papers. Tables and Figures should not be placed within the text, rather provided in separate file/s. 
Checklists have been developed for a number of study designs, including randomized controlled trials (CONSORT), 
systematic reviews (PRISMA), observational studies (STROBE), diagnostic accuracy studies (STARD) and qualitative studies 
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(COREQ, RATS). We recommend authors refer to the EQUATOR Network website (http://www.equator-network.org) for 
further information on the available reporting guidelines for health research, and the MIBBI Portal for prescriptive 
checklists for reporting biological and biomedical research where applicable. Authors are requested to make use of these 
when drafting their manuscript and peer reviewers will also be asked to refer to these checklists when evaluating these 
studies. 
COMMENTARIES 
Short commentaries on topical issues in health systems are welcomed - please email the editorial office prior to 
submission. Most such commentaries are commissioned by the editors, but the journal will also consider unsolicited 
submissions. Commentaries should of broad interest to readers of Health Policy and Planning, and while they are not 
research papers, they should be well substantiated. Manuscripts should preferably be a maximum of 1,200 words, 
excluding tables, figures/diagrams and references. 
The manuscript will generally contain a short set of key take-home messages. Tables and Figures should not be placed 
within the text, rather provided in separate file/s. 
HOW TO DO...OR NOT TO DO 
This series is meant to explain how to use a particular research or analytical method (e.g. social network analysis, discrete 
choice experiment etc.). The research or analytical methods discussed should be well accepted and clearly defined: this 
category of paper is not meant to address methodological debates but rather to help disseminate and promote the use 
of well-accepted methodologies.  
 
Manuscripts should preferably be a maximum of 3,000 words excluding tables, figures/diagrams and references. 
• The sections must be arranged as follows: i) Title page (as above), ii) Abstract, iii) Introduction, iv) Body of the 
paper, and v) References. Main sections should be coordinated by the author, and inserted between 
Introduction and Reference sessions. Please contact our office before submitting a manuscript in this category. 
Tables and Figures should not be placed within the text, rather provided in separate file/s. 
10 BEST RESOURCES 
This 10 best is a series of articles that identify and outline the 10 most useful resources from a range of sources to help 
facilitate a better understanding of a particular issue in global health. 
We often commission these articles but we also hear unsolicited suggestions. 
For acknowledgements, figures and measures see above. 
METHODOLOGICAL MUSINGS 
This series is meant to address methodological issues in health policy and systems research, where there is currently a 
lack of clarity about accepted research methods. This series is intended to support the development of the health policy 
and systems research field, through supporting methodological discussion.  
 
Manuscripts should preferably be a maximum of 3,000 words, excluding tables, figures/diagrams and references. 
• The sections must be arranged as follows: i) Title page (as above), ii) Abstract, iii) Introduction, iv) Body of the 
paper, and v) References. Main sections should be coordinated by the author, and inserted between 
Introduction and Reference sessions. Please contact our office before submitting a manuscript in this category. 
• For acknowledgements, figures and measures see above. 
INNOVATION AND PRACTICE REPORTS 
These short reports are narratives from the perspective of health managers operating at the national or sub-national 
level which focus on innovative approaches to strengthen health systems. Papers should highlight the practical 
experience of health managers or practitioners involved in taking action to strengthen health systems through innovative 
activities and new practices. The new activities and practices should preferably have been implemented for a sufficiently 
long time to allow authors to demonstrate the potential for sustained improvement or change in the health system. 
Examples might include practices to build capacity, develop new partnerships or restructure relationships within health 
systems. Papers should identify 2-4 key messages or lessons for consideration in other settings. We will not consider 
clinical and pharmaceutical innovations and practices. Manuscripts should be a maximum of 2,000 words. 
The manuscript will generally follow through sections: Key Messages, Abstract (no more than 300 words), Introduction, 
Methods, Results, Discussion, Conclusion, References. However, it may be appropriate to combine the results and 
discussion sections in some papers. Tables and Figures should not be placed within the text, rather provided in separate 
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file/s. In the main body of the paper, sub-headings may be useful to signal key elements of the experience reported. 
Reports must be led by local practitioners, managers or policy-makers. 
Submission process 
• Pre-submission language editing 
• Authorship 
• Originality 
• Online submission 
PRE-SUBMISSION LANGUAGE EDITING 
HPP asks all authors to ensure that their papers are written in as high a standard of English as possible before submission 
to the journal. If your first language is not English, to ensure that the academic content of your paper is fully understood 
by journal editors and reviewers, you may want to consider using a language editing service. Language editing does not 
guarantee that your manuscript will be accepted for publication. For further information on this service, please click 
here. Several specialist language editing companies offer similar services and you can also use any of these. Authors are 
liable for all costs associated with such services. If your first language is not English, to ensure that the academic content 
of your paper is fully understood by journal editors and reviewers is optional. Language editing does not guarantee that 
your manuscript will be accepted for publication. For further information on this service, please click here. Several 
specialist language editing companies offer similar services and you can also use any of these. Authors are liable for all 
costs associated with such services. 
AUTHORSHIP 
All persons designated as authors should qualify for authorship. The order of authorship should be a joint decision of the 
co-authors. Each author should have participated sufficiently in the work to take public responsibility for the content. 
Authorship credit should be based on substantial contribution to conception and design, execution, or analysis and 
interpretation of data. All authors should be involved in drafting the article or revising it critically for important 
intellectual content, must have read and approved the final version of the manuscript and approve of its submission to 
this journal. An email confirming submission of a manuscript is sent to all authors. Any change in authorship following 
initial submission would have to be agreed by all authors as would any change in the order of authors. 
ORIGINALITY 
Manuscripts containing original material are accepted for consideration with the understanding that neither the article 
nor any part of its essential substance, tables, or figures has been or will be published or submitted for publication 
elsewhere. This restriction does not apply to abstracts or short press reports published in connection with scientific 
meetings. Copies of any closely related manuscripts should be submitted along with the manuscript that is to be 
considered by HPP. HPP discourages the submission of more than one article dealing with related aspects of the same 
study. . For further information on the prior publication policy 
see https://academic.oup.com/heapol/pages/Prior_Publication. 
During the online submission procedure, authors are asked to provide: 
• information on prior or duplicate publication or submission elsewhere of any part of the work; 
• a statement of financial or other relationships that might lead to a conflict of interest or a statement that the 
authors do not have any conflict of interest; 
• a statement that the manuscript has been read and approved by all authors (see also section on authorship); 
• name, address, telephone and fax number of the corresponding author who is responsible for negotiations 
concerning the manuscript; 
• copies of any permissions to reproduce already published material, or to use illustrations or report sensitive 
personal information about identifiable persons. 
All papers submitted to HPP are checked by the editorial office for conformance to author and other instructions all 
specified below. Non-conforming manuscripts will be returned to authors. 
If authors are unsure about the originality of their manuscript or any part of it, they should contact the editorial office 
at hpp.editorialoffice@oup.com. 
ONLINE SUBMISSION 
Prior to submission please carefully read instructions on each type of paper and closely follow instructions on word 
count, abstract, tables and figures and references. This will ensure that the review and publication of your paper is as 
efficient and quick as possible. The Editorial Office reserve the right to return manuscripts that are not in accordance 
with these instructions.  
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All material to be considered for publication in Health Policy and Planning should be submitted in electronic form via the 
journal's online submission system. Once you have prepared your manuscript according to the instructions below, 
instructions on how to submit your manuscript online can be found by clicking here. 
CONFLICT OF INTEREST 
Authors must declare any conflicts of interest during the online submissions process. The lead author is responsible for 
confirming with the co-authors whether they also have any conflicts to declare. 
ETHICAL APPROVAL 
A requirement of publication is that research involving human subjects was conducted with the ethical approval of the 
appropriate bodies in the country where the research was conducted and of the ethical approval committees of affiliated 
research institutions elsewhere. A clear statement to this effect must be made in any submitted manuscript presenting 
such research, specifying that the free and informed consent of the subjects was obtained. 
FUNDING 
The following rules should be followed: 
• The sentence should begin: ‘This work was supported by …’ 
• The full official funding agency name should be given, i.e. ‘the National Cancer Institute at the National 
Institutes of Health’ or simply 'National Institutes of Health' not ‘NCI' (one of the 27 subinstitutions) or 'NCI at 
NIH’ - see the full RIN-approved list of UK funding agencies for details 
• Grant numbers should be complete and accurate and provided in brackets as follows: ‘[grant number ABX 
CDXXXXXX]’ 
• Multiple grant numbers should be separated by a comma as follows: ‘[grant numbers ABX CDXXXXXX, EFX 
GHXXXXXX]’ 
• Agencies should be separated by a semi-colon (plus ‘and’ before the last funding agency) 
• Where individuals need to be specified for certain sources of funding the following text should be added after 
the relevant agency or grant number 'to [author initials]'. 
An example is given here: ‘This work was supported by the National Institutes of Health [P50 CA098252 and CA118790 to 
R.B.S.R.] and the Alcohol & Education Research Council [HFY GR667789]. 
Oxford Journals will deposit all NIH-funded articles in PubMed Central. See Author self-archiving policy for details. 
Authors must ensure that manuscripts are clearly indicated as NIH-funded using the guidelines above. 
PERMISSIONS 
Authors are reminded that it is their responsibility to comply with copyright laws. It is essential to ensure that no parts of 
the submission have or are due to appear in other publications without prior permission from the copyright holder and 
the original author. Materials, e.g. tables, taken from other sources must be accompanied by a written statement from 
both author and publisher giving permission to HPP for reproduction. 
COPYRIGHT 
Upon receipt of accepted manuscripts at Oxford Journals authors will be invited to complete an online copyright licence 
to publish form.  
Please note that by submitting an article for publication you confirm that you are the corresponding/submitting author 
and that Oxford University Press ("OUP") may retain your email address for the purpose of communicating with you 
about the article. You agree to notify OUP immediately if your details change. If your article is accepted for publication 
OUP will contact you using the email address you have used in the registration process. Please note that OUP does not 
retain copies of rejected articles  
It is a condition of publication in Health Policy and Planning that authors assign licence to publish to Oxford University 
Press. This ensures that requests from third parties to reproduce articles are handled efficiently and consistently and will 
also allow the article to be as widely disseminated as possible. In assigning licence to publish, authors may use their own 
material in other publications provided that the Journal is acknowledged as the original place of publication, and Oxford 
University Press is acknowledged as the original Publisher. 
THIRD-PARTY CONTENT IN OPEN ACCESS PAPERS 
If you will be publishing your paper under an Open Access licence but it contains material for which you do not have 
Open Access re-use permissions, please state this clearly by supplying the following credit line alongside the material:  
Title of content  
Author, Original publication, year of original publication, by permission of [rights holder]  
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This image/content is not covered by the terms of the Creative Commons licence of this publication. For permission to 
reuse, please contact the rights holder. 
PRIOR PUBLICATION POLICY 
Please review our prior publication policy. We expect authors to disclose any prior dissemination including via a website 
or at national meetings. 
OFFPRINTS 
All authors are supplied with a free URL linking you to a press-ready PDF version of your article. If you wish to order 
offprints please visit the Oxford Journals Author Services site. 
CHANGE OF ADDRESS 
Please notify the editors of any change of address. After manuscript acceptance, please also notify the publishers: 
Journals Production Department, Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK. Telephone +44 
(0) 1865 556767 , Fax +44 (0) 1865 267773. 
IMPORTANT NOTES TO AUTHORS 
The manuscripts will not be returned to authors following submission unless specifically requested. 
PROOFS 
Authors are sent page proofs by email. These should be checked immediately and corrections, as well as answers to any 
queries, returned to the publishers as an annotated PDF via email or fax within 3 working days (further details are 
supplied with the proof). It is the author's responsibility to check proofs thoroughly. 
PERMISSION TO REPRODUCE FIGURES AND EXTRACTS 
Permission to reproduce copyright material, for print and online publication in perpetuity, must be cleared and if 
necessary paid for by the author; this includes applications and payments to DACS, ARS and similar licensing agencies 
where appropriate. Evidence in writing that such permissions have been secured from the rights-holder must be made 
available to the editors.  
It is also the author's responsibility to include acknowledgements as stipulated by the particular institutions. Please note 
that obtaining copyright permission could take some time. Oxford Journals can offer information and documentation to 
assist authors in securing print and online permissions: please see the Guidelines for Authors section 
at https://academic.oup.com/journals/pages/access_purchase/rights_and_permissions.  
Should you require copies of this then please contact the editorial office of the journal in question or the Oxford Journals 
Rights department on journals.permissions@oup.com . 
For a copyright prose work, it is recommended that permission is obtained for the use of extracts longer than 400 words; 
a series of extracts totalling more than 800 words, of which any one extract is more than 300 words; or an extract or 
series of extracts comprising one-quarter of the work or more. For poetry: an extract of more than 40 lines; series of 
extracts totalling more than 40 lines; an extract comprising one-quarter or more of a complete poem.  
SUPPLEMENTARY DATA 
Supporting material that is not essential for inclusion in the full text of the manuscript, but would nevertheless benefit 
the reader, can be made available by the publisher as online-only content, linked to the online manuscript. The material 
should not be essential to understanding the conclusions of the paper, but should contain data that is additional or 
complementary and directly relevant to the article content. Such information might include more detailed methods, 
extended data sets/data analysis, or additional figures. 
It is standard practice for appendices to be made available online-only as supplementary data. All text and figures must 
be provided in suitable electronic formats. All material to be considered as supplementary data must be submitted at the 
same time as the main manuscript for peer review. It cannot be altered or replaced after the paper has been accepted 
for publication, and will not be edited. Please indicate clearly all material intended as supplementary data upon 
submission and name the files e.g. 'Supplementary Figure 1', 'Supplementary Data', etc. Also ensure that the 
supplementary data is referred to in the main manuscript where necessary, for example as '(see Supplementary data)' or 
'(see Supplementary Figure 1)'. 
OXFORD OPEN ACCESS 
HPP authors have the option to publish their paper under the Oxford Open initiative; whereby, for a charge, their paper 
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